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In the 1990s the estimated prevalence of depression was two thousand times higher 
than in the 1960s (Leader 2008a; 2013). This astronomical rise in depression 
corresponded with the launch of blockbuster antidepressants released in the late 
1980s: selective serotonin reuptake inhibitors (SSRIs). Perhaps the most well-known 
of these drugs is Prozac, which, as evidenced by the book and subsequent film Prozac 
Nation, became a pop culture phenomenon (Wurtzel 1994; Skjoldbjærg 2001). This 
thesis argues that the increase in depression diagnoses after Prozac hit the market is 
reflective of a broader narrative within the treatment area. Historically, what constitutes 
a pathological low mood has invariably been defined by those purporting to have a 
treatment. Indeed, the marketing of treatments routinely corresponds with diagnostic 
marketing.  In contemporary societies, treatment is primarily defined and controlled by 
mammoth commercial entities: multinational corporations. The proposed solution is 
invariably pharmacological in the form of drugs such as Prozac. 
 
Adopting an investigative methodology inspired by traditional social scientists, such as 
Derek Layder (1993), and investigative journalist Mark Lee Hunter (2011), this thesis 
examines the marketing activities of antidepressant manufacturers. The long shadow 
cast by Prozac over the depression treatment market is unavoidable and integral to 
understanding contemporary issues in this area. With this in mind, it is essential to use 
an approach which embraces and foregrounds the historical context. Furthermore, as 
Layder (1993) argues, history envelops every aspect of the research process, and, as 
such, history should be prioritised and treated as a method in and of itself. 
 
This research identifies evidence which suggests that the increase in depression 
diagnoses and antidepressant prescriptions is due, in part, to unethical marketing 
techniques, or, more specifically, covert marketing that targeted medics and charities. 
For example, doctors were flown to exotic islands by pharmaceutical companies, a 
charity was paid to covertly promote marketing messages, not to mention that I could 
handwrite this thesis a thousand times over with pens sporting antidepressant brand 
names. These activities are indicative of a pharmaceutical industry driven by 
medicalisation, or pharmaceuticalisation. However, in light of public criticism over such 
practices companies have subsequently endeavoured to ensure that the promotion of 
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antidepressants follows ethical guidelines. Today, there are more rigorous regulations 
pertaining to gift giving and hospitality, and, indeed, this research verifies this shift 
towards greater transparency in these practices. However, such improvements are 
mitigated by what Abraham (2008) designates as ‘neo-liberal corporate bias.’ Hence, 
as pharmaceutical companies self-regulate their marketing activities, this regulation is 
often refracted through self-interest and the profit motive. Overall, this investigation 
demonstrates that depression continues to be defined by the Big Pharma companies 
that promote drug treatments, which leaves the door open for future research when 
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1.1 Introduction  
Over the past decade alone, prescriptions for antidepressants have doubled (NHS 
Digital 2017). Resultantly, approximately one in ten adults are now estimated to be on 
these drugs at any given time (Lewer et al. 2015). One would expect that when a 
treatment becomes popular the symptoms addressed by a treatment would decrease, 
whilst the number of diagnoses would stay the same, capped by the condition’s natural 
occurrence within a population. However, after blockbuster antidepressants, such as 
Prozac, hit the market, diagnoses of depression have increased. Leader (2008a) notes 
that  in the 1960s the prevalence of depression was estimated at 50 per million, 
whereas by the 1990s this had increased to 1 in 10. The most recently available figures 
from the Office for National Statistics (ONS) estimate that up to 1 in 5 people currently 
experience depression or anxiety (ONS 2018). Furthermore, the World Health 
Organisation (WHO) estimates that 1 in 4 people in European countries experience 
common mental illnesses such as depression and anxiety every year (World Health 
Organization 2017).  
  
For some, the rising number of depression diagnoses signifies a reduction in stigma 
around mental illness. Stigma is known to prevent individuals from seeking treatment 
for depression (Barney et al. 2006). Therefore, perhaps struggling individuals now feel 
more comfortable talking about their problems, which, in turn, leads to an increase in 
the use of antidepressants as more individuals gain access to treatment. Similarly, if 
more people present to their doctors with symptoms of eczema, then we would expect 
to see a similar increase in the prescription of emollients and steroid creams. This 
proposed explanation for the exceptional growth of antidepressant prescriptions in the 
UK over the last quarter of a century can be described in economic terms as a simple 
supply/demand model. That is to say, as more individuals present to their GPs with 
depressive symptoms, there is a greater demand for antidepressants which is met by 
an increased supply by manufacturers, and finally an increase in prescriptions. 




As Leader (2008b) points out, the concept of depression itself is inextricably linked to 
its pharmaceutical treatments. Leader argues that ‘it seems to have occurred to no 
one purveying a medical cure for depression that the remedy may function as a mirror 
for the malady’ (Leader 2008b, p. I). Whilst I am in full agreement with Leader’s 
(2008b) identification of a link between illness and its treatment, I question whether 
this mirroring is unintentional and unnoticed by antidepressant manufacturers. 
 
More critically, scholars argue that diagnoses of depression have expanded far 
beyond the truly unwell population to include individuals experiencing normal human 
emotions (Dowrick and Frances 2013). This phenomenon is commonly referred to as 
medicalisation (Conrad 1992; Conrad and Leiter 2004; Conrad 2005; Conrad and 
Schneider 2010; Smith 2014). Medicalisation can be a relatively neutral phenomenon 
that occurs because of natural shifts in societal norms and priorities. Childbirth is an 
illustrative example of a practice which has become subject to medicalization over the 
last century, and, indeed, few would argue that this has not had a positive impact on 
the experience and outcomes of childbirth. Some critics have gone one step further, 
ascribing the increase in diagnoses to pharmaceuticalisation (Abraham 2010). 
However, pharmaceuticalisation specifically refers to the expansion or blurring of the 
boundaries between illness and drug treatments to increase pharmaceutical demand 
(Abraham 2010). This idea of pharmaceuticalisation is in agreeance with Conrad’s 
(2005) finding that medicalization had become increasingly driven by commercial and 
market factors, namely, pharmaceutical companies.  
 
This thesis attempts to apply the concept of pharmaceuticalisation/medicalisation to 
understand depression and the growth of the antidepressant market, whilst, 
simultaneously, using depression as a case study through which to extend the concept 
of pharmaceuticalisation by looking at the business management or marketing 
dimensions of this process. Specifically, this is done by examining the business 
interactions between pharmaceutical companies and their audiences. In so doing, this 
thesis contributes to socio-medical literature by highlighting the business aspect of 
pharmaceuticalisation, whilst also casting light on an industry that hitherto has 




Antidepressants have been used for the treatment of depression for decades 
(Improvement 1986; Gardner 2003; Lawlor 2012). Hanganu-Bresch (2011, p167) 
notes that the very existence of antidepressant drugs prompts debate over what 
constitutes health, illness and, on an even deeper level, humanity. Hangani-Bresch’s 
(2011) observation is especially pertinent to the case of Prozac. A member of the most 
popular type of antidepressants, SSRIs, Prozac became a cultural phenomenon with 
it proponents arguing that it rendered its takers better human beings (Kramer 1994).  
 
SSRI prescriptions continue to rise in the UK, with their success often being attributed 
to the marketing efforts of pharmaceutical companies (Gardner 2003; Greenberg 
2010). In their paper for the British Medical Journal, Light and Lexchin (2012) observe 
that pharmaceutical companies spend nineteen times more on marketing than 
research and development.  
 
For almost half a century, there has been extensive debate over the use of marketing 
and advertising methods to promote drugs aimed at treating mental illness. However, 
when comparing the issues raised by authors such as Goldman and Montagne (1986) 
and those raised by Gardner (2003), it is apparent that, whilst critical ideas are gaining 
traction, the core debate has changed very little during this period. Both papers argue 
that advertising antidepressants leads to the over-medicalisation of depression.  
Although the debate itself has been ongoing for decades, there has been a dearth of 
contributions from business schools. Organisations are at the heart of arguments 
about the increase in depression diagnoses and antidepressant prescriptions. 
Whether it is pharmaceutical companies, health authorities, third party advertising 
agencies or British royal collages, large organisations are front and centre in this topic. 
It is therefore anticipated that conducting investigative work into this topic, from within 
the broad discipline of business management, will provide a new perspective and 
make a unique contribution to extant understanding of pharmaceuticalisation as a 
product of business and marketing decision-making. The case study for exploring this 
process of pharmaceuticalisation is depression and antidepressants. 
 
One reason why there has until now been scarce business research in this area is 
perhaps down to difficulties in gaining access. In fact, the pharmaceutical industry itself 
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has a reputation for extremely limited levels of transparency (Dhalla and Laupacis 
2008; McCubrey and Rah 2009; Poitras and Meredith 2009; Lee and Kohler 2010; 
Ross et al. 2012; Goldacre et al. 2013). A novel methodology designated as 
investigative social science (Douglas 1976; Levine 1980; Ho et al. 2006) offers an 
alternative mode through which business scholars can research the covert marketing 
of antidepressants. Most commonly utilised in sociology, investigative social science 
describes the incorporation of techniques originally developed within investigative 
journalism into traditional social science research. Within this approach, data is 
gathered by 'following the line of enquiry' and allowing different modes of data 
collection to inform each other. For example, a potential interview participant may be 
identified and contacted from a documentary source. Investigative social science is 
deemed to be especially appropriate for topics involving issues of transparency as it 
allows for an in-depth, creative exploration of what initially may appear to be small, 
unsupported findings. Following in the tradition of investigative journalism, findings are 
corroborated by inviting viewpoints from all sides of a debate. How investigative social 
science specifically applies to the present research will be discussed in detail in the 
methods chapter. 
 
Through an investigative approach, this research aims to explore the role of various 
organisations (public and private, but also third sector) in mediating and manipulating 
the popular understanding of depression, and in terms of increasing the 
commodification of its treatments. Marketing messages and the underlying motives 
will be discussed in depth, as well as practitioners’ perspectives on these messages. 
Other sources of information on depression and its treatments will also be examined, 
such as disease awareness campaigns, television programmes and websites. The 
socio-political history of psychiatry will also be dissected in light of the arguments that 
the profession used depression to legitimize itself and is too close to the 
pharmaceutical industry (Moncrieff et al. 2005; Insel 2010). Ultimately, this research 
aims to contribute to the debate over whether the increase in depression diagnoses 
and growing antidepressant prescriptions, is due to disease mongering, medicalisation 
or pharmaceuticalisation. Through examining the business activities of antidepressant 
manufacturers, this research contributes to the socio-medical literature which coined 
the aforesaid terms. This research marks the first investigation within the discipline of 
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business management into antidepressant marketing. In so doing, this thesis thus 
contributes to both business management and socio-medical literature by providing a 
new understanding of pharmaceuticalisation, medicalisation and disease mongering 
as products of business activities. 
 
Theoretically, this thesis is underpinned by an approach developed by Michael Billig. 
Billig (2013) argues that social analysis should not rely on a single approach, but 
rather, draw on different theoretical ideas. Therefore, this thesis does not shoehorn 
findings into a singular, overarching theory. Rather, a ‘light-touch’ approach is used, 
that, when appropriate, draws upon a number of useful theories in a magpie-like 
fashion.  
 
1.2 An Overview of the Thesis 
Chapter 2, which follows this presents a review of existing literature, and identifies how 
the present research will contribute to the field. More specifically, it situates the 
research within the boarder literature of antidepressant marketing and makes the case 
that further research needs to be conducted, especially from management schools. 
 
Chapter 3 is the methods chapter. There, I provide a detailed account of the methods 
of data collection employed in the research, before proceeding to delineate the 
epistemological and ontological perspectives which informed their selection. Particular 
attention is given to the concept of ‘investigative social science’ which permeates 
every aspect of this research. The methodology utilised in this research also draws 
upon traditional social scientists, such as Becker (2007), Layder (1993) and Billig 
(2013), as well as investigative journalists like Hunter (2011). The argument put 
forward in this chapter is that this approach allows me to investigate a powerful 
industry characterised by low-levels of transparency, and better equips me to research 
issues of broad societal importance (Marinetto 2015). 
 
In the methods chapter, I draw upon the work of Derek Layder (1993) to make the 
case for historical analysis being classed as a method in and of itself. From this 
perspective, chapters 4 and 5 which are entirely historical can be considered the first 
findings chapters. In chapter 4, I draw upon secondary sources to trace the genealogy 
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of pathological low mood from its humble beginnings in the form of acedia and 
melancholy, to the modern-day diagnosis of depression. Chapter 5 explores the 
parallel history of depression treatments. Through examining the evolutionary history 
of depression and its treatments an integral narrative emerges: depression has 
consistently been framed by the organisations who claim to treat it. The church 
explained it in terms of demon possession, Freud as repression, and pharmaceutical 
companies as a chemical imbalance. The chapter proceeds to outline how we have 
yet to fully understand the mechanisms and causes of depression. In other words, a 
vacuum exists in our collective knowledge, and as will be shown in this thesis, 
wherever there is a vacuum, interested parties will step in. 
 
Chapter 6 turns its attention to the manufacturers of antidepressants: Big Pharma. As 
noted previously, this thesis is defined by historical context, and, as such, this section 
begins by exploring the history of the pharmaceutical industry itself. The 
pharmaceutical industry occupies a unique political position in the UK, and thus 
understanding its operation and its relationship to the NHS is integral for 
understanding the antidepressant market. Chapter 7 then focusses on the industry 
employees who disseminate marketing information. Pharmaceutical sales 
representatives (PSRs), commonly known as ‘drug reps’, are almost as iconic as 
Prozac itself, appearing in Hollywood films such as Love and Other Drugs, John 
Grisham novels, and television program such as The Simpsons and The Big Bang 
Theory. They are the foot soldiers of the industry. When a new antidepressant is 
released to market, prescribers often learn about it (either directly or indirectly) through 
PSRs. PSRs are often characterised in the media as manipulators who seduce doctors 
into prescribing their medicine at any cost. This chapter interrogates this popular 
depiction. Drawing upon interviews with eight PSRs who have sold antidepressants, I 
examine what it means to be a pharmaceutical sales representative. Further to this, I 
question the extent to which pharmaceutical sales representatives use manipulative 
tactics to influence prescribing. 
 
Chapter 8 focusses on the frequent targets of antidepressant marketing: healthcare 
professionals. Healthcare professionals are the gatekeepers of the NHS. On a micro 
level they hold the power of the prescription pad, and on miso and macro levels they 
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are involved in decisions of drug approval and whether a particular hospital or health 
board should pay for a drug. It is as gatekeepers that healthcare professionals find 
themselves most purely on the receiving end of marketing efforts, however many 
healthcare professionals also collaborate with industry. I describe some such 
healthcare professionals as locksmiths. They advise companies on how to appeal to 
gatekeepers. Historically healthcare professionals who chose to collaborate with 
pharmaceutical companies have been depicted as ‘greedy pigs’. However, my 
interviews with collaborators indicates a more complex, symbiotic relationship. Once 
again, as seen in chapter 5, a vacuum emerges. Training budgets for healthcare 
professionals halve, and antidepressant manufactures present an opportunity for free 
education. 
 
In the UK it is illegal to advertise prescriptions directly to the public. This creates a 
challenge for antidepressant manufacturers looking to increase demand for their new 
product. It is not, however, illegal to promote awareness of a condition treated by 
prescription medicines. The corporate sponsorship of depression awareness 
campaigns has been commonplace in the UK since the 1990s. In the history chapters 
the case was made that depression has been consistently defined by those who treat 
it. Through providing information about depression to the public corporate funded 
depression awareness campaigns are a key component of this narrative. Chapter 9 
dissects corporate funded depression awareness campaigns in the UK from the very 
first one in 1992, to the most recent in 2016. What emerges is a shift in agenda, from 
using campaigns to covertly disseminate marketing messages, to a more political 
motive. Antidepressant manufacturers now align themselves with charities to bask in 
their ‘political and rhetorical power’ (Loseke 1997). Using the symbolic resources of 
charities to improve their reputation and aid in getting their product approved by health 
boards and formularies. 
 
Finally, the last findings chapters look towards the future of the antidepressant market. 
The history chapters presented the narrative that antidepressants may be usurped as 
the primary treatment option for depression, and the industry responsible for their 
development may be heading towards a ‘winter of discontent’. However, chapters 
6,7,8 and 9 demonstrate how the industry is adapting to recent challenges. These 
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short final chapters present the threats (chapter 10) and opportunities (chapter 11) 
facing antidepressant manufacturers. Are we entering a new era of depression 
treatment where symptoms of low mood will be treated with virtual reality or new 
medical devices? Or, can pharmaceutical companies continue their hegemony over 
the depression treatment market? 
 
Ultimately this research makes the argument that depression has been consistently 
defined by those who claim to provide a treatment. Most recently this has been done 
by pharmaceutical companies which have, at times, used unethical methods to 
promote the condition and increase antidepressant sales. This has resulted in 
scandals which have proved unprofitable for the industry. Resultantly the industry has 
increased regulation and improved overt practices which have been publicly criticised. 
However, as the industry is both self-regulated and required to make a profit, covert 





2. Literature Review 
 
2.1 Introduction 
The ethical status of the pharmaceutical industry or ‘Big Pharma’ is a contentious 
subject, receiving attention from all corners of both academia and the media. Critics 
argue that the pharmaceutical industry is corrupt, wielding too much power which 
ultimately results in a poorer deal for patients (Goldacre, 2012). Whilst criticism of the 
pharmaceutical industry is widespread (Arndt 2006; Brody 2007; Dumit 2012; 
Götzsche 2013), others however, emphasise that that the industry plays an essential 
role in both the economic and public health of society (Leisinger 2005,2009,2011).  
 
I will be reviewing four types of literature relevant to this thesis: literature on Big 
Pharma, literature on pharmaceutical marketing, literature on pharmaceuticalisation 
and literature on antidepressants. This literature review will begin by drawing upon 
relevant literature to briefly establish what is meant by ‘Big Pharma’: its antecedence, 
and its connotations. Attention will then be turned specifically to the marketing 
practices of pharmaceutical companies, with an emphasis on the ethical debates 
surrounding such practices. Critical concepts such as disease mongering, 
medicalisation and pharmaceuticalisation will be defined and discussed drawing upon 
key literature from the disciplines of marketing, medicine, sociology, medical 
anthropology and business ethics. 
 
Subsequent to acknowledging the respective strengths and limitations of the academic 
literature, examples of critical journalistic literature on the pharmaceutical industry will 
also be considered. After reflecting on the themes and concepts identified in both the 
academic and alternative literatures, the manifestation of such concepts in the field of 
psychiatry will them be presented and discussed. Finally, I will situate the present 
research within extant literature and debates, discuss what theories will be drawn 
upon, and delineate how the research will contribute to the field.  
 
2.2 Studying ‘Big Pharma’ 
Big Pharma is the nickname given to the vast global pharmaceutical market which in 
2016 had a revenue of over $1 trillion USD (Statista 2018). Big Pharma is also 
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commonly used abstractly to refer to some or all of the following large companies: 
Johnson & Johnson, Roche, Pfizer, Novartis, Sanofi, GlaxoSmithKline, Merck & Co, 
AbbVie, Bayer, Abbott Laboratories, Eli Lilly & Co and AstraZeneca amongst others. 
Whilst these companies are the largest in terms of revenue, and most of them have 
released antidepressant products over the past three decades, the industry is also 
comprised of more specialist, medium-sized companies. The key smaller players in 
the antidepressant market are the German company, H. Lundbeck, and the French 
company, Servier. To provide a comparison, last year Servier declared a revenue of 
around a quarter of that declared by the Prozac manufacturer, Eli Lilly (Servier 2018). 
Although these companies are smaller, for brevity I am using the term Big Pharma to 
refer to all relevant players in the market, which, in terms of antidepressants, includes 
Servier and H. Lundbeck. 
 
Whilst the pharmaceutical industry is occasionally depicted as comprising innovative 
companies that produce lifesaving drugs (Vallée 2013), it is more commonly presented 
in the media as ruthless, dishonest and greedy (Zwick 2010). Resultantly, public trust 
in the pharmaceutical industry is consistently waning (Brown and Calnan 2010; Kata 
2012; Fort 2014; Hernandez et al. 2014). Leisinger (2005) argues that such criticisms 
are due, in part, to a dissonance between the industry’s self-perception of its 
responsibilities and the perceptions of the wider public, whereas Hernandez et al. 
(2014) cites public scandals as the reason for diminishing trust. The following section 
establishes what precisely is meant by ‘Big Pharma’, who it is comprised of, and what 
its purpose is. 
 
As noted by Leisinger (2005), there is often a conflict between Big Pharma’s self-
perception of its role in society and how other stakeholders, such as the general public, 
view its role. Whilst Leisinger (2005) examines this dissonance specifically in relation 
to corporate social responsibility (CSR), it is also possible that this dissonance exists 
in other business activities, such as marketing communications. There is an emergent 
body of mainstream journalistic literature presenting critical perspectives of the 
pharmaceutical industry and its use of marketing (e.g.Healy 1997,2004; Angell 2005; 
Law 2006; Brody 2007; Greenberg 2010; Goldacre 2012; Healy 2012c; Davies 2013; 
Götzsche 2013). Although, of course, this mainstream literature is not subject to the 
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peer-review process that academic journal articles go through, that is not to say that 
these books are without value.  
 
Goldacre’s (2012) book Bad Pharma is perhaps the most well-known of its kind in 
recent years. Goldacre (2012) provides an overview of the ethical issues facing the 
modern pharmaceutical industry, and his book is aimed at a broad target audience of 
practitioners, pharmaceutical industry employees and the public. Previously employed 
as a columnist for The Guardian, in addition to being well-published in academic 
journals (Goldacre 2007,2009; Goldacre et al. 2013), Goldacre illustrates how 
investigative journalistic techniques and rigorous academic evidence can be combined 
effectively in the exploration of potentially hidden phenomena.  
 
Similarly, White Coat Black Hat by(Elliot 2010) utilises journalistic methods to explore 
anecdotal evidence about the relationship between medicine and the pharmaceutical 
industry. Focusing on the historical development of the marketing of pharmaceuticals, 
Elliot (2010) uses narrative to propose how well-meaning individuals can become co-
producers of unethical behaviours.  
 
These publications, and others like them, utilise the methodology of investigative 
journalism. Although journalistic techniques are often criticised within academia (May 
1994, p. 133), Hilgartner (1990) argues that the criticism and dismissal of popular 
science within academia may operate as a device to reinforce hierarchy and safeguard 
the position of academia at the top of that hierarchy. There is also a line of argument 
that suggests that journalism is actually becoming increasingly scientific in nature 
(Meyer 2002). Such literature, which Mayer terms ‘precision journalism,’ shows 
increasing rigour and blurs the lines between social science and journalism (2002, p. 
vii). The scientific turn in journalism is also evident in data journalism, which will be 
discussed later in the chapter.  
 
Although some branches of journalism are demonstrating increasing rigour, it is 
impossible to ignore the trend towards less reliable content in other areas. In recent 
years journalism has been subject to increasing amounts of criticism. One accusation 
is that journalism is becoming ‘churnalism’, simply recycling content from pubic 
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relations wires (Davies, 2008). Moreover, after the 2016 US election the term fake 
news rose in popularity. Initially the term was used to describe news which was 
factually untrue, however the term has since become a political weapon typically used 
against mainstream liberal news sources (Tandoc jr. et al. 2018). It therefore cannot 
be assumed that all journalism is rigorous and of a high quality, rather, each enquiry 
must be appraised on its own merits. 
 
Whilst Goldacre’s (2012) and Elliot’s (2010) work is somewhat journalistic in nature, 
this does not necessarily detract from the validity of their findings. Both authors utilise 
investigative approaches to explore corruption within an enormously powerful and 
profitable industry. Furthermore, by presenting their findings and discussions in 
narrative form, such books are more accessible to a broader audience, and, as such, 
have a greater potential to impact the social world.  
 
Later in this chapter, I suggest that marketing literature is limited by the needs and 
interests of its target audience of pharmaceutical industry employees. Similarly, 
popular non-fiction can also be limited by an awareness of its audience. Consequently, 
the commercial element of these publications cannot be ignored. Given that it is 
displayed on the shelves of retailers such as WHSmith, Waterstones, and increasingly 
major supermarkets, non-fiction is encumbered by a responsibility to entertain readers 
as well as educate them. Hence, awareness of the commercial readership may 
contribute to the inclusion of somewhat overstated claims, such as ‘the whole edifice 
of medicine is broken’ (Goldacre 2012, p. ix). Given that books like Goldacre’s (2012) 
acknowledge that pharmaceutical funding can skew the information presented in 
educational materials and journal articles, it is not altogether unreasonable to question 
whether funding from publishers can skew the information presented in these kinds of 
publications. 
 
It is thus important to be cognisant of the entertainment aspect when reading 
investigative non-fiction, and to read such literature with the same critical eye one 
would apply to academic literature. Provided that one identifies and acknowledges the 
potential biases of mainstream literature, it can still be utilised as a useful resource. In 
fact, the biases presented in such literature can provide additional useful information 
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about the audience  (Fitzgerald 2007, p. 283). As acknowledged by Becker (2007), 
whose work will be discussed in more detail in the methods chapter, every source is 
expedient for telling us about something, it simply takes time and thought to identify 
what that something is.  
 
 
2.3 Studying Big Pharma Marketing 
Attention will now be turned to the marketing practises of the pharmaceutical industry, 
and the ethical implications of these practices. In an article for the BMJ, Light and 
Lexchin (2012) found that the industry spent 19 times more on marketing than it did 
on research and development. Further to this, Malerba and Orsenigo (2015) posit that 
marketing has become the primary function of pharmaceutical companies, an idea 
which will be discussed in more detail in chapter 6. 
 
As with every aspect of the pharmaceutical industry, the marketing of drugs is 
conceptualised differently by different populations. In the literature, such differences 
are often predetermined by the discipline in which the author works. The key 
disciplines in discussions of pharmaceutical marketing are marketing, medicine, 
sociology, medical anthropology and business ethics. This section will discuss in turn 
the manifold contributions made to pharmaceutical marketing by each of these 
academic disciplines. 
 
2.3.1 Marketing Studies and Pharma Marketing 
Whilst the literature in other disciplines focuses on the patient or ‘end consumer’ of a 
pharmaceutical transaction, marketing literature is primarily concerned with the 
vender, that is, the pharmaceutical companies themselves. Marketing literature tends 
to be written from the perspective of the industry itself, discussing the benefits of 
marketing methods for pharmaceutical companies. This is exemplified by the 
extensive literature on the use of drug reps to market pharmaceuticals (Scharitzer and 
Kollarits 2000). 
 
Such literature tends not to acknowledge any potential conflict of interest involved in 
marketing pharmaceuticals to healthcare professionals (Scharitzer and Kollarits 
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2000), focusing instead on how marketing methods can be used to maximise 
pharmaceutical demand (Smith and Cooper-Martin 1997).  
 
The critical view of pharmaceutical marketing that one encounters in some medical 
literature is less evident in the marketing literature. What the critical medical literature 
refers to as ‘disease mongering’ (Arndt 2006; Moynihan and Henry 2006), marketing 
literature describes as ‘disease branding’ and ‘condition branding’ (Angelmar et al. 
2007). 
 
Literature on disease branding tends to frame itself as being concerned primarily with 
educating the public about diseases, their symptoms and cures. The credibility with 
which authors present this stance however, varies considerably. For example, both 
Angelmar et al. (2007) and Parry (2003) write enthusiastically about the benefits 
disease branding poses to pharmaceutical companies and their profitability. In doing 
so, Angelmar et al. (2007) and Parry (2003) align themselves more with traditional 
marketing objectives, such as sales and profit, and less with public education. This is 
exemplified by the branding strategies advanced by Parry’s (2003). Parry (2003) 
proposes three key condition branding strategies: increasing the perceived importance 
of a disease; reducing stigma around a disease; creating a new condition and then 
introducing a new product (drug) to meet the needs of the new condition.  
 
Parry’s (2003) substitution of the word product for drug is indicative of a wider 
underlying assumption inherent to much marketing literature, which is that 
pharmaceuticals are no different from standard consumer products (Parry 2003; 
Angelmar et al. 2007; Parsons 2007). 
 
This view, which could be defined as the product-based view of pharmaceuticals, has 
been criticised by authors from other disciplines (Goldacre 2012). These authors argue 
that such a view is ultimately harmful to patients for whom the differences between 
two drugs has a greater impact than the differences between two standard 
commodities, such as toilet paper or perfume. It is worth noting that at the time of 
publication, Parry was an employee of the pharmaceutical company, GlaxoSmithKline, 
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and therefore it is possible that his views may have been reflective of those held across 
the industry at that time.  
 
A second form of disease branding literature, predominantly coming out of a public 
services marketing perspective, is less overt about its links to treatment (Long et al. 
2008). This strand of literature aligns itself more with what it frames as desirable public 
outcomes as opposed to financial ones (Lefebvre and Flora 1988; Long et al. 2008), 
and  therefore bears some resemblance to socio-medical literature. 
 
Regardless of whether marketing literature adopts either a positive (Parry 2003; 
Angelmar et al. 2007) or neutral (Long et al. 2008) stance towards the pharmaceutical 
industry, it tends to be criticised heavily by medical authors. In contrast to the claim 
that disease branding and condition branding educate the public, Hall and Jones 
(2008) argue that they are instead used as ‘a deliberate method of increasing markets 
for pharmaceutical products’. Furthermore, Hall and Jones (2007, cited in Hall and 
Jones 2008) note that only profitable diseases and conditions tend to be branded in 
this way.  
 
Whilst the marketing literature does vary in terms of its perceived motives and industry 
links, the amorality that characterises the literature from this perspective is almost 
universal. Having said this, Parsons (2007) is one author who does acknowledge the 
ethical debate around disease branding.  
 
Parsons presents disease branding as an illustrative case through which to apply her 
framework ‘Five Pillars of Ethics for Public Communication’ (Parsons 2004, cited in 
Parsons 2007), which she purports could be used to “operationalize ethics” in 
marketing communications decision-making (Parsons 2007).   
 
Parsons’ (2007) paper stands out in its discipline due to its direct acknowledgment of 
the ethical dimension of pharmaceutical marketing.  However, Parsons (2007) only 
engages with the debate insofar as it can benefit pharmaceutical companies. By 
presenting disease branding as a way of ‘neatly sidestepping’ the ethical criticisms 
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associated with drug branding, Parsons (2007) can, simultaneously, acknowledge the 
ethical debates whilst maintaining the status quo of her field. 
 
In summary, marketing literature on pharmaceutical marketing tends to be amoral and 
treats drugs as analogous to standard consumer products. Given that this discipline is 
predominantly populated by former and present pharmaceutical company employees 
(Parry 2003), it is likely that this literature best reflects the values and assumptions of 
the companies themselves.  
 
2.3.2 Medical Anthropology 
Medical anthropologists have written extensively on many aspects of pharmaceutical 
industry practices (Van der Geest et al. 1996; Rasmussen 2004), including the 
emergence of literature in the last decade on marketing (Oldani 2004; Martin 2006). 
 
Medical anthropological literature on pharmaceutical marketing tends to utilise 
qualitative methods, such as ethnography, in-depth interviews and documentary 
analysis. These methods generate, deep, complex insights into marketing methods, 
as well as the historical and contextual factors which precede marketing decisions. 
This contextual background is described by medical anthropologists as the ‘moral 
economy’ of the pharmaceutical industry (Rasmussen 2004, p. 3; Martin 2006, p. 158). 
 
Utilising this concept of the moral economy, Martin (2006) explores the attitudes of 
employees within the pharmaceutical industry during the 1950s and 1960s, when 
psychoactive drugs such as antidepressants first appeared on the market. Martin 
(2006) goes on to present the ambivalence of pharmaceutical industry employees 
today, using data collected from interviews with existing employees working in 
pharmaceutical marketing. Martin’s (2006) analysis of the historical antecedents of 
phenomena is characteristic of her field as a whole.  
 
Described as an ‘autoethnography’ and a ‘memory ethnography’, Oldani’s (2004) 
research predominantly draws upon historical data, especially his own experiences of 
working as a pharmaceutical sales representative. Given that Oldani’s (2004) 
perspective has shifted since exiting the profession, he claims to be able to remember 
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and reflect critically on the opinions and ideas of his previous ‘native’ self. Whilst the 
validity, reliability and generalisability of Oldani’s (2004) work can be criticised, it 
nevertheless offers key insights into the lived experience of a pharmaceutical sales 
representative which is impossible to explore without such biases. 
 
Both Martin (2006) and Oldani (2004) exemplify the primary occupation of the 
discipline with narratives from pharmaceutical employees. This presentation of 
industry beliefs and understandings can, to some extent, align the literature with 
marketing literature, however, in contradistinction to marketing literature, medical 
anthropological literature acknowledges the ethical and moral implications of 
marketing methods, through the discussion of the moral economy (Martin 2006), and 
through the presentation of critical arguments (Oldani 2004). 
 
2.3.3 Business Ethics 
Whilst neither the marketing nor medical fields typically address ethical debates 
related to ‘Big Pharma’ directly, the field of business ethics focuses primarily on 
questions such as ‘How can a corporation, given its economic mission, be managed 
with appropriate attention to ethical concerns?’ (Goodpaster 1991, p. 53) By 
concerning itself with questions of ethics, allied with an understanding and awareness 
of the wider business context, business ethics presents an interesting potential 
framework through which to analyse the activities of the pharmaceutical industry. 
 
There is a large body of literature on the ethics of marketing and selling to consumers 
within business ethics (e.g. Mulki et al. 2009), in addition to a small amount of literature 
examining the use of direct to consumer marketing to advertise pharmaceuticals 
(Parker and Pettijohn 2003), and the CSR of product recalls (Cheah et al. 2007).  
However, the discussion of the ethics of marketing pharmaceuticals has hitherto 
received limited attention in the academic literature. Buckley’s (2004) paper 
‘Pharmaceutical Marketing – Time for Change’ is one of the few papers within this 
perspective that addresses ethical debates pertaining to pharmaceutical marketing. In 
contrast to the medical literature, Buckley (2004) acknowledges that the remit of the 
pharmaceutical industry is to make a profit and draws attention to the wider market 




By examining the industry from a business ethics perspective, Buckley (2004) is thus 
able to, simultaneously, be critical of certain marketing activities, such as those that 
contribute to ‘disease mongering’, whilst understanding the role of underlying market 
forces. In so doing, she is able to make credible normative suggestions. Although 
Buckley (2004) successfully provides an overview of the ethical concerns associated 
with pharmaceutical marketing, there is little research of this kind that has been 
conducted since and, today, over a decade after the publication, the industry is likely 
to have changed.  
 
The paucity of business ethics literature examining the ethics of pharmaceutical 
marketing is indicative of a polarisation within the literature, which will be discussed in 
the following section. 
 
2.3.4 Evaluation of Academic Literature 
Thus far, the review of the academic literature has discussed the ethical status of the 
marketing practices of the pharmaceutical industry and identified a polarization in the 
respective approaches. At one end of the scale, authors within socio-medical literature 
have a tendency to voice strong criticisms against the marketing practices of the 
pharmaceutical industry, to the extent of being accused of bias (Rubin 2004). Such 
literature is almost wholly concerned with the impact of marketing practices upon 
patient welfare (e.g. Wazana 2000; Morgan et al. 2006; Fugh-Berman and Ahari 
2007), and although the field has yet to demonstrate a conclusive link between 
marketing and patient outcomes, the presence of this discussion in the literature 
testifies to the ethical debates. However, this literature fails to acknowledge the wider 
context of the pharmaceutical industry, most notably the role of market forces. The 
failure to adequately acknowledge these factors renders the recommendations 
generated by these papers less applicable. Furthermore, the integrity of the literature 
as a whole is partially undermined due to the conflictual relationship between medical 
journals and the pharmaceutical industry. However, the nature of this relationship, and 




At the opposite end of the spectrum, traditional marketing literature tends to present 
an amoral view of the pharmaceutical industry. Endowing the industry with no extra 
ethical responsibilities beyond those of standard commodity manufacturers, the 
literature is concerned only with ethical debates insofar as it impacts upon its primary 
objective of informing effective marketing practices (Parsons 2007). 
 
Literature from other disciplines seems to lie somewhere between these two 
perspectives, with socio-medical literature written by sociologists representing the 
closest to the that produced by medical authors; the small body of economics literature 
aligns more closely with the amoral imperatives of marketing literature. Literature from 
the field of medical anthropology can be characterised as aligning with marketing 
literature insofar as it reproduces industry narratives, however its exploration of the 
moral economy and presentation of critical ideas locates it closer to the middle of the 
spectrum. Business ethics also has the potential to occupy the middle ground, as 
illustrated by Buckley (2004). However, as of yet there is still a scarcity of research 
from this perspective, and therefore more research is required to establish whether 
such an approach can be successful in mediating such a polarised area of research. 
Reflecting on the limitations of the current body of academic literature, the following 
section will discuss alternative forms of literature, specifically mainstream investigative 
non-fiction.  
 
2.4 Pharmaceuticalisation Literature 
When medicalisation is predominantly characterised by pharmaceutical interventions 
it is referred to as pharmaceuticalisation. The topic of pharmaceuticalisation has been 
addressed primarily within socio-medical literature. This literature is crucial for 
understanding both the development of depression and its pharmaceutical treatment. 
The relationship between medicalisation and pharmaceuticalisation is analogous to a 
Venn diagram. There is a considerable amount of overlap between the two concepts, 
but pharmaceuticalisation can exist with no medical diagnosis (particularly with respect 
to over the counter drugs), and conditions with no pharmaceutical treatment can be 
medicalised (Abraham 2010). This section examines literature relating to the role of 
the pharmaceutical industry in medicalisation. This is a topic which has been 
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addressed by academics from sociology and medicine, as well as by popular non-
fiction authors. Both areas of literature will be discussed in turn. 
 
2.4.1 Socio-Medical Literature 
Medicine and sociology converge in their discussion of pharmaceutical marketing. 
Socio-medical literature differs from purely medical literature insofar as it addresses 
the wider social structures influencing healthcare, as opposed to using the natural 
sciences to explore the epidemiology and treatment of conditions themselves.  Such 
literature tends to be primarily concerned with patient outcomes (Procyshyn et al. 
2004; Perlis et al. 2005; Amaral 2006), and leans towards a utilitarian ethical 
perspective, although ethical debates are rarely explicitly mentioned (Lexchin et al. 
2003). The vast majority of literature examining debates over the ethical status of 
pharmaceutical marketing comes from this perspective (e.g Healy 2006; Moynihan 
and Henry 2006; Tiefer 2006; Abraham 2009; Ebeling 2011). 
 
Although it constitutes a cohesive body of literature, there are subtle differences 
between socio-medical literature written by medical authors and that from sociologists. 
Consequently, I will firstly examine literature written by medical authors, before moving 
on to discuss the contributions of sociological authors.  
 
Socio-medical literature written by medical authors adopts a relatively critical stance 
when discussing pharmaceutical marketing practices (Healy 2006; Moynihan and 
Henry 2006; Tiefer 2006). Medical authors have been especially critical of the use of 
PSRs to market directly to prescribers, arguing that such marketing practices serve 
only to increase prescription costs (Wazana 2000, Morgan et al 2006, Fugh-Berman 
and Ahari 2007, Ladd et al 2010, Spurling et al 2010).  
 
An equally critical body of literature has also been published about disease mongering 
and medicalisation. Most notably, a special issue on disease mongering was published 
by the medical journal Public Library of Science Medicine (PLoS) in 2006 (Moynihan 




Although each of the papers in the special issue focused on a specific condition, such 
as sexual dysfunction (Tiefer, 2006), bipolar disorder (Healy, 2006) or restless leg 
syndrome (Woloshin and Schwartz, 2006), the papers collectively discussed the 
antecedence and impact of disease mongering. As Amaral (2006: e317) notes, all 
these conditions ‘share the fact that they represent a spectra of symptoms felt by 
virtually everyone, but which for some people can reach a point at which they become 
disturbing’. The PLoS collection testifies to the predicament medical practitioners face 
as the definition, diagnosis, and treatment of diseases continues to blur, a process 
which is encouraged and exacerbated by an industry which profits from this emergent 
ambiguity. The authors, many of whom are medical practitioners themselves, express 
concern for patients whose conditions are medicalised and ‘corrected’ by 
pharmaceuticals (Healy 2006, Woloshin and Shwartz 2006, Tiefer 2006). It is 
important to note that even in cases of severe medicalisation, where the boundaries 
of a disease classification have blurred heavily into the realms of normal human 
experience, there still exists a core of individuals who are suffering with severe 
symptoms and in need of treatment.   
 
The collection addresses the potential negative effects of disease mongering in detail. 
However, less attention is granted to the possible beneficial outcomes of increased 
disease awareness. Moreover, the collection presents no insight into the wider 
business context of disease mongering, in turn, neglecting the wider contextual 
phenomena which contributes to the issue. 
 
The uniformly critical stance adopted by medical authors has also been subjected to 
severe criticism. On the subject of PSRs, Rubin (2004) argues that medical authors 
are often guilty of confirmation and selection biases, by seeking out only negative 
results. Furthermore, Rubin (2004) states that the potential benefits of such activities 
are unduly dismissed because the studies, according to the standards of other areas 
of medical writing, are deemed to be unscientific.  
 
Rubin (2004), a Professor of Economics, provides an in-depth overview of the potential 
outcomes, and reasons behind such outcomes, which may occur from using PSRs. 
However, he suggests that prescribing a branded drug as opposed to a generic one 
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has little impact on a patient’s health. Whilst this is true in the immediate sense, at a 
broader level, high prescription costs can limit the level of treatment available to other 
patients, especially in the UK where healthcare is funded by the NHS.  
 
As aforementioned, sociologists are also key contributors to the socio-medical body 
of literature. Whilst socio-medical papers written by sociologists share many 
commonalities with those written by medical authors, there are a few notable 
differences. Firstly, whilst medical authors refer to the phenomenon of medicalisation, 
(Moynihan and Henry 2006, Amaral 2006, etc.) medical sociologist Abraham (2009) 
takes the argument a step further, describing the phenomenon of 
‘Pharmaceuticalisation’. Abraham (2009:100) describes this as ‘the process by which 
social, behavioural or bodily conditions are treated or deemed to be in need of 
treatment, with medical drugs by doctors or patients.’ By directly referring to drugs, 
literature on pharmaceuticalisation holds the pharmaceutical industry to account in a 
way which literature on medicalisation written by sociologists traditionally has not 
(Conrad and Schneider 1980, Zola 1972).  
 
Although much of the literature is critical of the pharmaceutical industry’s marketing 
practises, the field is not unanimous in its criticism of Big Pharma. (Morgan 1984) 
purports that medical journals and pharmaceutical companies have a symbiotic 
relationship, which, in turn, benefits the journals’ practitioner readership. Morgan 
(1984) suggests that, rather than undermining the quality of a journal’s content, the 
presence of pharmaceutical advertisements serves as a mechanism to maintain 
quality, arguing that it would be in neither the journal nor the pharmaceutical 
companies’ best interest to present biased information as it would harm the credibility 
of the journal. In the event of this, Morgan (1984) argues that the principal reason for 
advertising in academic journals would vanish, and, hence, journals are incentivised 
to retain and improve credibility through the publication of accurate information to 
attract and maintain advertising revenues.  
 
An example of a more positive attitude towards pharmaceutical funding is found in a 
roundtable discussion paper by Donnell et al. (2009), in which all the authors 
acknowledge a degree of conflict in accepting pharmaceutical funding for continuing 
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medical education (CME). However, two of the contributors, Donnell and Fox, 
ultimately conclude that the funding benefits medicine to a greater degree than it 
hinders it, whilst Backer et al. (2000) suggests that the relationship with the 
pharmaceutical industry can be symbiotic if managed correctly.  
 
Viewed as a whole, the socio-medical literature provides a nuanced discussion of 
pharmaceuticalisation and its attendant issues. As one might expect, the literature 
provides rich insights into the role of healthcare institutions and the experiences of 
healthcare professionals. However, the literature fails to provide sufficient insights into 
the role of business and marketing practises in the pharmaceuticalisation process. 
 
2.4.2 Journalistic Literature  
As previously outlined, existing academic literature on Big Pharma is not without its 
limitations. Medical literature must contend with the perception that journal content is 
biased due to the reliance on pharmaceutical advertising revenues (Morgan 1984). 
Similarly, marketing literature can suffer from bias due to the interests of its authors 
and the implied readership. Marketing literature on the pharmaceutical industry is 
written with the implicit assumption that it is desirable to increase sales, as this is the 
will of consumers of such research (pharmaceutical companies). Business ethics, 
however, has yet to produce a cohesive body of literature to contribute to the debate. 
Furthermore, Dunne et al. (2008) found that academic literature within business and 
management journals failed to engage with critical political and social debates, which 
undermines the purpose and relevance of the literature.  
 
As with the broader literature on the ethicality of the pharmaceutical industry, there is 
also an emergent psychiatry-specific body of critical mainstream literature. Davies’ 
(2013) ‘Cracked’ is a prime example of investigative, journalistic research that focuses 
specifically on psychiatry and the pharmaceutical industry. In a similar vein to the 
present research, Davies dedicates a chapter solely to the marketing of psychoactive 
drugs and antidepressants. Touching upon some of the issues raised thus far in the 
literature, such as medicalisation and disease mongering, Davies also criticises the 
pharmaceutical industry for its marketing methods. Davies goes onto conduct 
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a whistle-stop tour of the key arguments, including direct-to-consumer marketing, 
ghost writing, and the use of industry sponsored ‘Key Opinion Leaders’ (KOLs).  
 
Crazy Like Us (2011) by investigative journalist Ethan Watters presents the argument 
that America is exporting mental illnesses to the rest of the world. Most relevant to this 
research is Watters’ (2011) examination of the evidence related to the depression 
epidemic in Japan, subsequent to the condition being promoted there as a ‘kokoro no 
kaze’ or ‘cold of the soul.’ Central to Watters’ thesis is the idea that mental health 
diagnoses are socially mediated and culturally bound. Resultantly, they can be 
influenced by societal changes, including those initiated by pharmaceutical 
companies.  
 
Such books serve to enlighten and entertain a lay audience and, although undoubtedly 
lacking the rigor and depth of analysis of traditional academic research, they are still 
useful for highlighting potential avenues for future research. 
 
Two of the most critical books of this kind are Joanna Moncrieff’s (2007) The Myth of 
the Chemical Cure: A Critique of Psychiatric Drug Treatment and Irving Kirsch’s (2009) 
The Emperor's New Drugs: Exploding the Antidepressant Myth. The mythology that 
each author is referring to is the chemical imbalance theory, which has been promoted 
by pharmaceutical companies as a cause of depression. However, this fact has not 
been proven and Kirsch (2009) proposes that the theory depends on the efficacy of 
antidepressants. In fact, he argues that antidepressants are barely better than a 
placebo, and, therefore, the theory is incorrect.  
 
Thus far terms such as 'treatment' and 'antidepressant' have been used, however, as 
Moncrieff (2007) frequently highlights, the use of such loaded terms is far from 
unproblematic. The way in which drugs prescribed to treat mental health conditions 
are marketed has been covered extensively by Moncrieff. Moncrieff (2008) is critical 
of the disease-based view of pharmaceuticals, which conceptualises drugs as 
treatments or cures targeted at specific conditions or symptoms. Instead Moncrieff 
proposes a drug-based view of pharmaceuticals, which posits that psychoactive drugs 
create an ‘altered state’ rather than returning the body to a state of normalcy (Moncrieff 
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2008, p. 15). In support of this argument, Moncrieff (2008) notes that psychoactive 
drugs have the same effect on the brains of healthy volunteers as they do on people 
diagnosed with mental illnesses. Hence, although it is possible that the altered states 
generated by such drugs are beneficial for people with mental illness, this largely 
depends on an individual’s drug response and individual preferences. Whilst the drug-
based view offers an expedient framework through which to comprehend psychoactive 
drugs, terms such as antidepressant will continue to be used throughout this research 
due to the lack of succinct, widely understood alternatives. Furthermore, other terms 
with etymological baggage, such as ‘patient’ and ‘mental illness’ will also be used, 
again due to a lack of better alternatives (Moncrieff 2008, p. xi). 
 
Whilst Goldacre’s Bad Pharma provides an overview of the pharmaceutical industry 
as a whole, Greenburg’s (2010) ‘Manufacturing Depression’ focuses specifically on 
the role of pharmaceutical marketing in depression. As with ‘Bad Pharma’, 
‘Manufacturing Depression’ is also shaped, in part, by its author’s journalistic 
experience. Informed by a wide range of academic and non-academic sources, 
including medical journals, the Old Testament and personal experience, Greenburg 
(2010) exemplifies how knowledge of the social world is not solely limited to traditional 
academic sources, an outlook shared by Becker (2007) whose work will be discussed 
in more detail in the methods chapter.  
 
This research will therefore aim to investigate the expanding UK antidepressant 
market, by fusing together the socio-medical concepts of medicalisation and 
pharmaceuticalisation with business concepts and ideas around strategic marketing.  
 
Throughout this section, I have assessed the literature on pharmaceuticalisation, 
noting that authors from both medicine and sociology have identified that it is driven 
by the marketing practices of pharmaceutical companies. However, there is hitherto 
been no contribution to this literature by business or marketing scholars. Furthermore, 
there is a lack of awareness about the business dimension of pharmaceuticalisation 
within socio-medical literature. Consequently, there is clear opportunity for this 
research to introduce a business and marketing dimension to the discussion by 
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Having presented and discussed academic literature from a rage of disciplines on the 
ethical status of the marketing of pharmaceuticals, it is apparent that a polarisation 
exists within extant literature. Socio-medical literature written by medical authors 
concerns itself entirely with patient welfare to the neglect of the wider business context, 
as well as being criticised for the level of criticism directed at the pharmaceutical 
industry (Morgan 1984). Conversely, marketing literature represents only the interests 
of the pharmaceutical industry, and, as such, fails to engage fully with debates over 
the ethical status of marketing activities. The discipline of business ethics offers an 
alternative framework through which to consider the marketing activities of the 
pharmaceutical industry, by virtue of its acknowledgement of the dual obligations, or 
more accurately conflicting obligations, facing pharmaceutical companies.  
 
Therefore, this research aims to contribute to the field of business ethics, whilst 
drawing upon concepts established within other disciplines, such as medicalisation, 
pharmaceuticalisation, disease mongering/branding and the moral economy. 
Methodologically, the research draws upon the investigative approach of authors such 
as Goldacre, Watters and Elliot, as well as a wider body of non-medical investigative 
literature, which will be discussed in further detail in the following chapter. 
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3. Methods: An Investigative Social Science of Big Pharma 
 
3.1 Introduction 
As discussed in the literature review, an investigative methodology has been applied 
previously in research into the pharmaceutical industry. However, no research from a 
business ethics perspective has hitherto utilised this methodology. Therefore, this 
thesis aims to make a methodological contribution to knowledge in this area, by 
demonstrating how an investigate methodology can be expedient for business ethics 
research. Furthermore, the argument will be made that this methodology presents an 
exciting and dynamic opportunity for academic research more broadly, due to its ability 
to facilitate the exploration of important unexplored social phenomena.  
 
This chapter begins by delineating the nature of the research and outlining its principal 
aims. The ontological and epistemological underpinnings of the research will then be 
established. Given that the methodological approach utilised in this research is 
relatively novel, close attention will be paid to unpacking investigative social science. 
Finally, the chapter examines debates pertaining to its usage, before providing a 




The aim of this research is to explore the manifold ways in which the pharmaceutical 
industry has historically marketed, and currently markets, antidepressants.  
  
• Are the increased use of antidepressants and the increase in rates of 
depression linked, and, if so, how are they linked? 
• What methods have been used to market antidepressants, both historically and 
presently? 
• Are pharmaceutical companies using disease mongering and 
pharmaceuticalisation to promote antidepressants? 
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• How have the marketing practices of antidepressant manufacturers changed in 
the face of commercial and political challenges, such as scandals, regulations, 
and the impending patent precipice for blockbuster antidepressants?  
 
3.3. Epistemology/Ontology 
The nature of the social world, and what a social science researcher deems to qualify 
as knowledge of the social world, directly informs the methodology that one adopts as 
a researcher. The ontological and epistemological beliefs that underpin this research 
will now be elucidated. 
 
Epistemological debates are circular in the sense that we turn to knowledge to answer 
the question of what can or cannot be viewed as knowledge (Johnson and Duberley 
2000, p. 4). Whilst the circularity of this pursuit may thus appear trivial, C. Wright Mills 
noted that ‘Awareness of (philosophical debates of knowledge) enables us to become 
more conscious of our conceptions and our procedures’ (1959, p. 120). With this in 
mind, the following section delineates the epistemological and ontological 
presuppositions which have directly informed and coloured this research. 
   
The literature review identified that research into the marketing of methods of 
pharmaceutical companies invariably derives from one of five academic disciplines 
(sociology, medicine, anthropology, marketing or business ethics), each of which has 
its own epistemological and ontological conventions.  
 
Work published from a medical perspective tends to be informed by positivist 
epistemological assumptions, that draw upon the conventions of the natural sciences 
to establish causation. Marketing literature also has a positivist slant, albeit to a lesser 
degree than the medical literature. Marketeers, particularly those professionally 
involved in marketing, are inherently interested in the causal links between inputs and 
outputs, such as advertising expenditure and sales. Sociological literature tends to be 
more heterogenous, whilst the contribution from the discipline of business ethics is too 
scarce to draw out any meaningful inferences about epistemological trends. Overall, 
much of the literature on pharmaceutical marketing methods tends to come from a 
more positivist perspective, utilising quantitative methods to establish causation. 
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Whilst positivist research has provided manifold insights into the range of phenomena 
associated with pharmaceutical marketing methods, certain facets of the phenomena 
simply cannot be explored from this perspective. This is because, as Brigley notes, 
positivist research ‘fails to address the range of ethical nuances which may be at work 
in particular contexts’ (1995, p. 220). 
 
It is worth noting here that journalism itself is also experiencing epistemological 
tensions, akin to those which have existed in academia for decades. The emergence 
of 'data journalism' (Parasie 2014; Coddington 2015) had increased the popularity of 
positivism in a profession historically characterised by its interpretivist approach. Data 
journalism refers broadly to the practice of obtaining, analysing, and presenting 
quantitative data for journalistic purposes (Coddington 2015). Miller (2015) posits that, 
although data journalism offers many new opportunities for news stories, it is 
paramount that ethical guidelines are revised and re-established before such practices 
become commonplace. The sheer quantity and quality of information available via data 
journalism goes beyond the level of comprehension of the pre-existing understanding 
of journalism within society. Miller (2005) fears that perusing data journalism without 
revisiting ethics could compromise the future sustainability of journalism.  
 
Although, traditionally, the marketing of pharmaceuticals has been approached from 
a positivist perspective, the present research is informed by more of an interpretivist 
perspective. Interpretivism is described by Bryman (2012, p. 28) as being ‘concerned 
with the empathic understanding of human action’, rather than simply explaining it. 
More specifically, this research is informed by Giddens’ (1984) theory of structuration. 
Concerned with ‘neither the experience of the individual actor nor the existence of any 
form of societal totality, but by social practices ordered across space and time.’ 
(Giddens 1984, p. 2), structuration provides an expedient framework for considering 
the links between structures (e.g. ‘rules and resources’) and social systems (e.g. 
‘relations between actors or collectives’). When applied to this research, structuration 
enables the exploration of how depression and its treatments are and have been 
presented, with a focus on how this presentation is influenced by, and influences, 





Structuration is also favoured due to its dismissal of dualism, such as the kinds of 
epistemological divisions identified in extant literature. Rather, Giddens proposed that 
both structure and human agency should be seen as ‘mutually constitutive dualities’ 
(Giddens 1984, p. 28). As both structuration and interpretivism acknowledge the 
embeddedness of the researcher in any research, the social and cultural 
understandings of the researcher are drawn upon in this research to engage with the 
meaning presented in the documents and interviews (Giddens 1984; May 1994).  
 
Moreover, as well as existing within a social and cultural context, we also exist within 
an historical context. In other words, in the process of writing this I am making sense 
of my decisions by linking them to the ideas of thinkers who have gone before me. 
Hence, this methods chapter might have been completely different had it been written 
ten years ago or ten years in the future. History is thus inescapable and imbues every 
aspect of the research process. Of course, it is the ubiquity of history that causes it to 
be overlooked. We swim through it like fishes in water. However, Derek Layder makes 
the case for foregrounding history within social science research:  
Since the topic of history traces the changing norms of social behaviour 
and institutions over time, it is essential to incorporate such concerns 
in the strategies we use to conduct social research (Layder 1993, p. 6). 
 
For example, whilst a swastika in Germany in 1910 might have been recognised as a 
symbol of good luck, after its proliferation by the Nazi party, the symbol came to carry 
an entirely different meaning. Without an understanding of its contextual history the 
meaning of the symbol cannot be understood. Layder (1993) characterises social 
reality as interwoven and textured. That is to say, there are multiple levels and 
dimensions, all of which exist, and can only be understood, within the context of 
history. Layder uses an example of sexual harassment in the workplace to illustrate 
his approach:  
In order to understand what is involved in a particular instance of sexual 
harassment at work we have to be aware of how different macro and 
micro aspects combine to produce the specific instance. Thus, we must 
be aware of how macro elements like gender division operate in terms 




He argues that macro social forms are interwoven with all layers of social experience, 
and, as such, are inseparable. Hence, we cannot understand an interaction between 
two people in isolation from these macro factors, be it an instance of sexual 
harassment involving two colleagues, a meeting between a pharmaceutical sales 
representative and a doctor or, indeed, an interview with a psychiatrist conducted by 
a researcher. In each scenario, we must first understand the history of the context. 
Further to this, each layer, as demonstrated in Table 1, must be understood in relation 
to what has come before it.  
 
Table 1: Layder’s (1993) Research Elements 







Macro social forms (e.g. class, 
gender, ethnic relations) 
Setting 
Immediate environment of 
social activity (schools, family, 
factory) 
Situated Activity 
Dynamics of face-to-face 
interaction 
Self 




Layder (1993) places such importance on history that it becomes a method in its own 
right, which is how it will be considered in this thesis. A scenario such as a 
pharmaceutical sales representative promoting an antidepressant to a GP is heavily 
embedded in history: the history of the NHS; the history of the pharmaceutical industry 
and their relationships; the history of depression as an illness, and its various 
treatments; how stigma surrounding mental health and pharmaceutical treatments has 
changed historically. The historical legacy of SSRIs like Prozac is unavoidable when 
considering the marketing of current antidepressants. Layder’s (1993) history-centric 
methodology is therefore well suited to the study of antidepressant marketing. 
 
Although interpretivist ideas such as structuration (Giddens 1984) and Layder’s (1993) 
modern social theory are expedient approaches through which to approach the topic 
at hand, it is important to note that these approaches are not a panacea, and, indeed, 
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these approaches are not without their criticisms. As Kelliher (2011, p. 45) notes, whilst 
interpretive research is excellent for exploring context in great detail, it is often 
criticised for its lack of generalisability, validity and reliability. These arguments are 
usually made about the research methods and designs associated with an interpretive 
epistemology, and, thus, issues of research generalisability, validity and reliability will 
be discussed in more detail later in this chapter, along with how an interpretive 
epistemological framework influences one’s methodological choices. 
 
 
Ontologically, this research is based on the constructionist belief that the social world 
is deeply interconnected with social phenomena and that meaning is continuously 
constructed by social actors. Strauss et al. (1963) exemplified how this ontological 
perspective can inform research by examining the interaction of social entities in a 
medical setting. The research of Strauss et al. identified a ‘negotiated order’ (1963, p. 
308) between various professions at a psychiatric hospital, observing that ‘general 
understandings’ between doctors and nurses were consistently being revised, revoked 
and established. For the purposes of this research, this ontological perspective 
underpins the conceptualisation of the organisations involved in the marketing process 
of antidepressants and depression itself: The Royal College of Psychiatrists 
(RCPsych), The Royal Collage of General Practitioners, and pharmaceutical 
companies. Similar to the research of Strauss et al. (1963), these organisations are 
comprised of individuals who are responsible for defining and negotiating the meaning 
of depression within their organisation, and, in turn, for wider society.  
 
As discussed in the introduction chapter, this thesis does not evangelically adhere to 
a single overarching theory. Indeed, Billig (2013) laments the way in which PhD 
students are indoctrinated into a single theoretical perspective in a manner more 
motivated by politics than rigour. In contrast, a flexible theoretical approach allows a 
researcher to better answer a research question by engaging with the data and using 
theory only where it is useful and insofar as it contributes to understanding and 
meaning. Consequently, this research engages with ideas from across multiple 
disciplines, including business management, marketing, medicine, sociology and 
anthropology. Billig (2013) also purports that, as theoretical approaches evolve within 
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disciplines, they create ‘in groups’ within which academics can talk to each other and 
exclude outsiders. This research aspires to speak to multiple disciplines, contributing 
knowledge to both socio-medical literature and business management. A single, over-
arching theoretical perspective would thus reduce the utility of this research, rather 
than increasing it. 
 
3.4 Investigative Social Science  
Social scientists are not the sole practitioners of social science. This is an idea 
discussed in depth by Howard Becker in Telling About Society: 
My own professional colleagues – sociologists and other social 
scientists – like to talk as though they have a monopoly on creating 
such representations [of society], as though the society they produce 
is the only “real” knowledge about that subject. That’s not true… …That 
kind of talk is just a standard professional power grab. Considering the 
ways that people who work in other fields – visual artists, novelists, 
playwrights, photographers, and filmmakers – as well as laypeople 
represent society will show analytic dimensions and possibilities that 
social science has often ignored that might otherwise be useful (Becker 
2007, p. 6). 
Society is studied by people across professions, cultures and classes. Within 
academia, we invariably elevate the voices of traditional social scientists whilst 
overlooking those voices from outside of the academy. However, as Becker observes, 
‘their solutions to standard problems tells us a lot and opens our eyes to possibilities 
more conventional practice doesn’t see’ (2007, p. 7). One such profession which can 
tell us a lot about society, in addition to teaching us new ways of problem-solving, is 
journalism. 
 
Kutler famously described journalism as 'history with a 5pm deadline' (Kutler 1990 
cited in Feldstein 2004). Feldstein reiterated this sentiment suggesting that journalism, 
and his own academic discipline of oral history, are 'like kissing cousins, with similar 
family roots and genetic material, they are related but separate; and each has much 
to teach the other (2004, p. 5).  
 
This belief that journalism and traditional academic disciplines can mutually benefit 
from a degree of cross-fertilization underpins the methodology of this research: 
investigative social science. Whilst relatively unexplored in business research, 
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investigative social science is not a new methodological phenomenon. Rather, 
investigative social science has been discussed in academic literature for more than 
thirty years under the synonyms of investigative reporting (Levine 1980), investigative 
research (Ho et al. 2006) and investigative social research (Douglas 1976). 
 
Influenced by the techniques of journalism, investigative social science can be 
characterised as the naturalistic in-depth exploration of a phenomenon (Ho et al. 
2006). Ho et al. note that investigative social science ‘is particularly suitable for 
uncovering, understanding, and reporting social phenomena that may be hidden from, 
or not easily accessible to observers’ (2006, p. 17). It is this feature of investigative 
social science, that is, its usefulness in exploring otherwise hidden phenomena, that 
led to it being selected for this research. It was expected that this approach would both 
fit well with the subject matter, and generate insights unexplored by previous research, 
particularly within business schools. Examples of research which has successfully 
utilised this approach includes the work of Scheper-Hughes (Scheper-Hughes 
2001,2002,2004), who used an investigative approach to explore organ trafficking.  
 
Through facilitating the exploration of otherwise hidden phenomena (Ho et al. 2006), 
investigative social science can contribute to the broadening of academic debates. 
The field of management studies, in particular, has been acknowledged as paying 
scarce attention to contemporary political and social issues (Dunne et al. 2008). 
Furthermore, Dunne et al. (2008) found that an overwhelming proportion of 
management research fails to acknowledge the links between business and wider 
social phenomena, such as war, violence, migration and race. As Dunne et al. note:  
A more recent survey, looking at the top 20 journals in the field of 
business and management, revealed similar results. As the authors 
commented, this shows a ‘general state of myopia on the part of 
business and management scholars towards a variety of political 
issues, even making a virtue out of ignorance (Dunne et al. 2008, p. 
217) 
 
It was anticipated that through adopting an investigative approach, informed by 
structuralism, this research would be able to better explore the practices and impact 




Although there are benefits to using an investigative methodology, previous 
investigative social scientists have attracted criticism. Douglas’ ‘Investigative Social 
Research: Individual and Team Field Research’ (1976) was one of the first books to 
highlight a more conscious overlap between journalism and academic research. 
Although praised for its entertainment value, critics slated the book on both moral and 
technical grounds (Gold 1977). Douglas engaged in morally and ethically dubious 
activity throughout the book, most notably by misleading research participants and 
ignoring their requests for anonymity. Gold described Douglas’ book as ‘blood boiling’, 
and urged readers to view the book as ‘a curiously inept attempt at satire’ (1977, p. 
655). Critics suggested that Douglas values the moral status of ‘Truth’ above all else, 
and therefore sees ‘Truth’ as worthy of behaving unethically for. However, by behaving 
unethically, Douglas sabotaged his research field and made future research 
impossible. Whilst Douglas’ vigilante approach to truth seeking has a Batman-esque 
appeal, what Hollywood films and comic books do not show is the aftermath of such 
an approach. Broken windows must be repaired, and broken trust takes even longer 
to fix. However, none of the critics of Douglas’ book argued against the premise of 
combining investigative reporting and social science, rather it was his execution that 
was deemed problematic. Above all, both Douglas and his critics remind us of the 
importance of of good research ethics. The contentious relationship between ethics 
and investigative research will be discussed in more detail later in this chapter.  
 
3.5 The Limitations of the Journalistic Method 
To warrant the usage of such a methodology in business school research, it is 
important to note why traditional journalism and academic social science research do 
not make easy bedfellows, even though they are natural allies in many respects. In 
the literature review, it was argued that journalistic literature can provide interesting 
and useful insights, however, mainstream journalism also has its limitations. This 
section begins by establishing what constitutes journalism. The limitations of 
journalism will then be discussed, along with consideration of how journalism and 




Consisting of various forms of written, audio and visual content, journalism is a broad 
concept that is referred to simultaneously as an industry, a profession, a literary genre, 
and an ideology (Deuze 2005). Journalism occupies an exclusive role in society where 
it is seen to both act as a lubricant for democracy, and constitute an essential 
component of freedom of speech (Deuze 2005). As a result, some branches of 
journalism act as a watchdog for society. This is exemplified by investigative television 
programs such as BBC’s Panorama, which on numerous occasions has drawn 
attention to cases of malpractice with the intention of stopping the offending individual 
or organisation (Ware 2006; Chapman 2011; Rowe 2014). 
 
However, there is an argument which suggests that journalism is currently in a state 
of flux and is less capable of acting as a watchdog in society due to its commercial 
interests. The book ‘The Watchdog That Didn’t Bark’ explores the role of journalism in 
the financial crisis, specifically how journalists failed to alert the public ahead of time 
(Starkman 2014). Furthermore, whether journalism is even qualified to make such 
judgements about what is in the best interests of society is also subject to contention. 
There have been occasions in which the watchdog function of journalism has had 
unintended negative repercussions, such as when Panorama explored the notion of 
brain death altruistic organ donation falling across Europe (Matesanz 2003). 
 
The privileged status of journalism in society, as well as its limited external regulation, 
has also raised issues pertaining to ethics. Most notably, the hacking of murdered 
teenager Milly Dowler’s mobile phone in 2002, not to mention the phone hackings of 
numerous celebrities, exemplified how journalistic privilege can be abused. The ethical 
issues raised by an investigative methodology will be discussed in greater detail in a 
later section.  
 
Traditional journalism is also invariably limited by constraints, be it time constraints in 
the form of deadlines or air-time, or spatial constraints like word-counts and column 
inches. Moreover, traditional journalism is often encumbered by a responsibility to 
entertain. The commercialisation of journalism, whether in the form of advertising 
revenue, subscription fees or a standalone purchase price, has resulted in extensive 
criticism from some authors. Critics argue that the commercialisation of journalism 
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restrains investigative journalism, which, in turn, has negative implications for 
democracy (Barnett 2002; Waisbord 2013). Furthermore, journalism, by design, 
places an emphasis on headlines to the detriment of richness and contextual detail. 
Contrary to these criticisms, a research paper by Rolland (2006) found that 
commercial news criteria stimulated the production of high-quality investigative 
journalism in Norway, which had a positive effect on democracy in the region.  
 
Although the entertainment requirement has not been entirely absent in academic 
literature, this has diminished over time. Having said this, the recent promotion of the 
impact agenda encourages academic researchers to consider the marketability of their 
research findings (Martin 2011). This increased focus and reliance on the responses 
of readers to one’s research will most likely change the focus of academic research to 
some degree, however the exact nature of this change is hotly debated (Martin 2011; 
Smith et al. 2011; Gray 2015). However, as Marinetto (2015) notes, academics do 
have time allocated to pursue research, and possess a skill-set which lends itself to 
such investigations. Therefore, Marinetto (2015) makes the argument that academics 
are the perfect candidates to take up the mantel of investigative inquiry. 
 
Commonly referred to as reporting, traditional journalism involves limited analysis, 
principally dedicated to describing findings to the audience, and perhaps drawing links 
to previous news stories or potential repercussions. However, when conducting 
academic research informed by the methodology of investigative journalism, greater 
scope exists for in-depth analysis. Findings can be explored and presented with 
reference to existing research, models and theories, thus going beyond simple 
description by weaving them into the fabric of extant knowledge.   
 
To develop the skills required to put such a methodology into practice, I attended four 
days of training with the Centre for Investigative Journalism (CIJ) in London. I took part 
in workshops such as ‘Investigating Corruption’ with Financial Times correspondent 
Tom Burgis, ‘Analysing Social Media’ with citizen journalist Eliot Ward Higgins, 
‘Interactive Storytelling’ with Sandra Gaudenzi from !F Lab, and ‘Story-Based Inquiry’ 
with Mark Lee Hunter. In addition to this, I attended two training days at the Cardiff 
School of Journalism where I shadowed students conducting their own investigations. 
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The training I engaged in granted me exposure to various kinds of investigative 
journalism. Investigative social science is a hybrid of social science and journalism, 
and, as demonstrated by Douglas (1976) and Levine (1980), the combination can vary 
from case-to-case. Workshops attended at the CIJ enabled me to pick between the 
various methods and approaches and decide which specific aspects of investigative 
journalism to incorporate in the research. Whilst I was inspired by the work of every 
presenter, my own mix of investigative social science is predominantly inspired by the 
work of the journalist, Mark Lee Hunter. Hunter (2011) uses an investigative approach 
to write organisational case studies without access. He uses his position as an outsider 
to his advantage, refusing access arrangements even when they are offered to retain 
his freedom and independence. Hunter’s brand of investigative journalism is known as 
‘Story-Based Inquiry’, and offers a model for analysing data gathered using narrative 
hypothesis testing. Data is organised in terms of potential narratives which then 
become hypotheses. These hypotheses are then tested by gathering further data, 
including data which could nullify the hypothesis. Hunter’s (2011) Story-Based Inquiry 
appealed to me because of its established track record in investigating businesses, as 
well as the clear, prescriptive nature of the approach. 
 
Whilst academia currently has no way of acquiring the special status which makes 
certain forms of journalism possible, in the same way that journalism can and is 
befitting from incorporating aspects of academia, academia can learn from journalism. 
For example, the journalistic ethos of serving society strongly resonates with C. Wright 
Mills’ (1959) depiction of the public intellectual. Although occasionally accused of 
being insular and out of step with contemporary issues (Dunne et al. 2008), 
incorporating journalistic inquiry into academia increases the range of topics available 
for research, including issues of immediate social consequence. Evidence of how such 
an approach can allow academics to engage with issues of social significance can be 
found in Jenkins and Blyton’s (2017) investigation into the garment manufacturing 
industry in India.  
 
This research utilises these ideas to address a topic with broad social relevance which 
has hitherto been neglected within business research. Moreover, by using an 
investigative approach, the power imbalance and issues associated with accessing 
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large, and seemingly impermeable, companies are diminished. For example, without 
the need to negotiate formal access, I do not need to fetter my results to appease 
industry gatekeepers. I also embrace a journalistic approach in the writing of this 
thesis. Another area in which journalism excels is in its ability to communicate to a 
broad audience. In contrast, academic writing is often accused of being overly 
exclusive, using jargon to alienate those outside of the discipline (Billig 2013). 
Therefore, in this thesis I try to write in a way which is understandable and free from 
unnecessary jargon in order to be understood by the legions (couple) of people who 
will read it. I also occasionally use poor attempts at humour and pop-culture references 
to slightly increase the readability of this beast. 
 
3.6 Methods 
Investigative journalist Bob Woodward (Woodward 2006,2012b,a,2013) notes that 
there are three ‘tracks’ to journalistic enquiry. The first, and most commonly used, is 
interviews. The second, which Woodward argues is currently underused, is 
documentary research. The final track is a form of casual observation. Woodward 
(2006) notes that facts can often be calibrated by physically going to locations, an idea 
which resonates with the present research.  
 
Drawing upon the work of Woodward and informed by the work of academic theorists, 
this research relies predominantly on interviews and documentary analysis. 
Woodward’s third track was also acknowledged, with findings calibrated along the way 
through the incorporation of tangible factors such as locations.  
 
There is a dearth of qualitative research on pharmaceutical marketing. Quantitative 
research has been integral to identifying the impact of traditional marketing activities 
upon prescription (Wilkes et al. 2000; Gönül et al. 2001; Campo et al. 2006). However, 
for this research it was decided that qualitative methods would allow for a richer 
exploration of the power dynamics between social actors involved in the marketing 
process.  
 
When outlining the epistemological and ontological underpinnings of this research 
earlier in this chapter, I used the work of Derek Layder (1993) to emphasise the 
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importance of history. Layder (1993) stressed that history permeates all layers of the 
research process, which is to say that every aspect of an investigation exists within an 
historical context. Therefore, research into a phenomenon should include an 
exploration of the histories of its component parts. Layder (1993) argues that history 
should be perceived as a method in its own right. In agreeance with this argument, I 
include findings chapters in this thesis which draw entirely on historical data. This 
section will outline the methods I used to collect data for this thesis. It begins by 
outlining the rationale for selecting interviews as the method of data collection, before 
proceeding to explain who was interviewed and how they were interviewed. Each 
interview included questions relating to the history of the person and their experiences 
of the broader landscape of antidepressant marketing. I then go on to describe the 
portion of my data which most encompasses Layder’s (1993) agenda: documents.  
 
3.6.1 Interviews 
Abraham and Reed (2002) use an investigative approach to recruit interview 
participants. The paper focuses on the politics of drug development regulations. 
Therefore, like this research, the paper examines the pharmaceutical industry and its 
attendant complex structures. Although they do not explicitly name their approach an 
investigative methodology, they do describe it as such in the methods section. 
Referring to participants as ‘informants’, the authors note that each respondent was 
selected on the basis of the expertise they were expected to hold. The paper also opts 
for an investigative lilt when describing the process of fact-checking claims. Similar to 
Story-Based Inquiry (Hunter 2011), the authors partook in a version of hypothesis 
testing to identify potential truths. In so doing, Abraham and Reed (2002) testify to how 
an investigative approach is useful for researching the pharmaceutical industry.  
 
My own approach to conducting interviews was heavily influenced by Abraham and 
Reed’s (2002) research. Respondents were selected for their specialist knowledge 
and expertise, and, due to the lack of transparency within the industry, this was 
prioritised above recruiting either a random or representative sample. For this reason, 
following the example set by Abraham and Reed (2002), I will also refer to participants 
as informants throughout this thesis. In so doing, I hope to emphasise the value of the 
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information each person provided me with, in the context of an industry renowned for 
its secrecy. 
 
Interviews took place with a variety of respondents, including general practitioners, 
pharmaceutical industry employees, and industry critics. Respondents were given 
information sheets about the research in advance, and, prior to being interviewed, 
given time to decide if they wanted to take part in the research. Upon deciding to be 
interviewed, participants were then asked to sign a consent form. For those 
respondents who were unable to be interviewed in person, phone or video chat 
interviews were conducted. In the case of these interviews, consent to record the 
conversation was a prerequisite. This was explained to respondents in the information 
sheet and reiterated via email prior to the phone interview. Verbal consent was then 
obtained and recorded verbally prior to the interview commencing. 
 
Due to the investigative nature of the research, interviews differed in terms of length, 
tone, and the questions asked, as per the style of interview described by Gilbert (1994, 
p. 136) as ‘non-standardised’. The interviews were thus treated as ‘guided 
conversation(s)’ where the objective was ‘find out what kinds of things are happening’ 
(or have happened) ‘rather than to determine the frequency of predetermined kinds of 
things that the researcher already believes can happen’ (Lofland 1971, p. 76). Whilst 
the non-standardised technique was mainly selected because of its practicality, it was 
also selected for its ability to facilitate discovery (Gilbert 1994, p. 136), which is 
conducive with the investigative approach. Furthermore, this style of interviewing  has 
also been deemed suitable for addressing complicated or sensitive subject matters 
(Gilbert 1994, p. 138). 
 
All interviews were semi-structured, comprising a list of questions and topics 
generated ahead of time based on previous findings. However, questions would be 
freely added or omitted based on respondents’ answers.  
 
Mulinari (2013) argues that academics frequently depict the pharmaceutical industry 
as ‘omnipotent controllers of drug markets’, thus overlooking the role of other 
stakeholders. In a 2013 paper, Mulinari presents a more optimistic perspective, 
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exploring how various stakeholders engage in activities which inhibit 
pharmaceuticalisation. Mulinari’s (2013) work exemplifies the complex nature of the 
wider pharmaceutical marketplace. Comprising multiple stakeholders, the 
antidepressant market retains this complexity; hence, multiple stakeholder groups 
have been interviewed for this research. 
 
Pharmaceutical Industry Employees 
Eight pharmaceutical industry employees were interviewed for this research. Each of 
these informants had experience in marketing roles. All informants had worked as Key 
Account Managers, previously known as PSRs or ‘drug reps’. Other roles they worked 




In the UK, it is illegal to advertise prescription drugs directly to consumers. Therefore, 
in most cases, healthcare professionals are the target audience for advertising 
materials. Healthcare professionals were thus the largest group interviewed. Ten of 
these informants were contacted using the Disclosure UK database published in June 
2016. This database lists the payments made to healthcare providers and 
organisations in 2015. The database contains over 50 thousand entries and thus 
relevant healthcare professionals were selected by searching for payments from 
companies which were working on an antidepressant at that time. Eight of these 
healthcare professionals had done consultancy work for several different 
antidepressant manufacturers, and can also be considered as KOLs within the 
industry.  
 
Medical Public Relations (PR) Agency Professionals 
Medical PR agencies play a key role in the marketing of pharmaceuticals, particularly 
in terms of launching new products. Traditionally, PR agencies liaised with the press 
to protect, enhance or build their reputation. In the pharmaceutical industry and 
broader healthcare industry, PR encompasses a broad range of activities, including 
educational services. For this reason, PR consultancy and healthcare communications 
can in some cases be interchangeable (Elliot 2004). Furthermore, (Brezis 2008, p. 86) 
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suggests that public relations agencies can play in important role in the phenomena 
of disease mongering.  
 
Patient Groups 
Patient groups are organisations, often charities, who claim to provide support for 
patients suffering from a specific condition or type of condition. In this case, patient 
groups may be depression specific, or more broadly concerned with mental illness. 
Patient groups are of interest in that they produce information documents, run disease 
awareness campaigns, and, more generally, provide a key source of information for 
patients and the public. An ongoing debate around patient groups concerns the status 
of pharmaceutical funding. Within the depression/mental health cohort of patient 
groups, there is a split between organisations who do receive pharmaceutical funding 
and those who refuse such donations. Patient groups proved the most difficult to 
access for this research, however one interview eventually took place with an 




The ethical status of the pharmaceutical industry is a contentious subject which 
provokes lively public debate. As discussed in the literature review chapter, there is 
an emergent body of journalistic books commentating on the activities of the 
pharmaceutical industry. The authors of these publications also engage in debates via 
blogs, newspapers and public talks. Whilst the authors of these books are 
professionals whose careers are closely intertwined with their views, there is also a 
community of more casual commentators. These individuals often run blogs in their 
spare time, where they comment on industry news as it arises, along with conducting 
their own online investigations. 
 
Patients 
Individuals who have personally experienced depression were not sought out on 
ethical grounds. However, due to the prevalence of depression, two of the individuals 
interviewed can be considered as dual-stakeholders. That is to say, as well as 
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belonging to one of the categories above, they also had first-hand experience of 
depression and its treatments and chose to discuss their experiences in the interviews. 
 
3.6.2 Conducting Interviews 
Ultimately, I was able to interview 45 informants, amounting to over 50 hours of 
recorded data. Informants were selected based on the  specialist knowledge they were 
expected to have, inspired by Abraham and Reed’s (2002) selection method. The first 
interview took place in May 2015, whilst the final interview occurred in December 2016. 
Over the course of 19 months, I conducted interviews at an approximate rate of one 
every two weeks. Throughout this time, recruiting and interviewing informants was a 
full-time job. I used a snowball sampling approach, asking informants for further 
contacts and recommendations of who to approach next. However, every snowball 
must have a beginning, and this proved to be extremely difficult and time-consuming. 
I mined my social circle for contacts, trawled blogs, books and journal articles for 
names which may be helpful. The most difficult category to find informants from was 
the charity sector. Lack of full time staff was pointed to as a reason charities could not 
speak to me. Eventually one informant from a charity agreed to be interviewed after I 
searched for them on Companies House and contacted them via their company. 
Fortunately I gathered hundreds of documents on charity activities, including company 
accounts, leaflets and internal documents which compensated for the lack of interview 
data from the sector. 
 
Although my informants were diverse in terms of their relationship to the 
antidepressant marketing process, they tended to share two key characteristics: they 
were all very intelligent, and very busy. These two factors dominated our pre-interview 
discussions. Most informants had an intimate relationship with research, having either 
conducted it themselves, and/or spent their careers critiquing and applying the 
research of others. Therefore, to gain the trust of these experts I often had to engage 
in detailed discussions about my methodology, research questions and previous 
research experience. On three occasions, I sent prospective informant’s copies of my 
Masters dissertation as part of this ongoing discussion. Fortunately, and reassuringly, 




Once the individual agreed to be interviewed, the process of arranging a date and time 
began. Due to the busy schedules of informants, this was a process that could take 
months at times. One psychiatrist had to reschedule six times, whilst a GP would only 
find the time to be interviewed if I were able to pay them. When I explained that I did 
not have ethical approval to pay informants, they responded that I should approach a 
pharmaceutical company for money, so that I would be able to pay them. Needless to 
say, the interview did not go ahead. Typically, there was a month between the 
individual agreeing to be interviewed and the interview itself taking place. The record 
was a pharmacist with whom it took nearly nine months to identify a suitable date.  
 
Although finding and negotiating with informants was at times a taxing process, it was 
also extremely valuable and illuminating. I learned from Becker (2007) that everything 
tells us something. From these discussions with informants, I learned about their 
particular relationship with data, their reservations in discussing such a sensitive topic, 
and gained insight into their day-to-day lives. All of this informed my understanding of 
what Layder (1993) refers to as macro research elements. Table 2 below provides a 
brief overview of my interview data, whilst a more comprehensive table about the 
informants can be found in Appendix A. 
 
Table 2: Table of Informants 
Title No. 
Charity 1 
Industry Commentator 3 
Medical PR 5 
Pharmaceutical Sales Rep 8 








3.6.3 Documentary research 
Just as Woodward (2006) noted that documentary sources are rarely used to their full 
capacity in journalism, Atkinson and Coffey (2004, p. 56) ‘urge qualitative researchers 
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to pay proper attention to the forms and functions of such documents’. Documentary 
sources allow the researcher to examine the past and reflect on contemporary issues 
(May 1994, p. 1340). Furthermore, The International Consortium of Investigative 
Journalists (ICIJ) strongly favour documentary research as a key weapon in their 
investigative armoury (ICIJ 2018). Atkinson and Coffey (2004) purport that 
documentary research is best conducted from somewhat of an interpretivist 
epistemological standpoint. Therefore, documentary research was also selected as a 
method, in part, due to its synergistic relationship with the identified epistemological 
and ontological standpoint of the research.  
 
Organisations by their very nature generate hordes of documentary evidence, some 
of which is in the public realm and some of which is private. Marketing actively 
produces documents, and given that marketing was the focus of this research, 
documentary research was selected as an essential part of the investigative process. 
 
Documents are not neutral (Atkinson and Coffey 2004). As documents are often 
intrinsically biased by design, some may argue that they should be dismissed as 
corrupt data. Atkinson and Coffey (2004, p. 68) note that documents, like all other texts 
and utterances are ‘recipient designed’, and, as such, reflect assumptions about the 
intended audience. With respect to this research, the biased nature of documents is 
beneficial, and is viewed as a feature as opposed to a bug. The meaning of documents 
is shaped by many factors, including the status of the author, the historical context, 
the status of the perceived audience, and the intended function of the document. Such 
features are therefore being logged and extensively considered, which adds to the 
richness of the data gathered and subsequent analysis. Again, as noted by Becker 
(2007), everything tells us something. Hence, while an antidepressant advert may not 
provide an unbiased depiction of depression, it could still prove extremely helpful in 
identifying the marketing messages that the company has chosen to promote. 
Furthermore, attention should also be paid to what documents leave out, because, as 
(May 1994, p. 138) notes, what is not said can sometimes be more telling than what 
is. May’s (1994) point takes on particular relevance within this research when 




Documents were gathered throughout the entirety of this project. From very early on 
in the process, I would spend hours on end sat at my computer trying to understand 
at the most basic level how the industry operated. By the end of my data collection 
period in December 2016, I could identify and track down a specific document with the 
precision of a millennial looking for their partner’s ex’s private Instagram pictures.   
 
Through shadowing journalists at the Cardiff School of Journalism, I learned how to 
submit effective Freedom of Information Act (FOIA) requests. The FOIA provides the 
public with access to information held by public organisations. To increase the 
likelihood of being successful, a FOIA request must be specific in describing the data 
requested. In this research, FOIA requests were particularly useful for gaining access 
to the breakdown of a charity’s financial accounts. Such information was not available 
via the charity commission website, and not published publicly by the charity in 
question (Depression Alliance (DA); therefore, gaining access to these accounts via a 
FOIA request allowed me to identify the exact financial value of payments made to the 
charity by various antidepressant manufacturers.  
 
I gathered historic documents from three physical archives: The Royal College of 
General Practitioners (RCGP), RCPsych, and Cardiff Central Library. Additionally, I 
obtained documents from online archives and databases: The Daily Mail, The 
Guardian/Observer, AdPharm, The Prescription Medicines Code of Practice Authority 
(PCMPA), Disclosure UK, and the Drug Industry Document Archive (DIDA). Overall, 
my documentary data gathering resulted in a diverse collection of nearly 500 
documents, including media coverage, legal proceedings, journal adverts, leaflets, 
internal memoranda and emails. These documents were gathered and analysed in 
tandem with the process of contacting informants and conducting interviews, as 
outlined by Hunter’s (2011) ‘open source strategy’ which will be discussed in more 
detail in the following section. 
 
3.7 Issues Related to Good Research Practice 
I made a timetable at the very beginning of my PhD journey. A line of boxes plotting a 
seamless journey from gathering literature, to gaining ethical approval, to writing up 
and submitting. As alluded to by various self-proclaimed PhD ‘survival’ guides (a term 
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which makes light of the poor mental health often experienced by PhD students), 
progress did not occur along a linear path.  
 
This section presents an honest account of the practical barriers which, at times, called 
into question whether the research could be completed. The centuries-old Japanese 
art of Kintsugi involves repairing broken ceramics with precious metals. The golden or 
silver lines draw deliberate attention to the cracks, whilst, simultaneously, 
strengthening the artefact. Similarly, in this research the stress points were galvanised, 
and, ultimately, provided support for the investigative approach of the thesis. 
3.7.1 Ethical approval 
Gaining ethical approval forms an essential part of any research project involving 
human participants. As the proposed research involved semi-structured interviews, 
more specifically interviews with NHS employees, ethical approval was paramount. 
Due to the intention to interview NHS employees, it was identified early on that there 
may be cause to apply for NHS ethical approval. The first step in establishing whether 
NHS ethical approval was required involved determining whether the proposed 
research was classified as research according to the guidelines of the NHS. One of 
the criteria for research is that it should be generalisable. Due to the methodology 
used in this particular study, it was uncertain whether the results would be 
generalisable, and so further clarification was sought from various staff at the health 
board, university ethics committee, and the National Institute for Social Care and 
Health Research (NISCHR). 
 
Once it had been established that the study constituted research, the application 
process to gain approval from the NHS ethics committee and NHS research and 
development approval began. The application involved, amongst other things, an 87-
page long online form with questions such as ‘What is the primary outcome measure 
for the study?’ and other questions with either multiple choice options or numerical 
tick-boxes. Due to the investigative methodology employed in the research, many of 
the questions were impossible to answer in an honest and accurate manner. This is 
because the privileged societal role occupied by journalism means that practices are 
subject to very little external regulation, as any regulation can be viewed as a threat to 




The friction between journalistic research and ethical approval bodies, particularly 
health boards, has been extensively documented by Australian researchers (Rolland 
2006; Bacon 2007; Davies 2011a,b). These authors emphasise the importance of 
such research, but lament that bureaucratic organisations are ill-equipped to deal with 
ethical approval requests from these types of research.  
 
In the case of this research, the investigative, qualitative methodology clashed with 
the strict, regimented expectations of the NHS process. The NHS deals with 
applications for clinical trials, research involving human tissue samples, genetics, and 
vulnerable individuals, and therefore a rigorous ethical approval process is vital and 
should be commended. However, the NHS is currently missing an ethical approval 
avenue for investigative, qualitative research. 
 
After many emails, on the advice of the university NHS ethical approval advisor and a 
representative of the health board, it was noted that if the research did not involve 
recruiting participants via NHS institutions then a favourable opinion from the NHS 
ethics committee and NHS research and development approval was not needed. This 
left only the standard business school ethical approval to be obtained. Although in the 
case of this research a loophole was identified that meant that the project did not need 
to go through full NHS ethical approval, this does not negate the fact that the current 
system is not adequately equipped to deal with applications using an investigative 
social science methodology.  
 
3.7.2 Access 
Originally, efforts were made to gain access to a pharmaceutical company directly to 
interview key personnel.  However, after sending many emails and making many calls, 
it was established that this may not be possible. Pharmaceutical giants are highly 
taciturn organisations, and difficulties in gaining access are a common experience of 
many researchers studying the pharmaceutical industry and other powerful 
organisations. In this case, the initial setbacks in terms of gaining access to a 
pharmaceutical company only served to reinforce the investigative methodology of the 
study. The vast power imbalance between researcher and company, whilst resulting 
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in many ignored emails, also established the research as a prime area in which to use 
investigative social science (Ho et al. 2006).  
 
Instead of gaining traditional access via the organisations themselves, I adopted an 
‘outward-in’ approach favoured by Hunter (2011). Rather than beginning my 
investigation within the metaphorical and physical boundaries of an organisation, I 
instead began by drawing upon the masses of freely accessible information. I signed 
up to mailing lists which were popular among various stakeholder groups. I gathered 
newsletters, press releases and read forum posts. We live in an age where companies 
are continuously disseminating information via social media platforms, so I followed 
organisations on Twitter and YouTube. The privilege of conducting my research within 
Cardiff Business School was that it afforded me access to other sources via paid-for 
services, such as Lexis-Nexis, Mintel and FAME. When I was initially denied formal 
access to the organisations I was studying, I was disappointed and unsure as to how 
to proceed with my investigation. However, Story-Based Inquiry allowed me to focus 
on the sources I did have access to, rather than those I did not. My investigation 
ultimately followed what Hunter (2011) refers to as an ‘open source strategy’, which is 























This chapter has presented the methodological approach adopted in this research, 
and the theoretical and practical considerations which supported its selection. An 
investigative methodology was adopted for this research due to the inherent power 
imbalance and perceived lack of transparency present in the pharmaceutical industry. 
Formal access was denied and so an investigative methodology informed by Hunter’s 
(2011) Story-Based Inquiry approach was chosen.  
 
I have outlined how I collected data through conducting interviews and collecting 
documents. Additionally, through drawing upon the work of Layder (1993), I have 
emphasised the importance of historical context, and explained why history will form 
an integral part of the findings chapters. The following chapter is emblematic of this 




















4: The Historical Anatomy of Depression 
 
4.1 Introduction 
As emphasised by Layder (1993), each intertwined layer of social reality can only be 
understood in relation to its historical context. Beyond simply serving as a short 
introduction or a footnote, Layder (1993) considers the analysis of history to be a 
method in and of itself. It requires data collection and analysis, which, in turn, 
influences our analysis and understanding of more contemporary research issues. 
Thus, in accordance with Layder (1993), historical research has been adopted formally 
as a method in this thesis. Both this chapter and the proceeding one are findings 
chapters. Rather than simply describing the past, then, primary and secondary 
sources of historical data have been analysed to explore the relationship between 
symptoms of low mood and the treatment of such a condition. In doing so, a trend 
emerges in which the conditions that are related to low mood, are constantly defined 
by those who claim to be capable of curing it. The problem is thus framed to fit the 
solution. This finding is revisited throughout the thesis as it permeates all aspects of 
the research. 
 
This chapter, the first of two historical chapters, focuses on the history of depression 
as a diagnosis. Prior to the coinage of the term depression, other terms such as 
spleen, nerves, bile, hypochondriasis, fits, hysteria and being ‘down in the dumps’ 
have been used to describe symptoms which we may today associate with depression 
(Rousseau 2000). Historical figures, such as Vincent Van Gogh (Blumer 2014) and 
John Keats, are said to have suffered with this condition. Indeed, works such as Van 
Gogh’s Sorrowing Old Man (1890) and Keats’ ‘Ode on Melancholy’ (1819) are pointed 
to as expressions of the artists’ inner turmoil. Van Gogh and Keats are just two 
examples of individuals who experienced depressive symptoms long before Prozac 
hit the market. The purpose of this chapter is to emphasise that depression has not 
always been framed as a pharmaceutical issue. In fact, the pharmaceutical industry’s 
involvement in symptoms of low mood is relatively recent and has contributed to the 
shift towards understanding depression as a medical diagnosis. Moreover, the notion 
that the these conceptual changes in the diagnosis of depression are a response to 
the prevailing treatment is not a novel one. Rather, this chapter presents the argument 
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that depression has consistently been framed by those who claim to hold the answer 
throughout history. This, in turn, helps them to market and sell a treatment. 
 
Diagnoses are ‘socially bound’ (Ali et al. 2010). Because of this, diagnoses do not 
remain stable across time or cultures. Due to the socially bound nature of diagnoses, 
the definition of depression and its predecessors have changed over time. Both this 
chapter and the following one present a genealogy of depression and trace its 
historical evolution as occurring in parallel with changes in the treatments available. 
This chapter presents the history of depression in relation to its treatments prior to the 
involvement of pharmaceutical companies. Firstly, I delineate the history of conditions, 
such as melancholia and acedia, which spans across most of the last two millennia, 
with reference to the role of the church as the primary mode of treatment during this 
period. Depression in the age of psychoanalysis (early 20th Century) will then be 
discussed, highlighting how the diagnosis changed in response to the work of 
psychoanalysts like Freud. 
  
It is important to acknowledge that what follows, with the exception of early 
Christianity, is primarily a Western-centric history of depression. This is not because 
Westerners have a monopoly on depression or the symptoms associated with it; 
rather, throughout history, across the globe there have been interesting and 
compelling attempts to make sense of these symptoms and experiences. However, 
due to spatial and time constraints, and for clarity’s sake, Western interpretations have 
been foregrounded in this thesis.  
 
4.2 Pre 19th Century 
Accounts of extreme low mood predate the coinage of the term depression. 
Throughout history, examples exist of individuals for whom persistent low mood had 
a profoundly negative impact upon their lives. If such individuals were alive today, then 
they would likely be diagnosed with depression. However, depending on their social 
and historical context, these figures instead may have received a diagnosis of 
melancholia or acedia. This section will explore pre 19th Century understandings of 
low mood. I will examine the diagnoses of melancholia and acedia and illustrate how 




4.2.1 1600-1700s: The Church and Marketing the Melancholia Cure 
The historical diagnoses which most closely relate to the modern diagnosis of 
depression are melancholia and acedia. Melancholia is considered by Rousseau 
(2000) and most authors in the field (e.g. Jackson 2008; Leader 2008b) as the primary 
precursor to modern depression. A combination of the words melas, meaning black 
and kholé, meaning bile, the word melancholia came about when the Four Humours 
theory of medicine rose in popularity around 400 B.C. The Four Humours theory 
suggested that there were four liquids in the body, and an imbalance of these (which 
everyone had) led to various conditions, ailments and temperaments. Melancholy was 
considered one of the four temperaments associated with these humours. As 
melancholia during this period was defined not by symptoms but by a common cause, 
(an excess of black bile, which could not actually be proven or measured), melancholia 
had a wide range of symptoms from the psychological to the physical. Although the 
condition was broad, Hippocrates noted that in most cases an excess of black bile led 
to feelings of fear, sadness, despondency, sleeplessness, aversion to food and 
irritability, all of which are symptoms we would now equate with depression (Jackson 
2008; Telles-Correia and Marques 2015).  
 
Each humour could be characterised as either wet or dry or warm or cold. It was 
believed that an excess of one humour could be treated by exposing oneself to the 
opposite characteristics of that humour. Thus, if black bile was associated with the 
qualities of being cold and dry, then the treatment for an excess of black bile could 
involve spending time somewhere warm and wet, such as relaxing near a lake. 
 
The term melancholia persisted over the following millennia. Due to the socially 
constructed nature of labels, nuances surrounding the term’s usage changed during 
this time; however, many of the core features of the condition remained the same. The 
following extract from John Keats’ Ode to Melancholy (1819) paints a picture of the 
many symptoms that characterise the condition, which should be familiar to a modern 




‘No, no, go not to Lethe, neither twist 
Wolf's-bane, tight-rooted, for its poisonous wine; 
Nor suffer thy pale forehead to be kiss'd 
By nightshade, ruby grape of Proserpine; 
Make not your rosary of yew-berries, 
Nor let the beetle, nor the death-moth be 
Your mournful Psyche, nor the downy owl 
A partner in your sorrow's mysteries; 
For shade to shade will come too drowsily, 
And drown the wakeful anguish of the soul.‘ 
 
In writing this poem, Keats was influenced by the iconic book Anatomy of Melancholy 
by Oxford don and Church of England incumbent, Robert Burton (1857). First 
published in 1621, but subsequently revised and added to over the course of Burton’s 
lifetime, Anatomy of Melancholy is part medical textbook, part self-help book and 
completely genre defying. Burton drew upon vast readings from contemporary and 
historical literature, in addition to his own experience of melancholia, to define the 
condition and its symptoms, causes, and treatment. Moreover, Burton acknowledged 
that one of the reasons why he wrote, and continued to rewrite the book, was simply 
to distract himself from his own melancholia. Anatomy of Melancholy, as the title 
suggests, carefully dissects the condition over the course of anywhere from 600 to 
2000 pages depending on the edition. Burton’s unrelenting quest to understand and 
explain the condition makes it near impossible to discuss melancholia without referring 
to his work. 
 
In one passage Burton defines melancholy as follows: 
Melancholy, the subject of our present discourse, is either in disposition 
or in habit. In disposition, is that transitory Melancholy which goes and 
comes upon every small occasion of sorrow, need, sickness, trouble, 
fear, grief, passion, or perturbation of the mind, any manner of care, 
discontent, or thought, which causes anguish, dullness, heaviness and 
vexation of spirit, any ways opposite to pleasure, mirth, joy, delight, 
causing forwardness in us, or a dislike. In which equivocal and 
improper sense, we call him melancholy, that is dull, sad, sour, lumpish, 
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ill-disposed, solitary, any way moved, or displeased. And from these 
melancholy dispositions no man living is free, no Stoic, none so wise, 
none so happy, none so patient, so generous, so godly, so divine, that 
can vindicate himself; so well-composed, but more or less, some time 
or other, he feels the smart of it. Melancholy in this sense is the 
character of Mortality... This Melancholy of which we are to treat, is a 
habit, a serious ailment, a settled humour, as Aurelianus and others 
call it, not errant, but fixed: and as it was long increasing, so, now being 
(pleasant or painful) grown to a habit, it will hardly be removed. (1857, 
p. 93) 
 
From this, we learn that melancholy is the opposite of joy, that it can affect anyone, 
that it can be transitory or fixed, and that it is a response to grief or a serious ailment. 
Burton (1857) presents many contradictions throughout the book; for example, sex 
can cause melancholia in some people but cure it in others, being around other people 
is important for treating melancholia in some, whereas reading and writing alone can 
help other people. Rather than detracting from Burton’s (1857) characterisation of 
melancholia, these contradictions deepen the understanding of the reader. What 
Burton (1857) presents is a condition with a highly individualistic path. There is no 
single universal panacea presented because there are so many types of melancholia 
(including one which primarily affects scholars working alone on a large piece of 
work…), which present differently in different people and whose symptoms are 
alleviated by different things.  
 
Due to the socially mediated nature of diagnoses, the meaning of the term melancholia 
has shifted over the course of the two millennia that it has been in usage. However, in 
both Hippocrates’ four humours conceptualisation of melancholia, and Burton’s 
understanding which draws upon several theories, there is an underlying belief that 
melancholia treatment should be individualised. Burton (1857) notes that more sex 
may cure one person, whilst causing melancholia in another. The balance of the other 
three humours, in addition to how the imbalance presented in terms of symptoms, 
influenced how an excess of black bile should be treated. This idea persisted over the 
course of the millennia in which melancholia was in common-usage. Melancholia has, 
to some extent, remained part of the common lexicon (The Smashing Pumpkins’ 
seminal album on ‘the human condition of mortal sorrow’ (Daher 1998): Mellon Collie 
and the Infinite Sadness was released in 1995). However, the term has largely been 
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eclipsed today by depression which, as will be explored in the following chapter, has 
coincided with a less individualised approach to treatment. 
 
The genealogy of human beings points to several ancestors and cousins. Similarly, 
aspects of modern depression cannot only be seen in the conditions of melancholia 
and hysteria, but also in acedia (Jackson 1986). Also referred to as accidie, accedie 
and acedy, early conceptualisations of acedia characterise it as being separate from 
sin. Instead, it is characterised as more of an occupational hazard for Monks, Hermits 
and desert dwellers. Whereas melancholia is defined primarily by emotions, acedia 
also focuses on behaviour. That being said, comparisons between the two have 
consistently been made, particularly throughout the Middle Ages (Jackson 2008). 
Acedia is a type of listlessness that can lead to laziness, procrastination and neglect 
(Altschule 1965). It is also linked to feelings of dejection. Although originally separate 
from sin, acedia is now also thought of as the predecessor of sloth, one of the seven 
deadly sins. Furthermore, the condition was understood by some Christians as 
stemming from possession by the ‘noonday demon.’  
 
Literature on acedia is invariably not as expansive as that on melancholia, being 
almost entirely reserved for Christian texts. Due to the religious embeddedness of 
acedia, its treatment also came under the jurisdiction of the church. In some instances, 
particularly within ascetic communities, the ‘noonday demon’ would need to be 
exorcised. Within other church communities, those suffering with the condition for 
extended periods of time would be treated by being ignored. The sufferer’s brethren 
would be commanded not to interact with the sufferer, predicated upon the idea of 
acedia as being a sin and a personal failing (Jackson 1986). 
 
Treatments for acedia were less diverse and less individualised than those 
recommended for melancholia. This may be due to acedia being under the sole 
jurisdiction of large, all-encompassing religious entities. Ritzer’s (1983) 
McDonaldization theory has been used to demonstrate how in modern times the 
bureaucracy which characterises large corporations can lead to ‘irrational 
homogeneity’ in healthcare (Dorsey and Ritzer 2016, p. 16). Such bureaucracy is also 
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evident in large religious organisations, which may explain the uniformity of 
melancholia treatment during this time.  
 
4.3 1800s Early Medicalisation 
Although it is widely accepted that depression, or depression-like states, can be 
identified in the works of artists throughout time, relatively little work has been 
published exploring the history of the condition. Cultural historian George Rousseau 
(2000) strived to address this gap with his paper ‘Depression’s forgotten genealogy: 
notes towards a history of depression’. Rousseau (2000) focuses on the pre-1800 past 
of depression. Lexically, Rousseau differentiates between the pre-medicalised 
‘melancholia’ and the medicalised term ‘depression’ which emerged during the 17th 
and 18th centuries. The border between melancholia and depression, however, is not 
a clear one. Throughout the 18th century Enlightenment, although depression had 
become psychologised and medicalised, melancholia still existed, particularly in 
religious realms where it was associated with satanic possession. Overall, Rousseau 
(2000) suggests that there are a number of key features of depression’s pre-1800 
European history. Firstly, the condition developed in relation to the female gender. 
Rousseau (2000) points to the now debunked and defunct syndrome of ‘hysteria’, in 
addition to the work of Kay Redfield Jamison who notes that depression is in line with 
society’s notions of the female gender: passive, hopeless, dependent and sensitive. 
Secondly, in the 18th Century the condition became medicalised to some extent when 
it was seen to overlap with male madness. Although Rousseau (2000) also draws 
attention to the early theories of depression, such as its conceptualisation as a chronic 
condition from the Renaissance onwards, it is Rousseau’s exploration of depression 
and gender which is most compelling.  
 
There is a growing body of literature exploring the relationship between gender and 
medicalisation. Authors such as McHugh (2004) argue that, due to the way in which 
mental illness is categorised, biases are inevitable. Mental illnesses are ‘discovered’ 
and defined by the presence of clusters of ‘abnormal’ symptoms. The very idea of 
mental illness diagnoses is controversial. In his book Outsiders, Becker (2008) argued 
that deviants are defined by the way society labels them as deviants, rather than by 
any objective characteristic or behaviour. In terms of mental health diagnoses, then, 
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this means that diagnoses serve to alienate marginalised groups deemed to be 
unacceptable by broader society. In the West, psychiatric diagnoses have historically 
been, and continue to be, categorised by rich white males (Ali et al. 2010). Therefore, 
it is entirely possible that ‘otherness’ contributes to the medicalisation of phenomena 
in a similar vain to Becker’s (2008) ‘Outsiders’. The categorisation of homosexuality 
as a mental illness up until the 1970s (Gray et al. 2015) serves as a powerful example 
of this bias. 
 
Academics who engage with labelling theory disagree over the extent to which mental 
illness itself is created by, or in response to, society (Scheff 1971),  or whether it is 
simply a characteristic of normal human variation (Gove 1975). Whilst this debate is 
interesting, this chapter and the one that follows it are principally concerned with the 
genealogy of depression as a diagnosis, rather than the factors which contribute to an 
individual experiencing the symptoms of depression. Irrespective of the underlying 
condition, mental illness diagnoses themselves are socially constructed. Hacking 
(1999, p102) provides some nuance to this discussion by differentiating between 
interactive and indifferent types. Hacking notes that the social construction of some 
diagnoses could change the underlying condition because of how the person with the 
condition perceives themselves or is perceived by others – these would be interactive 
types. This, he argues is the case for attention deficit hyperactivity disorder (ADHD) 
where institutions treat people differently based on the diagnosis, and could also be 
the case for depression. Is important to emphasise, that debates surrounding the 
social construction of diagnoses should not invalidate the suffering of individuals with 
mental illnesses.  A rose by any other name could smell as sweet, and whether you 
are feeling suicidal because of a chemical imbalance, as an outcome of society telling 
you to feel that way, or because you fall somewhere on the normal spectrum of human 
experience, you nevertheless deserve help and sympathy. 
 
4.4 1900s: The Doctor and Marketing the Talking Cure 
The 1900s saw a seismic shift in both the understanding of depression and its 
treatment with the introduction of the ideas of Sigmund Freud. This section explores 
Freud’s impact on the depression treatment market, again positing that it follows an 




4.4.1 Talking Treatments 
A key turning point in the understanding of depression took place in in the late 19th 
century and early 20th century. Sigmund Freud (1921) introduced the world to 
psychoanalysis. Freud was a neuropathologist living and working in Vienna where he 
created the theory and practice of psychoanalysis. Freud proposed that psychiatric 
problems were a form of coping mechanism, a way through which to deal with 
underlying problems. These coping mechanisms were believed to be subconscious. 
Therefore, to treat a patient, the subconscious would need to be explored via talking 
treatments which addressed the history and childhood experiences of a patient. 
Famously, Freud theorised that children have unconscious sexual desires for their 
opposite sex parent, resulting in a hatred for the same-sex parent. Known as the 
Oedipus complex, Freud suggested that it manifested itself in boys as castration 
anxiety and girls as penis envy. Through his work creating and developing 
psychoanalysis, Freud became internationally famous. The term ‘Freudian slip’ 
remains in common usage, referring to an unintentional error in speech whereby a 
person’s subconscious feelings are revealed. A 1994 episode of the popular television 
program ‘Friends’ featured a musical number about Freud’s theory of penis envy: 
All you want is a dinkle,  
what you envy's a schwang’  
a thing through which you can tinkle,  
or play with or simply let hang (Friends 1994). 
 
Freud became, and, indeed, remains a pop-culture icon. Prozac, as I will discuss later, 
has followed a similar trajectory. With psychoanalysis, Freud developed an all-
encompassing theory of the psyche, which included an explanation and treatment 
model for symptoms of low mood. Freud perceived of melancholia as being linked to 
mourning. Whilst mourners are conscious of the loss they are experiencing, those with 
melancholia are not consciously aware of what they have lost (Freud 1917). In this 
way, he created a causality which fitted the very treatment he was offering. Freud’s 
treatment focused on uncovering patients’ hidden memories to help them deal with 
them and recover, and, thus, he believed melancholia to be caused by a loss which 
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had not yet been consciously addressed. This moulding of the causality of a condition 
in the image of the treatment being promoted is echoed later when pharmaceutical 
companies promote SSRIs to spread the idea that depression is caused by a lack of 
serotonin in the brain – the so-called, ‘chemical imbalance theory’. 
 
Although Freud differed from earlier authors in his beliefs surrounding the cause of 
melancholia, the symptoms he described seeing in patients bear some resemblance 
to those listed by Hippocrates in 400 BC: 
The patient represents his ego to us as worthless, incapable of any 
achievement and morally despicable; he reproaches himself, vilifies 
himself and expects to be cast out and punished. He abases himself 
before everyone and commiserates with his own relatives for being 
connected with anyone so unworthy. He is not of the opinion that a 
change has taken place in him, but extends his self-criticism back over 
the past; he declares that he was never any better. This picture of a 
delusion of (mainly moral) inferiority is completed by sleeplessness and 
refusal to take nourishment, and—what is psychologically very 
remarkable—by an overcoming of the instinct which compels every 
living thing to cling to life. (Freud 1917, p. 245) 
 
Freud’s approach proved very popular and it was continued and developed by many 
psychoanalysts who followed him, including Harry Stack Sullivan (Sullivan 1931), 
Wilhelm Reich (Reich et al. 1946), and Freud’s own daughter Anna Freud (Freud 
1946). Although each differed in their approach to psychotherapy, they all agreed with 
the basic premise that psychiatric illnesses were coping strategies to address 
underlying problems. Right up until the 1980s, a psychoanalytic approach to treating 
mental illnesses was favoured in both the UK and US (Smith 2014). However, as drug 
treatments grew in popularity, particularly in the wake of new SSRI treatments, 
conventions began to shift. 
 
Although psychoanalysis fell out of vogue in the 1980s, a second wave of talking 
treatments emerged. The most popular of these was Cognitive Behavioural Therapy 
(CBT). CBT has historically been used as an umbrella term for all kinds of behavioural 
therapies, some of which date back to the 1950s and 1960s. However, in common-
usage it now more typically refers to a specific kind of evidence-based therapy where 
a person is taught to identify cycles of unhelpful behaviour and break them. The 
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modern incarnation of CBT arose around the same time as SSRIs were being 
developed. CBT has been found to be more effective than drug treatments for some 
patients, particularly those with milder forms of depression (Dobson 1989). Further to 
this, CBT has also proved effective when used in tandem with drug treatments 
(DeRubeis et al. 1990). However, although CBT has consistently been identified as 
helpful, and is recommended as the first-line of treatment in the National Institute of 
Health and Care Excellence (NICE) guidelines, it has never reached the level of 
success or cultural significance reached by Freud and SSRIs. A psychologist 
interviewed for this research lamented how competing against drug interventions in 
some ways reduced the success of CBT: 
 
I suppose it's sort of more complicated. You can't just buy the drug you 
actually have to train people to deliver it… … and compared to the drug 
companies we don't have the whole marketing arm of it. I guess the 
drug companies can pay for the education of doctors and things 
(Fieldwork Interview, Psychologist 1). 
 
Throughout the interview, this psychologist identified manifold reasons as to why CBT has 
never reached the success one might expect of a treatment deemed to be effective. Most 
of these reasons centre around CBT being more ‘complicated’ and less convenient than 
SSRIs. As will be discussed later, the success of SSRIs was due, in part, to the ‘seductive’ 
simplicity of  the pill (Zuckerman 2018).  
 
4.5 Conclusion 
Diagnoses are socially mediated (Ali et al. 2010) and therefore change over time. 
Symptoms that we now associate with depression have historically been associated 
with other conditions, such as acedia, hysteria, and, most notably, melancholia. In 
each instance, the nature of the condition was partially influenced by the nature of the 
institution which treated it, which is most notable in the case of acedia and its treatment 
by the Christian church. As psychological treatments for depression began to emerge, 
depression itself became validated as a psychiatric diagnosis. As psychoanalysis rose 
in popularity and cornered the depression market, treatments for depression 
converged as they did historically for acedia. During the peak powers of 
psychoanalysis, the industry seemed impossible to usurp. The following chapter 
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5: The Pharmaceuticalisation of Depression 
 
5.1 Introduction 
The previous chapter examined the history of depression treatments apropos the ‘four 
humours’ school of medicine, the Christian Church and psychoanalysis. Today, when 
a person presents to a GP with depressive symptoms they are far more likely to be 
offered antidepressants than a talking treatment. This chapter traces the journey from 
there to here. That is, from an era where psychoanalysis appeared ‘too big to fail’ up 
until today where antidepressant prescriptions rise year-on-year. Following on from 
the previous chapter, the concept of pharmaceuticalisation will be used to explore how 
depression continues to be conceptualised to fit the prevailing treatment.  
 
The chapter is primarily structured around the lifespan of the blockbuster 
antidepressant, Prozac. Beginning a few decades before Prozac’s launch, I will start 
with the birth of the idea that made such a drug possible: the belief that low mood 
could be treated by medication. Early pharmacological treatments for depression will 
then be discussed, before turning attention to the launch of Prozac and other SSRIs.  
The impact that these drugs and their manufacturers have had on diagnostic criteria 
will then be analysed.  
 
5.2 1950-80: The Fall of Freud and the First Antidepressants 
Freud died in 1939, and although talking treatments remained the norm, in the late 
1950s a new branch of medicine was emerging. This new branch of medicine 
suggested that psychological ailments could be treated, and even cured, via drug 
therapies.  
 
The antidepressants that were discovered in the late-1950s are commonly split into 
two categories based on their mode of action: Tricyclic Antidepressants (TCAs) or 
Monoamine Oxidase Inhibitors (MAOIs) (Healy 2004). The drugs were often poorly 
tolerated by patients which led to either their discontinuation or lowering of the dosage 
that had been deemed effective. Common side effects of TCAs included blurry vision, 
dry mouth, nausea, confusion, emotional blunting, and dizziness (Tueth 1994), 
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whereas MAOI’s were known to react dangerously with certain foods (McCabe 1986). 
Furthermore, both classes were fatal if one overdosed on them. Although they had 
less than favourable side-effect profiles, both MAOIs and TCAs were found to be 
effective in treating depression (Thomson et al. 1982; Paykel et al. 1988), and the idea 
of being able to treat a mood disorder with a pill was a compelling one. 
 
As discussed in the previous chapter, mental health conditions and religious discourse 
have a rich history, and the development of drug treatments for these conditions 
testifies to this fact. The birth of modern psychopharmacology was greeted with a 
religious fervour (Martin 2006). In 1957, Collegium Internationale 
Neuropsychopharmacologium (CINP), the first international scientific organisation 
dedicated to psychopharmacology, formed at a meeting in Milan. At the meeting, it 
was decided that Pope Pius XII should attend the meeting the following year. 
Accepting the invitation, Pope Pius XII made a speech praising the potential of drugs 
to treat mental illness. Elsewhere, such drugs were referred to by Frank Ayd Jr. as a 
‘blessing for mankind’ (Healy 1996, p. 84). 
 
Ayd Jr. is considered to be a ‘founding father of psychopharmacology in the USA’ 
(Findling cited in Martin 2008). He received the first permit from the Food and Drug 
Administration (FDA) in America to use chlorpromazine to treat patients with 
schizophrenia. At the time, such patients would typically be subjected to lobotomies, 
and so Ayd Jr’s. work is believed to have saved many individuals from potentially 
disabling operations. Building upon his success in treating schizophrenia, he believed 
other ‘brain diseases’ would be best treated with medication, and so turned his 
attention to depression. 
 
Ayd Jr’s. (1961) book Recognising the Depressed Patient represented a turning point 
in the conceptualisation of depression and its treatment. Distributed worldwide by 
pharmaceutical company, Merck, the book helped promote the idea that depression 
was a medical disease that could be treated with drugs (Healy 1996, p. 99). Prior to 
sponsoring the launch of the book, Merck acquired the patent for a new TCA 
amitriptyline. The company therefore had a financial interest in promoting depression 




Ayd Jr’s. book would be the first of many to be distributed by pharmaceutical 
companies to inform healthcare professionals about depression and its treatments 
(e.g. Tylee et al. 1996). Critics view this practise as disease mongering, which is when 
a condition is aggressively promoted as an illness, and over-medicalisation, which 
refers to when the boundaries of a condition are expanded to include healthy 
individuals (e.g. Moynihan and Henry 2006). The specific message presented by Ayd 
Jr’s. book could also be understood more precisely as pharmaceuticalisation, as the 
publication promoted the idea that depression was a disease which could benefit from 
drug treatments (Abraham 2010).  
 
Whilst it can be argued that books such as Ayd Jr’s. contributed to medicalisation in a 
negative way, medicalisation is not always negative (Gray et al. 2015). Therefore, Ayd 
Jr’s. role in medicalisation could potentially be seen as a positive one, drawing 
attention to depression, reducing stigma and educating the medical community 
(Greenberg 2010, p. 12). I have found no evidence to suggest that the text was ghost-
written, or even that Ayd Jr. himself received funding from a pharmaceutical company 
prior to the book’s publication. Although a dearth of evidence does not necessarily 
mean that Ayd Jr. was unbiased in his writing of the text, it is possible that he wrote 
the book with the noble intention of helping patients. His book may then have been 
cherry-picked by Merck due to its alignment with their marketing objectives. 
Regardless of his intention, the outcome remains pharmaceuticalisation due to 
Merck’s involvement. 
 
MAOIs and TCAs paved the way for more research into antidepressant medications. 
Companies were particularly interested in developing an antidepressant with fewer 
side-effects than MAOIs and TCAs. In 1971, a new compound was synthesised: 
zelmidine. The compound was part of a novel class of drugs referred to as SSRIs. Due 
to its different mechanism of action, SSRI zelmidine did not exhibit the problematic 
side-effects of MAOIs and TCAs. Subsequently, the drug was launched to market in 




Mulinari (2015) interviewed scientists and managers involved with the development 
and launch of Astra’s drug Zelmid. Mulinari (2015) illustrates how friction between 
commercial objectives and rigorous science can lead to issues. Standard scientific 
practice dictated that a drug should undergo testing to discover the optimal dose, and 
typically patients should be started on a lower dose, before gradually increasing to the 
optimal dose. However, marketeers liked the idea of starting on a full dose of 200mg 
on day one, which was likely higher than the optimal dose. The simplicity of a single 
dose was attractive, and Astra’s management saw this as an indicator of the drug’s 
excellence to doctors.  
 
Astra’s marketing proved effective, and from its launch in 1982 to 1983 Zelmid was 
prescribed to over 200,000 patients (Mulinari 2015). Because of Astra’s simple but 
aggressive marketing, the magnitude of Zelmid’s success was unprecedented for the 
time. However, in addition to being the first SSRI to reach the market, Zelmid was also 
responsible for the first SSRI scandal. In addition to more common side-effects, 1 in 
every 10,000 patients who took Zelmid developed Guillain–Barré syndrome, which 
could result in paralysis and left some sufferers permanently unable to walk. In June 
1983, the British authorities threatened to withdraw the drug from the market, and in 
September Astra completely withdrew Zelmid from the market. Mulinari (2015) notes 
that, whilst the drug was ultimately withdrawn, it nevertheless signalled to other 
companies about the profitability of the antidepressant sector, thereby paving the way 
for Prozac. In its short lifespan, Zelmid displayed features of what would become the 
classic SSRI narrative: from success to scandal. 
 
5.3 1980-2000: The Birth of a Blockbuster 
In his paper ‘The Shifting Engines of Medicalisation’, Conrad (2005) argues that, prior 
to the 1980s, pharmaceutical companies merely facilitated the medicalisation process, 
rather than being a primary engine of it. Indeed, the scenario above between Ayd Jr. 
and Merck would lend support to this idea. However, this soon changed, and 
pharmaceutical companies went onto become ‘major players in medicalisation’ 




In 1989, Prozac (chemical name Fluoxetine) was launched in the UK. Prozac was a 
member of the new class of drugs known as SSRIs. SSRIs act by increasing the levels 
of serotonin in the brain. They are therefore based on what is now known as the 
‘chemical imbalance theory’, which, although not scientifically proven, gained a lot of 
traction in popular culture (Leo and Lacasse 2008).  
 
Prozac itself became a cultural sensation. Frasier (2001) draws upon the Betsky 
(1997) definition ‘magnets of meaning’ to argue that Prozac achieved iconic status and  
became a magnet of meaning during the 1990s. Indeed, the drug rose to fame like no 
other before it. In the UK, as it is illegal to advertise prescription drugs to the public, 
we are largely unfamiliar with drug brand names. However, even today Prozac is the 
most well-known and recognised brand name antidepressant in the UK.  
 
Prozac’s iconic cultural status had not been seen before in the pharmaceutical 
industry. However, its trajectory to fame was typical of its human celebrity 
counterparts. As Kramer notes, Prozac was: ‘renowned, followed by rumours, then 
notoriety, scandal, and lawsuits, and finally a quiet rehabilitation’ (Kramer, 1994: xvi).  
 
Compared to their predecessors, SSRIs were believed to be far safer. This belief, 
however, was not immediately shared with the public, many of whom were sceptical 
about the use of drugs to treat depression. The public had a negative perception of 
psychoactive drugs due to high profile cases of addiction and overdose, such as Judy 
Garland’s death via a barbiturate overdose in 1969. Therefore, across the globe, 
depression awareness campaigns were conducted to educate the public and 
healthcare professionals about depression and its treatments. In the UK, this took the 
form of the Defeat Depression Campaign (See Chapter 9 for more details). This 
campaign was partially funded by Eli Lilly and, to a lesser extent, SmithKline Beecham 
(now GlaxoSmithKline (GSK). The precise impact that this funding had on the 
campaign will be discussed in more detail in a later chapter. However, for now it is 
simply important to acknowledge that the campaign was a success and is credited 
with increasing the number of antidepressant prescriptions in the UK in the early 1990s 
(Paykel 2001). As (Leask 2002) notes, the beginning of the 1990s signalled a cultural 
shift in how health was perceived. Due to improvements in access to education, and 
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the growing influence of the media, public expectations of healthcare provision 
increased. This shift created a culture fertile to the idea presented in the Defeat 
Depression Campaign that low mood should not be tolerated, but, rather, treated. 
 
5.4. 2000-2017: From Patent Precipice to Public Paranoia 
Prescriptions for Prozac and other blockbuster SSRIs, such as Seroxat (paroxetine) 
and Zoloft (sertraline), continued to rise. However, as we learned from the case of 
Zelmid, the SSRI narrative is always characterised by success and scandal.  
 
5.4.1 Seroxat Scandal  
The SSRI paroxetine was marketed in the UK by SmithKline Beecham (now 
GlaxoSmithKline), under the brand name ‘Seroxat’. In the US, the drug was marketed 
under the name ‘Paxil’. The drug was advertised as the only SSRI safe to use by 
adolescents (Keller et al. 2001) and, resultantly, was commonly prescribed to 
teenagers and young adults. However, a pattern seemed to emerge whereby some 
young people were committing suicide soon after beginning the medication. Critical 
psychiatrists, such as Healy (Healy 2003), noticed this pattern. However, as suicidality 
is a symptom of depression, it was difficult to prove that these suicides took place 
because of the medication as opposed to the depression.  
 
Indeed, if paroxetine was contributing to the suicides of children, then Healy (2003) 
and fellow critics concluded that it was likely that the clinical trials demonstrating the 
drug’s safety and efficacy in children had been misreported. As part of a growing 
movement to demand all data from clinical trials, Le Noury et al. (2015) campaigned 
against GSK to provide access to the original data for the trial known as Study 329. 
Eventually, GSK granted specific researchers’ access to the original data to allow for 
the study to be reanalysed.  
 
The paper which first published the results of the study in 2001 concluded that 
paroxetine was safe and efficacious for use in adolescents (Keller et al. 2001). 
Reanalysis of the study confirmed the researchers’ suspicions that the findings had 
been misreported. The trial participants (depressed teens aged 12-18) had been split 
into a treatment group and a control group who received a placebo. Upon re-analysing 
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the data, the researchers found that the participants who had received paroxetine were 
more likely to self-harm and commit suicide, whilst the drug showed no efficacy in 
teens. The manufacturers had thus actively hidden data that pointed towards the 
medication leading to suicide in young people. The decision to hide this data likely led 
to the death of children and young people, but as with most corporate crimes no prison 
time was served. 
 
Prozac’s iconic image did not protect it from scandal, as the increased risk of suicide 
was not limited to teens taking paroxetine. Prozac’s manufacturer Eli Lilly also hid data 
pointing to an increased risk of suicide when taking their drug.  
 
Data was also hidden on the likelihood of individuals experiencing withdrawal upon 
discontinuing SSRIs. Critical blogger Seroxat Secrets (2017) documents the 
withdrawal journey on their blog. Claims that drugs like Seroxat could cause 
withdrawal were rebutted. The depression awareness campaign ‘The Defeat 
Depression Campaign’ consistently refused to clarify what they meant when they 
consistently emphasised that antidepressants were not addictive. In response, they 
merely cited that there is ‘no street market for antidepressants’ (Crow to Kent, 1992a). 
As a later chapter will explore in more detail, this campaign was funded by 
pharmaceutical companies. 
 
The rise of SSRI antidepressants coincided with societal changes about what 
constituted depression. The companies promoting SSRIs also funded those who wrote 
the diagnostic criteria for depression (Cosgrove et al. 2006). Feelings which were 
previously considered part of the normal range of human emotions by DSM-II criteria 
were now potentially pathological in the DSM-III. Esposito and Perez (2014) highlight 
the importance of understanding this cycle, whereby conditions are defined by the very 
people promoting a treatment for it. These definitions are then treated as ‘fact’ and 
‘science.’ Mental health becomes corporatised which, in turn, leads to the illnesses 
themselves becoming commodities. Such a system is made possible by the broader 
social reality which dictates what is normal. In the case of Western countries, such as 
the UK, this is neoliberalism (Esposito and Perez 2014). Esposito and Perez’s (2014) 
paper on the relationship between neoliberalism and the corporatisation of mental 
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health argues that the rise of psychotropic medications, such as Prozac, are indicative 
of wider neoliberal motives: 
 
The individual becomes the focus of attention while the larger market 
society in which they live is largely ignored. The use of psychotropic 
drugs, of course, continues to be the primary approach to “treat” 
individuals by allowing them to overcome their personal challenges and 
“fit” into the prevailing market order. Fitting into this market 
society/order typically entails alleviating emotional/mental distress as a 
way to enhance people’s productivity and capacity to consume 
(Esposito and Perez 2014). 
 
5.4.2 Patent expiration 
‘A patent is a legal device that grants an inventor market exclusivity over a new 
invention or medication’ (Gupta et al. 2010, p. 2). Patents can be controversial. They 
can be expensive to maintain and defend and can act as a barrier to innovation. It is 
for this reason that patenting is decreasing in popularity in some industries. The case 
of Tesla, the market leader in luxury electric cars, who in 2014 chose to surrender all 
of their patents to the public is illustrative of this shift (Musk 2014). The company cited 
a desire to create a ‘rapidly evolving technology platform’ as one of the key reasons 
for doing so. Indeed, a tech culture of idea sharing in China is the reason that, contrary 
to tradition, most teenagers do not care about which brand of hoverboard lies beneath 
their tree at Christmas time.  
 
However, patents remain at the core of the standard business model in the 
pharmaceutical industry. This is because the costs associated with the research and 
development of drugs continues to rise, and thus incentives are required to encourage 
companies to conduct research and develop new drugs. Patents offer an incentive by 
providing an opportunity to profit exclusively for a limited period if a new drug reaches 
the market. It is wholly possible that if patents were abolished in the pharmaceutical 
industry, then new drugs would not be developed, particularly drugs for rare diseases. 
 
In the pharmaceutical industry, patents protect new drugs from ‘copycats’ for 20 years. 
However, as patents must be filed as soon as a new drug is discovered, and it can 
take years for a drug to be tested and get to market, this, in fact, leaves just over 10 
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years of exclusive rights in the marketplace. Many of the ‘blockbuster’ antidepressant 
drugs, such as Prozac, were released to market in the 1990s and have since come off 
patent. This means that the chemical compounds can be produced by other 
companies, which increases market competition and subsequently reduces prices. In 
2012, the generic market accounted for 36% of global market share (OBR 2015). 
 
Generic drugs are developed by generic pharmaceutical companies, separate from 
the larger big brand pharmaceutical companies. The generic drugs have the same 
active compound as the original branded drug; for example, copycats of Prozac also 
contain fluoxetine hydrochloride. Although both the branded original and all their 
generic counterparts have the same active ingredient, they often have different fillers, 
dyes, coatings, etc. Therefore, all generic drugs are subject to clinical testing to prove 
their safeness and efficacy.  
 
5.4.3 New Drugs 
Although the blockbuster drug, particularly in the case of psychoactive drugs, seems 
to be a thing of the past, a small number of new drugs for depression have been 
developed over the past few years. Compared with the SSRI golden age in the 1990s, 
very few drugs have been released to market since the turn of the century. 
Furthermore, many drugs that have been in development have failed to ultimately 
reach the UK market. Vilazodone (brand name Viibryd), is marketed in the US by the 
pharmaceutical company, Forest Laboratories. However, development of the drug for 
the UK and wider EU market was abandoned. The private healthcare system in the 
US means that several drugs which get approved in the US fail to be approved in 
countries with nationalised healthcare, due to the compounds not offering sufficient 
‘value for money’ to warrant approval. The drug levomilancipran (brand name Fetzima) 
is another example of this phenomenon, which was approved in the US but had its 
development discontinued elsewhere.  
 
In a move which could allow companies to avoid cannibalising the market for their 
existing antidepressants, some companies have researched adjunctive treatments for 
use with SSRIs. Prozac manufactures Eli Lilly had been researching one such 
compound up until 2013, when they announced they would be abandoning the 
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research due to a lack of evidence of its efficacy in a placebo controlled trial (Lilly 
2013). Irish pharmaceutical company, Shire, conducted further research into the use 
of their attention deficit hyperactivity disorder medication, lisdexamfetamine (brand 
name Vyvanse), as an adjunctive treatment for depression. However, this research 
was also abandoned due to a lack of sufficient evidence of its efficacy in 2014. The 
cessation of research into lisdexamfetamine coincided with a complete withdrawal 
from depression drug development by Shire. As the market has become more 
crowded and less profitable, several large pharmaceutical companies have withdrawn 
from the field.  
 
Although in recent years many would-be antidepressants have failed to reach the UK 
market, three have succeeded: Duloxetine (brand name Cymbalta), Agomelatine 
(brand name Valdoxan) and Vortioxetine (brand name Brintellix). Due to the tight profit 
margins in the generic market, they spend less money on marketing, instead 
competing over price via online catalogues. It is the companies behind these three 
drugs that have been at the forefront of antidepressant marketing in the UK over the 
past decade. Therefore, an understanding of these drugs, their features and their 
position in the market is essential. Each of these drugs has at least one novel feature 
compared with existing antidepressants. Most notably, each drug differentiates itself 
from others in the market by claiming to treat a symptom of depression hitherto not 
targeted by other antidepressants. 
 
Cymbalta 
In 2005, Eli Lilly, the manufacturers of Prozac, released a new antidepressant with the 
chemical name duloxetine and brand name Cymbalta. In the UK, the drug was 
marketed as a joint venture with German company Boehringer Ingram. The drug is 
described as working by inhibiting the reuptake of two neurotransmitters: serotonin 
and norepinephrine. The drug is therefore described as an serotonin norepinephrine 
reuptake inhibitor (SNRI) rather than an SSRI. 
 
Cymbalta was the first antidepressant to be approved to also treat psychosomatic 
pain. On Dragons Den or The Apprentice, this would be their unique selling point 
(USP). Marketing surrounding this medication thus focuses on the link between 
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depression and psychosomatic pain, with slogans like ‘Depression Hurts’ (Reid 2004). 
Research conducted by Lilly suggested that the drug was also useful for treating 
patients with ‘milder major depressive disorder’, where previously medical guidance 
had indicated that antidepressants were not necessary (Perahia et al. 2006). 
 
A systematic review published in 2012 by independent research network Cochrane 
found that Cymbalta was not significantly better than other antidepressants in the 
treatment of major depression (Cipriani et al. 2012). Furthermore, the authors note ‘As 
for all other new investigational compounds, the potential for overestimation of 
treatment effect due to sponsorship bias should be borne in mind.’ In summary, the 
authors purport that they found no evidence that Cymbalta is better than other 
antidepressants; in fact, they found it was worse than some (escitalopram and 
venlafaxine) and, given that most of the research on duloxetine is funded by the drug 
manufacturers, it is possible that the drug may be even less effective than their findings 
suggest.  
 
As Cymbata came to market over a decade ago, it is now off patent and is available 
in a generic formulation. Despite aggressive marketing, the drug was ultimately unable 
to replicate the success of Prozac, and, indeed, none of informants reported 
prescribing the drug even in generic form. 
 
Valdoxan 
Manufactured by independent French pharmaceutical company, Servier, Agomelatine 
(brand name Valdoxan) was released to the UK market in 2009. Unlike SSRIs, 
Agomelatine is similar in structure to the sleep regulating hormone melatonin, and for 
that reason is described as a melanotonic antidepressant. As the drug acts on the 
melenatonic system, it is claimed to regulate sleep patterns or ‘circadian rhythms’. 
Prior to the launch of Valdoxan no other antidepressant claimed to regulate sleep in 
this way, and, hence, this became the drug’s USP.  In addition to regulating sleep, the 
drug has also been described as having a favourable side-effect profile (Rouillon 
2006). Specifically, the drug does not have the sexual side-effects which often cause 
patients on SSRIs to discontinue treatment. Although the drug does not have sexual 
side-effects, it does have one particularly problematic side-effect: liver damage 
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(Freiesleben and Furczyk 2015). Resultantly, patients taking the drug cannot drink at 
all. This is especially problematic due to the increased propensity of individuals with 
depression to consume alcohol. In addition to abstaining from alcohol, individuals 
taking Valdoxan must undergo frequent blood tests to monitor liver function. 
 
Valdoxan is still on patent in the UK and Servier still have sole marketing rights over 
the compound. However, an industry informant stated that Servier have stopped 
marketing the drug as the blood tests are ‘a ball-ache’ for GPs (Fieldwork Interview, 
Rep 3). Although the drug is no longer being marketed in the UK, it is allegedly 
successful in private practice: ‘it's the favourite antidepressant in all of private practice 
because it has almost no side-effects at all, so there are all sorts of things that are 
unwritten but we all know about’ (Fieldwork Interview, Psychiatrist 6). 
 
Brintellex  
In November 2015, NICE published guidance for prescribers to include Vortioxetine 
(brand name Brintellex) as an option in the treatment of depression. Brintellex is an 
atypical antidepressant, and has been described in a paper sponsored by its 
manufacturer, Lundbeck, as ‘a novel antidepressant with multimodal activity’ (Sanchez 
et al. 2015). By this, the authors mean that the drug increases multiple 
neurotransmitters: serotonin, noradrenaline, dopamine acetylcholine, histamine and 
glutamate. The USP of this drug is that it is the first antidepressant which also claims 
to treat cognitive dysfunction. 
 
As Brintellex is still on patent, it is thus more expensive than drugs for which there is 
a generic alternative. Currently, NICE guidelines only suggest offering Vortioxetine to 
individuals who are experiencing treatment resistant depression, and have thus far not 
responded to at least two other forms of antidepressants (NICE 2015). Brintellex is 
unlikely to ever match the success of Prozac, and it would appear that the era of 
blockbuster antidepressants is over. However, antidepressants remain the most 






Due to the socially bound nature of psychological diagnoses (Ali et al. 2010), the 
definition and understanding of depression has changed over time. These changes 
consistently correspond with changes to the way in which depression is treated. 
Historically, the market for depression treatment was initially dominated by religious 
groups, later by psychoanalysts, and then by pharmaceutical companies. As Healy 
(1996) notes, someone has always had a vested interest in the way depression is 
treated, which, in turn, means that they have also had a vested interest in how 
depression is conceptualised and diagnosed. There is a continuing pattern of 
depression being framed by those promoting a treatment. The pharmaceutical industry 
has dominated the market for depression treatment for decades now. However, with 
patents expiring and new challengers emerging, the industry has faced several 
challenges in its attempts to replicate its earlier success.  
 
This section has traced the historical evolution of depression and its treatments. In the 
following chapters, I examine in greater detail how Big Pharma companies marketed 
a chemical solution to depression. This story takes us through the role of not only 
PSRs, hired from within the industry, but also outsiders such as healthcare 
professionals and charities. It demonstrates how the marketing of antidepressants has 
evolved beyond increasing demand via pharmaceuticalisation or disease mongering. 
Instead, I show that antidepressant marketing activities are influenced by a motivation 
to change the broader landscape of society to fit their objectives. In other words, 
medicalisation is not enough for understanding the commercial strategy of Big Pharma 
– it has a political role. This thesis concludes by considering the future of 
antidepressants, thinking about the respective challenges and opportunities for 
pharmaceutical companies promoting treatments for depression. The following section 
explores the next step in this larger narrative. It looks behind the veil of the industry 
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6: The Rise of Big Pharma 
 
6.1 Introduction 
The term antidepressant itself is clever branding. The word suggests that the drugs 
specifically target depression, and that depression is a singular identifiable thing that 
the drugs can then combat. If antibiotics kill bacteria, then antidepressants kill 
depression? Antidepressants are chemical compounds with an array of effects, some 
of which may sometimes be helpful in treating depression in some people. Moncrieff 
and Cohen (2006) refer to this as the ‘drug-centred’ view of medicine, as opposed to 
the disease-centred view. Moncrieff and Cohen’s (2006) drug-centred approach 
argues that we should acknowledge that there is no such thing as side-effects. Rather, 
there are simply effects, some of which are desirable and intended, and some of which 
that are not.   
 
Antidepressants (a term I will continue to use for ease of communication) are 
psychoactive drugs. Antidepressant manufacturers are also the generators of 
compounds which are used to treat other conditions. They are large pharmaceutical 
companies with rich histories long predating Prozac. Therefore, to make sense of the 
antidepressant market and the various activities of its players, like many of the films in 
the popular Marvel Cinematic Universe, we must first establish the industry’s ‘origin 
story’. Exploring this origin story is especially important because, as discussed in the 
methods chapter (and as reiterated throughout this thesis), history permeates every 
layer of the research subject. Antidepressants are inseparable from the industry which 
makes them. The perception of antidepressants has thus been influenced by the 
reputation of Big Pharma, while, in turn, antidepressants have been something of a 
lightning rod for issues within the industry. Furthermore, every marketing interaction 
between a pharmaceutical representative and a healthcare professional is defined by 
the accident of history that caused drug development to take place outside of the NHS. 
 
This chapter presents an overview of the pharmaceutical industry, which is crucial for 
situating and understanding how depression has become a business concern for Big 
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Pharma. It begins by drawing upon the work of Malerba and Orsenigo (2002), whose 
work plots the history of the pharmaceutical industry from its pre-war beginnings, 
through to the golden age which saw the discovery of antidepressants. I then proceed 
to outline its current state, which has led to Malerba and Orsenigo (2002) predicting 
its demise. Exploring the history of the industry, it becomes apparent that the 
reputation of Big Pharma has changed drastically over time. This issue will be 
presented and explored through the lens of scandal. Given that this reputation has 
influenced how the industry regulates itself, the chapter concludes by examining in 
detail the structure of self-regulation in the industry, and how it has changed in 
response to scandal. 
 
6.2 History 
Malerba and Orsenigo have written extensively on the history of the pharmaceutical 
industry. Their 2002 paper provides an especially detailed historical typology of the 
pharmaceutical industry. Consequently, their work is drawn upon in this chapter to 
analyse the historical development of Big Pharma. More specifically, their work is used 
to understand and periodise the development of Big Pharma and its involvement in 
antidepressants. Periodisation is the process of categorising the past into discrete, 
defined blocks of time to facilitate the study and analyses of history. In their 2002 
paper, Malerba and Orsenigo split the history of the industry into three eras: early 
history, the random screening period, and the advent of science. In 2015, they add 
‘the winter of discontent?’ to their typology. This chapter is therefore structured 
similarly, using and developing Malerba and Orsenigo’s (2002; 2015) periodization to 
facilitate the study and analysis of Big Pharma’s origin story, as well as its movement 
into the depression treatment market. Moreover, I adopt this general historical typology 
to consider and understand the specific historical origins of the antidepressant market 
and its domination by private corporations. 
 
6.2.1 Early History: War - What is it Good for?  
The pharmaceutical industry first emerged out of the German and Swiss synthetic dye 
industries during the mid-nineteenth century (Malerba and Orsenigo 2002). Drawing 
upon their knowledge of organic chemistry, companies such as Ciba, Sandoz, Bayer 
and Hoechst diversified into the manufacturing of drugs. Malerba and Orsenigo (2002) 
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note that it was not until the later years of the 19th century that the industry began to 
develop in the UK and US. However, rather than being subsidiaries of larger chemical 
companies, British and American companies were specialist pharmaceutical 
companies. Firms such as Wyeth, Eli Lilly, Pfizer, Waner-Lambert and Burroughs-
Wellcome all dealt specifically with pharmaceuticals. 
 
Periods of national conflict and war are frequently cited as periods of innovation, and, 
historically, this has been no different within the pharmaceutical industry. WWII 
generated increased demand for mass-produced antibiotics, which, in turn, led to the 
commercialisation of Penicillin that Orsenigo and Malerba (2002:4) identify as ‘a 
watershed in the industry’s development’. This is because the industry now had a 
model for producing medication quickly and efficiently in large quantities. Post war 
developments led to the growth and expansion of pharmaceutical companies, such as 
Glaxo Laboratories (a predecessor to Seroxat manufacturers, GSK) and future Prozac 
manufacturer, Eli Lilly. 
 
Whilst war certainly helped the development of Big Pharma, it was what happened 
after the war that was crucial for its growth and expansion. A key moment in the history 
of the pharmaceutical industry in the UK was the creation of the NHS in 1948. Prior to 
the NHS, healthcare was paid for differently by different groups of people. Although 
some working men had access to health insurance, this often failed to cover the cost 
of drugs and was only available to those who paid national insurance, thus invariably 
excluding women and children. For the most part, medication was paid for by patients 
out of their own pockets. Patients are price sensitive consumers (Strombom et al. 
2002), something that has been routinely demonstrated in recent years when 
uninsured Americans forgo necessary but expensive medical treatment due to cost. 
Therefore, patients often went without drug treatment if they could not afford it, thus 
reducing demand for medications. The NHS, for the first time, created a chain where 
the person receiving the drug treatment was not the person paying for it. Aneurin 
Bevan founded the NHS on three guiding principles: ‘that it meets the needs of 
everyone, that it be free at the point of delivery’, and ‘that it be based on clinical need, 
not ability to pay’ (NHS.uk 2018). Resultantly, demand for medications increased, and 




However, the pharmaceutical industry managed to remain private, thus leaving the UK 
with a nationalised health service but a private pharmaceutical industry. Abraham 
explores the issues associated with this dichotomy, observing that the modern 
pharmaceutical industry was already well underway before the health service became 
nationalised (2009, p. 936). The case for partial public ownership of the 
pharmaceutical industry was made by Harold Wilson prior to his success in the 1974 
election. However, the inertia already inherent in the pharmaceutical juggernaut prior 
to nationalisation, goes some way to explaining why, despite criticisms, it remained 
entirely private.  
 
Leask (2002) points out that the set-up of a private pharmaceutical market, working 
with and for a nationalised health service, had a huge impact on the nature of the 
pharmaceutical market. Healthcare was predominantly led by GPs who operated as 
individual practitioners. Negotiations during the formation of the NHS led to GP’s 
becoming contractors for the NHS rather than employees. This legislative relic remains 
in effect and has manifold repercussions which will be discussed in Chapter 8. For the 
pharmaceutical market at this time, the power held by GPs meant that the Health 
Authority had little to no influence over how GP practices were run. 
 
During this time, Leask (2002) notes that there was little price sensitivity within the 
market. Healthcare professionals were prescribing medicines for patients with little 
awareness of the cost of the drug, as this issue was simply not relevant for the doctor 
or the patient (as neither would be footing the bill directly). This lack of price sensitivity 
allowed pharmaceutical companies to increase profit margins. Large companies were, 
in turn, able to dominate communication with customers via ‘muscle marketing’ (Leask 
2002). Large companies hired large, focused sales forces who targeted individual 
practitioners for one-to-one conversations about the features and benefits of their 
company’s drugs. This signalled the birth of a sales technique which would later 




6.2.2 Random Screening 
The period from the end of WWII to the mid-1970s is referred to by Malerba and 
Orsenigo (2002, p. 4) as the ‘Random Screening’ period, as well as ‘the golden age of 
the pharmaceutical industry’. The commercialisation of penicillin demonstrated the 
profitability of drug development. Prior to this era, very few diseases had effective 
cures. There was therefore an ‘open field’ for companies to develop and market new 
drugs in the therapeutic domain with very little competition. Malerba and Orsenigo 
describe the environment at this time as ‘target rich’ (2002, p. 4), however scientific 
knowledge at the time was less developed. A ‘random screening’ approach was 
therefore adopted by companies to investigate ‘libraries’ of compounds via test tube 
experiments and animal testing. This process relied primarily on chance, and, indeed, 
only one in every 5,000 compounds ultimately reached the market (2002, p. 5).  
 
Although far from perfect, the screening process was successful and led to the 
discovery of several hundred new chemical entities throughout the 1950s and 1960s. 
Furthermore, the screening capabilities developed by companies were complex and 
difficult to imitate. This created a barrier for new companies entering the marketplace 
and is a key reason why the market is still dominated by early entrants to the 
pharmaceutical industry, which are described by Malerba and Orsenigo (2002) as the 
industry’s ‘oligopolistic core’.  
 
Moreover, as noted by Healy (2012b), there were changes to the patent system during 
this time which facilitated profitability. Process patents had been the norm in Europe 
prior to the 1960s. This meant that pharmaceutical companies were awarded patents 
based on the processes used to create the drug. If other companies were able to 
create the same compound using a different process, they would thus not be infringing 
on the patent. Innovation was therefore encouraged, and companies could compete 
against patents to find a cheaper way of creating a useful compound. In the early 
1960s, however, European countries switched to the US system of product patents, 
which protect the chemical compound regardless of how it was made. This transition 
reduced the incentive to innovate and discover a cheaper way of creating a drug. 
Consequently, this change in patent procedure increased the profitability of new drugs 
by reducing competition. Furthermore, Goldacre (2012) argues that this patent system 
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encouraged a greater emphasis on marketing compared to research and 
development. In doing so, product patents paved the way for blockbuster drugs like 
Prozac. 
 
6.2.3 The Advent of Science 
The third period in the industry’s history is referred to by Malerba and Orsenigo as 
‘The Advent of Science’ (2002, p. 6). This era began in the 1970s, and when Malerba 
and Orsenigo published their paper in 2002, they considered themselves to be still 
living in ‘The Advent of Science’. This era is characterised by advances in scientific 
knowledge which allowed companies to improve their screening process, and more 
efficiently identify potentially useful compounds. Moreover, understanding of diseases 
and drug mechanisms improved, further streamlining the drug discovery process. 
Knowledge of molecular and DNA levels led to the development of new 
biotechnological firms (NBFs), which, in turn, saw the advent of drugs such as insulin.  
 
Drug discovery and development became increasingly dependent on a wide, diverse 
and fragmented range of knowledge. Therefore, NBFs and more established 
pharmaceutical companies frequently had to collaborate to succeed. A ‘network of 
collaboration’ thus evolved during this time between pharmaceutical companies, NBFs 
and universities. 
 
The Advent of Science also led to the first blockbuster antidepressants: SSRIs. These 
drugs worked by altering the level of the neurotransmitter, serotonin. Because of this, 
SSRIs were sometimes described as being analogous to insulin, and so the chemical 
imbalance theory of depression was born. The marketing developments established 
during ‘Early History’ and the patent developments in ‘Random Screening’ provided 
antidepressant manufacturers with the perfect tools to create incredibly profitable 
branded medicines. 
 
6.2.4 Regulation Burden 
In their 2015 paper on the evolution of the industry, Malerba and Orsenigo updated 
their historical account by adding a fourth era entitled the ‘Winter of discontent?’, which 
covers the period between 2000-2010. The authors go so far as to question whether 
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we may be witnessing the demise of Big Pharma. This is down to the fact that 
advancements in knowledge and technology have increased the cost of bringing a 
drug to market.  Malerba and Orsenigo (2015) highlight that roughly the same number 
of new chemical entities were approved by the FDA in the early 1980s as the early 
2000s. However, the cost of research and development over this time increased thirty-
fold. Regulation has been blamed for this decrease in productivity. However, Malerba 
and Orsenigo (2015) note that, as well as regulation, there has also been success in 
terms of shortening development times. Moreover, the ‘open field’ of ‘The Golden Age’ 
has become occupied by a suite of products against which new medications must 
compete. The history of the coal industry provides us with a useful comparison for 
understanding this trend. What is close to the surface and most easily accessible is 
excavated first, whereas as time progresses more money and energy is required to 
access the remnants. 
 
Further to this, the collaborative sentiment of ‘The Advent of Science’ evolved into a 
deepening division of labour during the ‘Winter of Discontent?’. Large pharmaceutical 
companies outsource research and development to specialised biotech firms. Malerba 
and Orsenigo (2015) argue that this evolution has resulted in large pharmaceutical 
companies being at risk of losing their capacity to innovate, having instead now 
become simply ‘marketing-based organisations’. This acknowledgement that 
marketing has become the core competency of these organisations, rather than 
research and development, further supports the underlying premise of this thesis. 
Before we can understand the ethics of the pharmaceutical industry, however, their 
approach to marketing must first be examined.  
 
6.3 Pharma Scandals 
Malerba and Orsenigo (2015) note that, throughout the 1990s, the pharmaceutical 
industry enjoyed ‘a remarkable reputation in the eyes of the markets, policymakers 
and the people at large’. Macaulay Culkin had a similarly glowing reputation during 
this period. However, just as scandal almost always accompanies the fall of child stars 
in the form of narcotics convictions or jail-time, so too does it plague Big Pharma (or 




Public trust in the pharmaceutical industry has been eroded by scandal (Lofstedt and 
Way 2016). How did the industry fall from being a political darling to shorthand for 
corruption and mistrust? The answer: scandal after scandal. This section starts by 
looking at broader industry scandals across the respective drug classes, before 
proceeding to discuss the mechanisms which contribute to such scandals .  
 
6.3.1 Death by dangerous drugging 
The previous chapter looked in-depth at specific antidepressant scandals, and thus I 
will not discuss them at length in this chapter. However, Hernandez et al. (2014) posit 
that the Seroxat Scandal was the key turning point in terms of the public losing trust in 
the industry. Their paper exemplifies how the controversy surrounding 
antidepressants has acted as a lightning rod for a wider discussion of industry ethics. 
To quickly recap, GSK hid trial data which demonstrated that Seroxat increased the 
suicidality of young people. Rather than publish this data, they promoted it as safe for 
use in children, therefore likely contributing to the deaths of young people who would 
otherwise be alive today. Additionally, some patients taking Seroxat became 
dependant on the drug and found it very difficult to come off. However, GSK 
maintained that the drug was not addictive. The Seroxat Scandal went on to become 
part of the largest pharmaceutical industry settlement in history of $3 billion.  
 
However, it is important to note that the pharmaceutical industry has experienced 
scandals across multiple drug classes. The non-steroidal anti-inflammatory drug 
(NSAID), Rofecoxib (brand names Vioxx, Ceoxx and Ceeoxx), was considered a 
success for the pharmaceutical company, Merck & Co. Over 80 million individuals 
worldwide were prescribed the drug between 1999 and 2004. However, in 2004 the 
drug was removed from the market as it was shown that the drug resulted in a five-
fold increase in the risk of heart attack compared with naproxen (another popular 
NSAID). Again, the data on the side-effect of the drug was hidden, thus resulting in 
tens of thousands of avoidable heart attacks. 
 
Heroin addiction has soared in the US in recent years along with HIV infections. This 
epidemic has been the subject of multiple documentaries pointing towards the rise in 
use of opiate painkillers, such as oxycodone (brand name OxyContin), as a 
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contributing factor. Oxycodone was originally advertised by its manufacturers, Purdue 
Pharma, as less likely to be abused than other narcotics. A lawsuit settlement in 2007 
found Purdue guilty of misbranding, because they did not have enough evidence to 
support their marketing claim (Meier 2007). The company were ordered to pay $600 
million and three executives, including the president, pled guilty and agreed to pay 
$34.5 million in fines. During this period in which the company were actively 
advertising OxyContin as a lower risk, they earned $2.8 billion in revenue. 
 
Investigative podcast ‘Embedded’ (McEvers 2016) followed the story of a nurse and 
girl scout leader who ended up living in a drug den after becoming addicted to another 
opiate painkiller, oxymorphone (brand name Opana ER). She was originally 
prescribed the drug for a back injury she sustained whilst helping a patient. Opana ER 
was removed from the US market in June 2017 at the request of the FDA, because it 
was being abused by those taking it. The opioid crisis in America has reached such 
critical proportions that even problematic President Donald Trump has pledged to 
declare the crisis a national emergency (whether he will, of course, is yet to be seen) 
(Crow 2017). 
 
The US opioid crisis has received a lot of media coverage in recent years. Whilst the 
UK has not experienced an epidemic of US proportions, pharmaceutical companies 
have still been accused of contributing towards the over-prescription of such drugs. 
Stannard (2012) notes that prior to 2003 pain specialists had a very liberal approach 
to prescribing opioid painkillers. They held the view that pain was the enemy and opioid 
painkillers were their best weapon in this battle. Their beliefs were ‘facilitated by a tide 
of educational initiatives sponsored by pharmaceutical companies selling the next best 
thing’ (Stannard 2012, p. 7).  
 
6.3.2 Not Just Bad Apples but a Rotten Orchard? 
These scandals are not isolated cases; rather, they have drawn attention to underlying 
corrupt practices which facilitate such scandalous outcomes. What do the 
Goosebumps series of books, Sarah Palin’s memoir Going Rogue and the article 
publishing the results of rofecoxib clinical trials have in common? They were all 
allegedly ghost-written. R.L. Stein maintains that he wrote every book in the 
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Goosebumps series, and, indeed, there is little solid evidence to suggest that he did 
not, Palin’s ghost-writer’s diary was leaked by Salon, whilst an analysis of litigation 
documents by Ross et al. (2008) found that articles were ghost-written by Merck as 
opposed to the high-profile academics who received authorship credits. Ghost-writing 
is fairly commonplace in the industry. Indeed, one informant from a PR company I 
interviewed spoke candidly about providing a writing service for pharmaceutical 
companies. This involved matching companies up with authors who would write up 
their trials to a flattering and publishable standard, without being listed as an author.  
 
Scandals such as these have led to an erosion of trust in the industry. Both the public 
and healthcare professionals have become more sceptical towards the 
pharmaceutical industry as a whole. Goldacre’s (2012) ‘Bad Pharma’ further solidified 
this widespread distrust of the industry. Goldacre is a GP who began writing the 
column ‘Bad Science’ for The Guardian in 2003. The column exposed examples of 
how poor science was used to manipulate people and proved extremely popular. In 
2008, Goldacre published the book ‘Bad Science’ followed by ‘Bad Pharma’ in 2012. 
Goldacre summarises the thesis of ‘Bad Pharma’ as follows: 
 
Drugs are tested by the people who manufacture them… …unsurprisingly, 
these trials tend to produce results that favour the manufacturer…. …we only 
ever see a distorted picture of any drug's true effects… …This distorted 
evidence is then communicated and applied in a distorted fashion. In their forty 
years of practice after leaving medical school, doctors hear about what works 
through ad hoc oral traditions, from sales reps, colleagues or journals. But those 
colleagues can be in the pay of drug companies – often undisclosed – and the 
journals are too. And so are the patient groups. And finally, academic papers, 
which everyone thinks of as objective, are often covertly planned and written by 
people who work directly for the companies, without disclosure (Goldacre 2012, 
p. xi). 
 
‘Big Pharma’ was a commercial and critical success and remains popular today. ‘Bad 
Pharma’ ended with a call to action for healthcare professionals, academics, industry 
employees and the public. Goldacre subsequently used the success of the book as a 
springboard for the activist campaign ‘AllTrials.’ Echoing the sentiment of the final 
chapter of Goldacre’s book, the campaign offers resources on how to ‘fix medicine.’  
‘Bad Pharma’ was, however, less popular within the industry. The Association of the 
British Pharmaceutical Industry (APBI) issued a statement in response to the book’s 
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publication, stating that it highlights historic issues which are no longer a problem; 
indeed, one informant I spoke to accused Goldacre of scaremongering. 
 
6.4 Self(ish) Regulation 
The existence of such scandals begs the question: how is the industry regulated? We 
might expect companies which hold our lives in their hands to be subject to intense 
regulation. However, interestingly, the pharmaceutical industry in the UK entirely funds 
its own regulation, a regulatory style which has remained unchanged even in the wake 
of such aforesaid scandals. 
  
Government regulation is conducted by the Medicines and Healthcare Products 
Regulatory Authority (MHRA). The MHRA is an executive agency formed by the 
government to ensure the safety of medications and medical devices. They are 
responsible for activities such as regulating clinical trials, granting market authorisation 
for new medicines, and conducting post-marketing surveillance to monitor the side-
effects of medicines already on the market.  
 
As the MHRA is government run, it should function independently and prioritise the 
needs of the public. However, the MHRA is not funded by tax-payers. Instead, it is 
funded by fees administered to pharmaceutical companies. This funding model has 
led to accusations that the MHRA is biased and prioritises the interests of 
pharmaceutical companies over the safety of the public. Moreover, the current Chief 
Executive of the agency, Dr Ian Hudson, previously worked for GSK. Whether or not 
a history of working in the pharmaceutical industry should exclude someone from such 
a role is debateable, as experience in monitoring the safety of medications for a 
company could be valuable for the role. However, notably, Hudson defended GSK as 
an expert witness in a trial where he testified that he had seen no evidence to suggest 
that Seroxat had caused any person worldwide to commit suicide (Healy 2012a). 
 
The ABPI is a trade association comprising pharmaceutical companies. They 
introduced their first voluntary code of practice in 1958 (Herxheimer and Collier 1990). 
As a trade association, the ABPI both represents and comprises pharmaceutical 
companies operating within the UK. Due to the status of the ABPI as a trade 
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association, criticisms have been made regarding the phenomenon of ‘regulatory 
capture’. Regulatory capture occurs when the functions of a regulator are corrupted 
by sharing a common interest with the subjects of regulation. In the case of the 
pharmaceutical industry, by being both the enforcers and subjects of regulation, it is 
argued that regulation cannot be truly enforced (Herxheimer and Collier 1990). This 
issue is compounded by the lack of historic transparency that characterises the 
industry, which Abraham (2008) describes as ‘highly secretive. 
 
The core component of the regulation by the ABPI is the code of practice known 
througout the industry as ‘The Code’. The Code outlines the rules for promoting 
prescription medicines, and therefore serves as the regulatiory backbone for all of the 
activities explored in this thesis. The Code is revised every year or so, with the most 
recent version being released in 2016. For the purposes of this research, I have 
obtained all eight codes of practice (plus one addendum) from 2006 to 2016, as well 
as two which predates that period. Each year the number of pages increase (except 
in 2014-2015 where the number of pages stayed at 71), reflecting an overall trend in 
increasing regulation. More recent iterations of the code have seen the inclusion of 
sections on issues such as how to interact with patient groups, as well as the content 
of pharma-funded medical education. Conversely, rules on the value of gifts PSRs are 
asllowed to give to healthcare professionals have been scrapped in favour of an all-
out-ban. It is likely that this ban corresponds with the 2010 Anti-Bribary Act, a law 
which covers all businesses but is frequently cited as impacting most heaviliy on the 
pharmaceutical industry. The prescise impact of these changes in regulation will be 
explored in the following chapters. 
 
Infractions of The Code are dealt with by the PMCPA. Set up by the ABPI in 1993, the 
PMCPA holds courtlike hearings on alleged infractions to the ABPI code of practice. 
These take place in response to reports from other pharmacuetical companies, the 
media or the public that rules have been broken. Similarly to a court, the PMCPA 
explores whether an infraction has taken place, and what the reprocussions should 
be. The PMCPA highlights on their webside that they are ‘the self-regulatory body 
which administers the Association of the British Pharmaceutical Industry’s (ABPI) 
Code of Practice for the Pharmaceutical Industry independently of the ABPI’ (PCMPA 
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2018). Within their own definition, they characterise themselves as both outsiders 
(‘independent’) and insiders (‘self-regulatory’). They promote the idea of being 
separate from the ABPI, whilst, simultaneously, occupying the same floor of the same 
building on Victoria Street, London (ABPI 2018; PCMPA 2018). 
 
The PMCPA was established after Herxheimer and Colliers’ (1990) article criticising 
the ABPIs enforcement of The Code and monitoring of infractions. Ironically, 
Herxheimer and Collier (1990) noted that self-regulation favours regulating that which 
can be publically criticised. Twenty-eight years ago, Herxheimer and Collier (1990) 
succinctly explained ‘The ABPI's wish to secure compliance with the code seems 
weaker than its wish to pre-empt outside criticism and action: its self-regulation seems 
to be a service to itself rather than to the public’ (1990, p. 307). As discussed 
previously, the industry has been at the centre of numerous scandals since this article 
was published. However, the pharmaceutical industry continues to be self-regulated.  
 
The findings that are presented in the following chapters of this thesis emphasise the 
persisting relevence of Herxheimer and Colliers’ (1990) assessment. Abraham (2008) 
purports that we can assume overall ‘objective interests’ which go beyond individual 
behaviours or actions. With respect to the pharmaceutical companies, their objective 
interest is to maximise profits. This idea is in keeping with Bakan’s (2010) 
characterisation of corporations as psychopaths, who must always act in their self-
interest. Therefore, although the following pages paint the picture of an increasingly 
regulated industry, self-regulation, by definition, must always be selfish regulation.  
 
6.5 Marketing Methods 
As said previously, marketing has arguably become the core activity of large 
pharmceutical companies. The self-regulation of the pharmaceutical industry is 
perhaps most apparent when looking at companies’ marketing practices, as these are 
solely regulated by the ABPI. Marketing activities are therefore entirely self-regulated. 
Exploring marketing activities therefore provides a great deal of insight into the motives 
of the industry’s key players. Marketing regulations are published and frequently 
updated in the ABPI Code of Practice (‘The Code’) which is available online. Further 
to this, Malerba and Orsenigo (2015) found that marketing is now the core competency 
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of large pharmaceutical companies. Due to the outsourcing of research and 
development, such companies have become primarily marketing organisations. For 
these reasons, this thesis focuses on how pharmaceutical companies market their 
products. Prozac is frequently cited as one of the most iconic pharmaceutical brands 
of all time due to its successful marketing campaign, which makes antidepressants an 
ideal drug class to examine. 
 
Modern pharmaceutical companies use a variety of methods and approaches to 
promote their products. What follows is an overview of the core techniques used by 
companies to promote prescription medications, and an explanation of how they 
feature in this thesis. However, as the industry morphs and adapts in response to new 
guidelines and societal changes, the methods adopted by companies shift and blur 
accordingly. Consequently, this should not be understood as an exhaustive list, but, 
rather, an overview of the different ‘flavours’ of marketing methods used. 
 
Prescription medications cannot be advertised directly to the public; therefore, 
healthcare professionals are the primary targets of marketing messages. PSRs, 
commonly known as drug reps, are industry employees who have direct contact with 
healthcare professionals. They visit healthcare providers to inform them about (and 
promote) their company’s new medications. In response to regulatory changes and 
various scandals, the role of PSRs has changed in recent years, which will be explored 
in detail in the following chapter.  
 
PSRs are often also responsible for recruiting KOLs. KOLs are high status individuals 
who are respected in their field. Ordinarily, they are consultants and/or senior 
academics who are the tastemakers within healthcare practice. They may work for the 
industry by advising them on their marketing strategy and research methods, or by 
speaking publicly at industry funded engagements. Such engagements are often 
events where healthcare professionals receive continuing professional development 
(CPD) to keep their medical knowledge up-to-date. Companies also fund healthcare 
professional’s attendance at conferences where they invariably have a presence, 
using stands and posters to promote their newest medications. The interaction 
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between healthcare professionals and the pharmaceutical industry will be discussed 
in Chapter 8. 
 
Although, as aforesaid, pharmaceutical companies cannot advertise directly to 
consumers, they can fund campaigns aimed at raising public awareness about a 
condition. Such campaigns are often mediated by PR companies who work more 
broadly to massage the public image of pharmaceutical companies. These activities 
are explored in Chapter 9. 
 
The most overt and observable instance of such marketing can be found in trade 
publications and academic journals. Adverts usually take the form of either one-page 
or two-page spreads, which include images and information about the drug. Below is 
an example of a journal advert for antidepressant Valdoxan, which demonstrates the 
kind of imagery and messages which can be found in such adverts. 
 





Whilst gathering data for this thesis, I collected dozens of printed journal adverts. 
However, this marketing method is currently in a state of flux, as most healthcare 
professionals now view journals online with banner adverts that I have been unable to 
obtain copies of. No healthcare professionals I spoke to reported reading print 
journals. Therefore, rather than dedicate a whole chapter to the analysis of such 
documents, I chose to draw upon them instead as evidence of companies’ core 
marketing messages in other chapters. For example, in Chapter 9 I demonstrate how 
disease awareness campaigns funded by pharmaceutical companies can be used to 
covertly regurgitate marketing messages. 
 
6.6 Conclusion 
Although hard to imagine in a post ‘Bad Pharma’ (Goldacre 2012) world, the 
pharmaceutical industry was once highly trusted. Developers of life-saving 
innovations, many drugs developed during this time had a positive impact on both life 
expectancy and quality of life. However, as time progressed the cost of being 
innovative increased. In response to this pressure, large companies have outsourced 
research and development to instead focus on marketing, which is entirely self-
regulated. 
 
The reputation of the industry has plummeted since the 1990s in response to 
numerous scandals. Scandals involving antidepressants have served as a lightning 
rod for reducing public and professional trust in the industry. The issues highlighted in 
this chapter, including loss of reputation, self-interested regulation, and an increased 
focus on marketing are key for understanding the landscape of the modern 
antidepressant market. Each of the following findings chapters explores a smaller, 
more contained section of the larger biome. However, the issues outlined in this 
chapter are pervasive throughout. The following chapter develops in greater detail 
Conrad’s (2005) point about the increasing dominance of the pharmaceutical industry 
as a driver of medicalisation, through focusing on those directly involved in the 





7. Pharmaceutical Sales Representatives 
 
7.1 Introduction 
The previous chapter established that marketing has become the central activity of 
modern pharmaceutical companies. Leask (2002) wrote about the ‘muscle marketing’ 
that took place in the mid-20th century. This aggressive marketing was delivered by a 
travelling salesforce referred to at the time as ‘detailmen’. Detailmen visited healthcare 
professionals and provided them with ‘details’ about new drugs (thus the name 
detailmen). Although the term detailman has long since died out, pharmaceutical 
marketing is still dominated by a travelling salesforce, now commonly referred to as 
PSRs or ‘drug reps.’ As I write this, the recruitment agency ‘Indeed; is currently hosting 
437 job adverts for PSRs in the UK (in comparison, they are advertising 288 business 
management lecturer positions, 38 social science post-docs and 3739 barista jobs…) 
Evidently, these staff remain central to the marketing strategy of antidepressant 
manufacturers. They are the front-line, the industry foot soldiers (Fisher 1991). Their 
first-hand experience of promoting antidepressants to healthcare professionals make 
them integral to this investigation. 
 
Conrad (2005) argues that medicalisation is now driven primarily by pharmaceutical 
companies, but more details are required about how this works in practice. PSRs are 
on the front-line of the industry, communicating with customers on a daily basis, and 
promoting the messages of the company. Therefore, they provide a unique insight into 
the industry’s role in medicalisation. This chapter focuses on the information obtained 
from the interviews conducted with eight PSRs. Specifically, it explores their accounts 
in terms of what they tell us about the broader issues in antidepressant marketing. The 
chapter begins by defining the role of PSRs, highlighting how the terminology around 
sales work has changed in recent years. Following on from this discussion, PSRs’ 
accounts of their sales strategies are presented. Finally, attention will be turned to 
regulation and how changes in regulation have impacted upon the activities of PSRs, 
and, in turn, what this means for antidepressant marketing.  
 
Each informant was selected on the basis of their experience working for companies 
that market antidepressants. However, they each also had a background in promoting 
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a variety of drugs for physical and mental-health conditions, and observed that their 
experiences across these respective classes of drugs were very similar. Because of 
this, informants often spoke in broad terms about their activities, rather than referring 
to any single drug. The few instances where informants highlighted a specific 
difference in relation to antidepressants will be discussed in detail. 
 
7.2 Who are they and what do they do? 
As discussed in the methods chapter, this thesis is influenced by the work of Derek 
Layder (1993); in particular, his argument for foregrounding history and context in 
research. This section therefore sets out by examining the professional backgrounds 
of the PSRs interviewed. Secondly, I focus on the various job titles held by the 
informants, questioning whether the morally ‘dirty’ nature of the job has contributed to 
a rebranding of these roles.  
 
7.2.1 Professional backgrounds 
In 2005, The New York Times published an article by Stephanie Saul on the industry 
hiring practices for PSRs. The article, titled ‘Give me and Rx: Cheerleaders Pep-up 
Drug Sales’ accused the industry of seeking out and hiring cheerleaders from 
university cheer-squads (Saul 2005). One cheerleading coach interviewed for the 
piece noted that ‘[the pharmaceutical company] don't ask what the major is… 
…Exaggerated motions, exaggerated smiles, exaggerated enthusiasm – [the 
cheerleaders] learn those things, and they can get people to do what they want.’ (Saul 
2005, p. 28). Whilst no academic research has been conducted into this specific 
phenomenon, authors with medical backgrounds who have had contact with PSRs 
often characterise them as overwhelmingly attractive and friendly. 
 
Whilst cheerleading is not as popular in the UK, UK-based PRSs have still been 
described by authors as young, charming, attentive and attractive (e.g. Goldacre 2012, 
p. 279). Although very friendly, none of the PSR informants I spoke to divulged a 
history in cheerleading. However, they did discuss how they got started in the industry. 
Four entered the job directly from university with no prior experience in medicine (Reps 
1 2,3 and 4). Three entered the industry having already established a medical career 
in nursing or pharmacy (Reps 5,6, and 7). These PSRs were recruited by PSRs whilst 
97 
 
working in their medical role. The remaining PSR had established a career in a non-
medical field prior to transitioning into the industry (Rep 8).  
 
The professional background of the informants was particularly relevant in the case of 
those who had a history in medicine. These informants spoke passionately about 
patient outcomes and how their training on ‘the other side of the counter’ enabled them 
to better serve patients. Furthermore, they were less likely to use words such as ‘sales’ 
and ‘customer’ than those PSRs whose careers began in industry. Prior to interviewing 
these informants, I had been unaware of pharmaceutical companies hiring PSRs with 
medical backgrounds. This strategy conflicts with the typical stereotype of PSRs as 
young, sales-minded individuals. Instead, these informants were more mature, having 
already established a career prior to joining the industry, and were thus acutely aware 
of the impact their actions had on patients and the wider medical establishment. The 
unexpected diversity in the professional backgrounds of PSR informants is in keeping 
with a wider strategic shift observed in this thesis, which will be explored in detail in 
the second half of this chapter. 
 
7.2.2 Job Titles 
The term ‘drug rep’ can be found in almost every book criticising pharmaceutical 
industry practices (Goldacre 2012), as well as in film and television (e.g. Zwick 2010). 
The term is shorthand for PSR, which has traditionally referred to pharmaceutical 
industry employees who visit healthcare professionals to provide promotional 
information on drugs. However, the role of PSRs has broadened. In the ABPI code of 
practice, such employees are referred to simply as ‘representatives.’ It notes: ‘The 
term “representative” means a representative calling on members of the health 
professions and other relevant decision-makers in relation to the promotion of 
medicines.’ (ABPI 2016, p. 6). In addition to selling and promoting to prescribers, 
representatives are also involved in influencing decision-makers to get drugs 
approved, get them on formularies and change policies. The evolving responsibilities 
of PSRs has contributed to the splintering of the role into numerous similar, but slightly 
different, roles (see Figure 3), such as key account manager, territory business 
manager, NHS liaison manager, NHS project co-ordinator, medical representative and 
hospital specialist, amongst others. Informants explained that role requirements and 
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terminology differ between companies, but that there is invariably a hierarchy with 
more sales-oriented jobs towards the bottom, and policy-oriented jobs towards the top. 
 
There is a bit of a hierarchy so you kind of work your way up in the 
industry. So, you start with GPs, then there’s hospital specialist, then 
there is some kind of NHS liaison which is now kind of a market access 
type role, where you go and speak to budget holders and affect policy 
and guidelines and visit healthcare professionals, so that’s kind of the 
next level up (Fieldwork Interview, PSR 8). 
 




None of my informants currently held the traditional title of PSR. Instead, most held 
roles such as key-account manager, hospital specialist, etc. Whilst PSR still has some 
usage, it is decreasing in popularity in favour of alternative job titles. As mentioned 
previously, this is likely due, in part, to the changing marketplace, and changing 
responsibilities of representatives; however, there may also be other contributing 
factors to these changes. 
 
For instance, the roles of representatives are becoming more difficult to decode, whilst 
the responsibilities of the individual are not always clearly identified by their title. When 
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asked what their job entailed, one informant, whose specific job title I will not name for 
anonymity purposes, responded, ‘It’s a fancy title for a sales role’ (PSR 2). Although 
all my respondents engaged in self-described ‘selling’ activities, none of them had the 
term ‘sales’ explicitly in their job titles. Furthermore, the term ‘pharmaceutical’ was 
absent from all job titles.  
 
One theory for this change can be attributed to the idea of ‘dirty work’. The term dirty 
work was coined to refer to those occupations which may be perceived as degrading 
or disgusting (Hughes 1962). Whilst promoting pharmaceuticals is not dirty work in the 
same way as collecting rubbish or working with sewage, it could be considered morally 
dirty work. As Paharia et al. (2009) characterise, it is dirty work with ‘clean hands’. 
Morally dirty work is work which is stigmatised by society because of the ethical 
implications of the work. Examples of such occupations might be telemarketers, debt 
collectors and tabloid reporters (Ashforth and Kreiner 1999). Paharia et al. (2009) 
single out the pharmaceutical industry as morally dirty work in contemporary societies.  
 
In their review of existing literature on dirty work, Ashforth and Kreiner (1999) found 
that dirty workers were acutely aware of the social stigma associated with their 
profession. Contrary to expectations, however, the ‘dirtier’ the work, the higher the 
occupational esteem associated with it. Therefore, those doing morally objectionable 
jobs often fail to experience shame or doubt about their professions. Indeed, the 
informants I spoke to reproduced this narrative. Whilst they acknowledged the poor 
reputation of the industry and lamented its portrayal in the media, they nevertheless 
expressed pride in the work they did. The informant quoted below presented a view of 
the media which was common amongst all PSR informants. They highlight how their 
job (selling) can have positive consequences. 
I think generally good news doesn’t make the headlines does it. It's 
normally this drug costs this much money and the company refused to 
drop the prices, or this NHS trust can't afford funding in this postcode 
for this drug and it's very rare that ... I mean you kind of see positive 
things when you hear there's been a new breakthrough in this or a new 
breakthrough in that, but I think it very rarely puts it down to the fact 
that it's been all the money from selling past drugs that's meant that’s 
happened, so I still think there's a lot more that could be done to 
improve from a media perspective the industry... the take on how 




Ashforth and Kreiner (1999) sought to investigate this dichotomy of those who work in 
a stigmatised profession without feeling any shame. The extract above exemplifies 
what they refer to as reframing (Ashforth and Kreiner 1999, p. 421). This is when 
workers devalue negative attributions and recast their work in a positive light. This, 
once again, was common amongst the informants, who invariably focused on how 
their role in creating profit for their company had a positive societal impact (as with 
PSR 1), or helped patients.  
 
The authors also found that a similar phenomenon of ‘refocussing’ helped increase 
esteem among dirty workers. That is, ignoring the aspects of the job which are socially 
stigmatided and focusing instead on those which are less so. The evolution and 
diversification of job titles for PSRs may be an example of companies encouraging this 
refocussing, and attempting to increase occupational esteem. Removing the words 
‘pharmaceutical’ and ‘sales’ and replacing them with words like ‘medical’, ‘specialist’ 
and ‘manager’ may encourage workers to focus on the less stigmatised aspects of 
their jobs.  Job titles can therefore be used to mitigate the stigma associated with dirty 
work, as they can be rebranded to construct a positive identity (Ashforth and Kreiner 
1999).  
 
Therefore, it appears that the stigma associated with sales, the pharmaceutical 
industry, and the intersection of these in the term ‘PSR’ has also contributed towards 
this change in terminology, particularly in the wake of  the Seroxat scandal and others. 
Although none of the employees I interviewed currently held the job title of PSR, the 
term is still used as an umbrella term by informants and regulators. In this thesis, I 
therefore continue to refer to all those informants who engage with healthcare 
professionals with the aim of promoting a medication as PSRs. As exemplified by Rep 
2, a sales role with a fancy title is still a sales role… or is it? 
 
7.3 Are Drug Reps the Devil’s Foot-Soldiers? 
Earlier in this chapter, I presented the argument that the job titles of PSRs had 
changed in response to increased stigma. This section explores if and how the jobs 
themselves have changed. I discuss whether PSRs remain primarily sales people, or 
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if, in response to scandals and increased regulation, they have become technocratic 
experts. I begin by considering the critical argument that PSRs are simply sales-people 
using manipulative strategies to promote the prescription of their product. Secondly, I 
question the idea that PSRs have evolved along with their job titles, becoming 
objective experts who operate without an agenda. Ultimately, I draw upon Abraham’s 
(2008) notion of ‘neo-liberal corporate bias’ to argue that the improvements in the 
practices of PSRs, whilst rendering old stereotypes obsolete, are driven by 
enlightened self-interest, rather than out of a duty to patients. 
 
7.3.1 PSRs as Manipulators 
In the Hollywood film Love and Other Drugs, Jake Gyllenhaal plays, Jamie, who is a 
PSR. Jamie is trying to persuade doctors to switch from Prozac to Zoloft, using his 
charm and charisma to manipulate staff at surgeries. Adhering to the stereotypes 
outlined in the previous section, he is young and attractive, seducing everyone in his 
wake. In an interview on the podcast Science Vs., Dr David Tauben discussed how 
seduction can lead to increased prescriptions.  
It’s seductive. And I use the word intentionally because it’s seductive 
to be able to do something so difficult so simply [treat a condition with 
a pill]… …It’s seductive when you get pens and coffee mugs that 
market the product, and it’s seductive when they pick super attractive 
people (PSRs) (cited in Zuckerman 2018). 
 
Although ‘sales’ is no longer a word commonly used in the job titles of PSRs, PSR 2 
suggested that, at their core, all such roles are sales roles. Indeed, one healthcare 
professional I spoke to who trained PSRs likened the role to selling cornflakes. 
Numerous studies have found that engaging with PSRs has an impact on healthcare 
professionals’ prescribing patterns (Muikers et al. 2005; Katz et al. 2010). Healthcare 
professionals who interact with PSRs are also significantly more likely to prescribe 
new medications. This is why ex-rep Fugh-Berman and co-author Ahari (2007) 
suggest that PSRs have too much impact on prescribing decisions. This undue 
influence is reported as stemming from the use of questionable practices to manipulate 
prescribers. For example, the use of personality typing to target prescribers has been 
described in detail in extant literature and supports the stereotypical image of PSRs 
as manipulative. Furthermore, the practice of PSRs providing healthcare professionals 
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with gifts and hospitality has been criticised for its impact on prescribing (Katz et al. 
2010). This section presents an analysis of the use of these techniques and examines 
how they relate towards the negative perception of PSRs. 
 
7.311 Personality Typing 
Several ex-PSRs have written books and academic journal articles detailing the 
strategies they were taught to use whilst working in the industry (Oldani 2004; Reidy 
2005; Fugh-Berman and Ahari 2007). One common strategy discussed in all these 
accounts is personality typing. Fugh-Berman and Ahari (2007:621) noted that PSRs 
are trained to ‘assess physicians’ personalities, practice styles and preferences.’ The 
use of personality typing is pointed to by whistle-blowers as evidence of PSRs’ ability 
to covertly manipulate prescribers, and, as such, undermine evidence-based 
medicine. 
 
Personality typing is predicated on the idea that understanding the inner workings of 
a person gives rise to insight about how best to sell to them. In marketing terms, it can 
be referred to as a ‘micro-segmentation’ technique, which itself falls under the slightly 
broader umbrella of psychographics. According to McDonald and Dunbar (2004), 
psychographics refers to ‘a customer’s inner feelings and predisposition to behave in 
certain ways’ (p 158). There are various psychographic segmentation models which 
are popular in business-to-business selling, as evidenced in Figure 4 below which is 









As discussed in the previous section, PSRs engage with healthcare professionals who 
are primarily involved in prescribing or setting budgets and guidelines. Not all of the 
models outlined by Barry and Weinstein (2009) are relevant for my purposes here in 
this research. Indeed, there are other relevant models not outlined in this table, but it 
still offers insight into the nature of such typologies. Typically, sales people are 
directed to assess the psychographic attributes of an individual (e.g. personality, 
beliefs, values), assign them to a class based on their findings, and then tailor their 
sales pitch to reflect the classification of the individual.  
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Fugh-Berman and Ahari’s (2007) paper is now over a decade old and is focused 
exclusively on Ahari’s own experiences as a PSR in the US. However, my informants 
reported that personality typing is also used in the UK. They referred to some of the 
classifications included in the Myers and Snow typology and LAMP listed in Figure 4 
above, as well as the notorious Myers-Briggs personality test and other typologies. 
It’s just understanding how different people work. So, there’s loads of 
different models, but you know, different colours, or you know like the 
Myers-Briggs type indicator… kind of typing people and adapting your 
style for those people so that you get on with them, basically as 
customers, or have the best possible chance of having a relationship 
with them (Fieldwork Interview, PSR 1). 
 
The informant framed the approach as relationship-building and facilitating good lines 
of communication. After disclosing this approach, the informant added: 
That’s not meant to sound manipulative in any way, it’s just, you know, 
management skills I guess (Fieldwork Interview, PSR 1) 
All informants were acutely aware of the ‘unethical’ reputation of the pharmaceutical 
industry, and the criticisms regarding their influence as PSRs. The informant was keen 
to clarify that the approach was not intended to be manipulative. However, the line 
between what constitutes good communication and what is, in fact, manipulation is 
blurry, as evidenced by the ongoing debate surrounding targeted online advertising 
(Persily 2017). Having utilised psychographic methods throughout their career, one 
informant spoke of the personality trends they had identified within different 
specialties: 
Each specialty has its own personal traits. Orthopaedic surgeons tend 
to be alpha male, headstrong, kind of God-like figures who are quite 
brash and racist and sexist and the rest of it … whereas 
rheumatologists are soft, dermatologists very wet. You know, GPs tend 
to be quite boring. It’s easy to put them into a category, although it’s 
probably slightly unfair. But, yeah, psychiatrists tend to be slightly more 
eccentric, less rigid in terms of what their thoughts are in terms of 
prescribing. Keener to try new medication’ (Fieldwork Interview, PSR 
3). 
This informant enjoyed working on psychiatric medications due to the perceived 
openness of psychiatrists. A PSR selling an antidepressant can interact with 
psychiatrists, GPs, or a combination of the two. It is possible that the differences 
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between GPs and Psychiatrists observed by this informant were, in part, related to 
their relationship to the medicine they were promoting. GPs treat mild to moderate 
depression and, indeed, GP informants reported sticking quite rigidly to formal 
guidelines from NICE or their commissioning group. Conversely, psychiatrists see 
patients with severe, or ‘treatment resistant’, depression where the patient has not 
responded to previous medications. They thus have more freedom in prescribing 
branded antidepressants. This informant also noted that, as long as the healthcare 
professional was somewhat open to prescribing new medication, they could have ‘a 
lot’ of influence on prescribing. This acknowledgement was an anomaly in the 
interviews. Most PSR informants framed their work as primarily communicating 
information. They noted that, due to the distance between their conversation with the 
healthcare professional and the healthcare professional’s decision to prescribe, they 
had little control over the situation. This contradicts existing research which suggests 
PSRs have considerable influence on prescribing (e.g. Muikers et al. 2005; Katz et al. 
2010). Such research tends to compare the prescribing patterns of those who do see 




PSRs organise meetings with healthcare professionals to discuss their product and/or 
the broader disease area. Historically, this has included flying healthcare professionals 
to exotic locations and feeding them expensive meals. Examples such as these are 
verified by healthcare professional informants who were afforded such experiences by 
PSRs promoting antidepressants during the Prozac boom of the 1990s. Their role as 
recipients of such hospitality is discussed in more detail in the following chapter. This 
section focuses on the use of hospitality by PSRs to facilitate sales. 
 
Although examples of lavish hospitality are prevalent in accounts of activities in the 
1990s and in wider popular culture, more recently The Code has incorporated stricter 
rules regarding hospitality. The 2016 ABPI code of practice has over two-pages 
dedicated to the regulation of meetings, hospitality and sponsorship. The following two 
extracts articulate the core tenets of the regulation. 
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the venue must be appropriate and conducive to the main purpose of 
the meeting; lavish, extravagant or deluxe venues must not be used, 
companies must not sponsor or organise entertainment (such as 
sporting or leisure events) and companies should avoid using venues 
that are renowned for their entertainment facilities 
and 
the subsistence associated with the meeting must be secondary to the 
nature of the meeting, must be appropriate and not out of proportion to 
the occasion (ABPI 2016, p. 32) 
 
Prior to these changes in regulation, PSRs were able to take healthcare professionals 
for expensive meals at lavish locations. The most scandalous  example in the literature 
on PSR hospitality describes PSRs taking healthcare professionals to a strip club 
(Goldacre 2012, p. 281). The PSRs I spoke to only admitted to taking healthcare 
professionals for meals:  
I would have been allowed to have presented my product and um, 
talked to the doctors about a product, and then they would have sat 
somewhere else separate to the general public and had a meal 
(Fieldwork Interview, PSR 8) 
If the meal did not take place anywhere overly lavish, and cost less than £75 per-head 
(which, arguably, is still fairly lavish) then it is possible that such a meal would still be 
permissible today. One PSR noted that healthcare professionals became so 
accustomed to having the industry pay for hospitality, that they felt they deserved 
payment simply for listening to the PSR. 
People were asking you to sponsor a lunch meeting at a GP practice 
and you'd turn up and an invoice is provided, and you are expected to 
pay. There was no food and there was no other content of any financial 
sort of thing that had cost money, and yet there was an insistence that 
that opportunity to come and talk about your product you would pay. 
Although it was never termed in that way and I came across that in a 
few instances … I felt that it was an abuse by the healthcare 
professional of what they saw as an opportunity potentially just to 
charge sales reps for coming and speaking to them (Fieldwork 
Interview, PSR 2) 
This example would certainly represent a breach of The Code today, however due to 
the historical nature of the example it is unlikely that it constituted a breach at the time. 
None of the PSR informants I spoke to reported breaching any regulation regarding 
the provision of hospitality for healthcare professionals. However, breaches have 
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occurred. When breaches are reported and investigated, they are published on the 
website of the PMCPA, the organisation set up by the ABPI to assess complaints. One 
such example was investigated by the PCMPA after an ex-employee of Cephalon 
leaked a document which had been circulated to employees.  
 
The document included feedback from delegates the company had sponsored to 
attend a European congress in Lisbon. Testimony from the PSR included in the 
document stated ‘we then went to a few bars and to a club until 3am – a few good 
photos to prove it!!!’(PCMPA 2010). Receipts provided for the investigation highlighted 
that early-morning cocktails and spirits had been purchased for delegates using 
company money, in addition to evening meals ranging from £43-57 per-head, whilst 
on one evening the delegates had been taken to see a group of fire eaters. The 
PCMPA panel assessing the case concluded that the hospitality was not secondary to 
the congress, but, rather, the trip appeared to be a social event with a ‘general party 
mood’. A core concern of the panel, which is a branch of the industry’s self-regulation, 
was the impact that such activities would have on the reputation of the industry. The 
panel ultimately concluded that the company were guilty of providing excessive 
hospitality and ‘bringing discredit upon and reducing confidence in the pharmaceutical 
industry’. 
 
There are other examples of hospitality related breaches on the PCMPA website, 
however they appear to be relatively rare. In 2016, two cases related to hospitality and 
travel for healthcare professionals were found to be in breach of the ABPI code of 
practice. One found Actelion guilty of distributing frozen yoghurt at an exhibition stand 
(only limited quantities of biscuits, sweets or fruit are acceptable). The other, after a 
complaint raised by The Daily Telegraph, found Hospira guilty of flying UK healthcare 
professionals abroad without a valid and cogent reason. Once again, this was deemed 
by the PCMPA as bringing discredit to the industry. Although these instances are rare, 
they testify to the principal motive of the ABPI in regulating hospitality: protecting the 





In the early 2000s, the activist group ‘No Free Lunch’ (No Free Lunch 2017) ran a ‘pen 
amnesty’ whereby they encouraged healthcare professionals to send them their 
pharmaceutical industry branded pens. For every pen sent by a healthcare 
professional, they would receive a No Free Lunch pen in return. The ‘pen amnesty’ 
has since ceased as, due to the sheer number of branded pens they were receiving, 
they could not afford enough pens to replace them. The pharmaceutical industry 
branded pen has since become iconic, and serves as a lightning rod for the wider 
issue of small gift-giving by pharmaceutical companies to healthcare professionals.  
 
Despite ongoing criticism, the 2006 version of the ABPI code of practice still allowed 
PSRs to distribute ‘low-value’ gifts to healthcare professionals and other decision-
makers: 
A low-value promotional aid is one that has cost the donor company no 
more than £6, excluding VAT. The perceived value to the recipient must 
be similar. Items deemed unacceptable include those for use at home, 
such as table mats and road atlases. Acceptable items include pens 
and diaries. Provided that a promotional aid bears no more about the 
product than the brand or non-proprietary name and the company 
name, there is no need to include prescribing information (ABPI 2006, 
p. 28) 
PSR informants recalled how gift-giving was commonplace throughout this time: 
I would remember as a GP representative I’d have pens and I’d have 
post-it notes, and I’d have clocks and I’d have gloves, and sanitiser and 
they would all be branded with the company’s products on. And I’d have 
my garage with boxes of the stuff and I’d hand it all out in surgeries, 
and, obviously, that would leave little brand reminders with the different 
products around in the surgeries (Fieldwork Interview, PSR 8). 
The industry did the whole branded items, here’s a load of pens, here’s 
a load of post-its, here’s some sandwiches, here listen to me and I’ll 
give you a nice lunch while I blabber on about my product, and I think 
a lot of customers in the NHS have experienced that for a number of 
years (Fieldwork Interview, PSR 7).  
Within the medical profession, branded pens became something of a joke. However, 
Katz et al. (2010) found that even low-value gifts, permitted by The Code, can influence 
prescribing patterns. Katz et al. (2010) demonstrated that when a gift is received, even 
one of little value, a precedent is nonetheless set whereby the receiver feels somewhat 
110 
 
obliged to return the favour. Social psychologists theorise that this feeling of obligation 
is subconsciously influenced by ‘reciprocity norms’ (Sah and Fugh-Berman 2013). 
Moreover, the continuing physical presence of the brand within the prescriber’s office 
can itself be a form of influence. Indeed, prescribers may unconsciously develop trust 
in a brand simply from seeing it every day in their pen pot. As one informant noted, 
the decision to prescribe one medication over another is not always based on evidence 
alone: 
Part of it's going to be based on data, but every decision in life is based 
on an emotional factor as well and, simply put, if you added up all the 
attributes and data of one product, one pharmaceutical product and 
compared them in a great big table next to another product, I, or even 
a highly trained doctor, wouldn't be able to compute precisely the 
variables between those two things. You've got to come into an element 
of emotion around the choice they're making. Whether that’s familiarity, 
or whether that's whatever else that may be (Fieldwork Interview, PSR 
2). 
 
The idea that gift-giving increases familiarity with a brand was a key motivation cited 
by informants, who referred to such gifts as ‘brand reminders’ (PSR 8). The most 
recent version of The Code adopts a much stricter stance on small gift-giving: 
 
Gifts such as coffee mugs, stationery, computer accessories, diaries, calendars 
and the like are not acceptable. Gifts of items for use with patients in the clinic, 
surgery or treatment room etc, such as surgical gloves, nail brushes, tongue 
depressors, tissues and the like, are also not acceptable. Items such as toys 
and puzzles intended for children to play with while waiting must not be 
provided. Gifts of items for use in the home or car are unacceptable. (ABPI 
2016, p. 27) 
 
In this version of The Code the only gifts PSRs can leave are educational materials, 
such as leaflets, books, and cheap DVDs, which cannot be overwritten with other data. 
These changes to The Code demonstrate that the pharmaceutical industry is 
becoming more regulated in response to ongoing criticism. The oft-referred to 
stereotypes of PSRs using gifts and lavish hospitality to manipulate doctors into 




7.3.2 PSRs as Technocratic Experts 
Thus far, the critical portrayal of PSRs as covert marketeers and manipulators has 
been explored and critiqued. Evidence suggests that PSRs did historically wield too 
much influence. Rather than being guided by medical facts, prescribers were, albeit 
only to some extent, influenced by the gifts and hospitality administered by PSRs. 
More recently, changes in regulation have reduced the capacity of PSRs to influence 
prescribers in this way. So, in the absence of branded pens and fancy hotels, what do 
PSRs do now? This section explores the notion that the role of a PSR has become 
more technocratic, that is, that they have evolved from acting as purely sales-people 
to patient-focused experts. Firstly, two core PSR strategies are presented which are 
suggestive of this move away from prioritising profits at all costs towards prioritising 
patient outcomes. The PSRs interviewed felt strongly that the industry has changed 
for the better, and, as such, that the critical view of the industry presented in books 
such as ‘Bad Pharma’ are out-of-date. With this in mind, the section concludes by 
outlining their views on the ethics of the industry. 
 
 ‘The Right Patient’ 
One strategy mentioned by almost every PSR informant centred on being ‘patient-
focused’ and specifying ‘the right patient’ for the drug. One informant, an ex-nurse, 
spoke passionately about using their role to improve the lives of patients.  
I talked very much about the right kind of patients and how it would 
benefit a patient … and, you know, not downplaying any side-effects 
and things but helping to educate doctors or the nurses about how they 
might manage that particular side-effect to make sure the experience 
for the patient was as good as possible as well (Fieldwork Interview, 
PSR 5) 
Whilst this informant was particularly empathetic towards patient needs, perhaps as a 
result of their history in nursing, other informants specified that being ‘patient-focused’ 
was not purely altruistic, as highlighting the ‘right patient’ also had commercial 
benefits. 
If you actually do your job and you put the patient, whoever the patient 
is in your particular disease area, if you put the patient at the centre of 
the work you’re doing, whether that’s project work, whether it’s 
conversations with clinicians, you always focus on the patient, then 
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actually, you won’t go far wrong because that’s what people (healthcare 
professionals) are trying to do … What you’re trying to do as a company 
is get much more effective care in the particular disease area you’re 
working in (Fieldwork Interview, PSR 8) 
In this way, being patient-focused works in an analogous fashion to profiling the 
personality types of healthcare professionals. Healthcare professionals are motivated 
by wanting to help their patients, therefore PSRs can use being patient-focused as a 
means through which to build trust and rapport. Furthermore, PSRs reported using 
patients as illustrations, asking the healthcare professional, for example, to imagine 
the next patient they encountered who had treatment resistant depression or suffered 
from certain negative-side effects. The PSR would then talk about how trying their 
medication with that patient could be beneficial. The term ‘appropriate use’ also 
occurred several times to describe a medicine being prescribed only with the ‘the right 
patient’ and in the correct dosage.  
‘A large part of training is to get (PSRs) to be patient-focused and to 
make sure they identify, or help medical people identify the right person 
who will benefit the most from any particular treatment they’re involved 
in selling … It’s always about appropriate use and who those patients 
should be. I think, overall, it’s very patient-focused, but with a 
commercial aspect which, unfortunately, wins the day. But, as I say, we 
wouldn’t be here if we didn’t do that. If you let your heart rule your head 
every time you’d be bankrupt, believe me’ (Fieldwork Interview, PSR 6) 
The need to specify that they are promoting the drug only for usage in patients who 
will benefit from taking it should be redundant. However, the ‘Seroxat Scandal’ serves 
as a powerful example of how antidepressants have historically been promoted for 
inappropriate usage in adolescents, which, ultimately, resulted in suicides. In the wake 
of such scandals, the industry is keen to improve its reputation and avoid future 
scandals. Therefore, this promotion of ‘appropriate use’ in ‘the right patient’ should 
lead to healthcare professionals having a positive experience when prescribing the 
drug and, in turn, making them more likely to prescribe it again, rather than 
experiencing a bad reaction which could lead to another scandal or the healthcare 
professional never prescribing the drug again.  
 
Overall, the interview data suggests that the profit motive still drives the strategy 
enacted by PSRs. This is reflected in the personality typing which is still in use, 




Key Account Management 
The use of the title ‘key account manager’ by many companies to describe their PSRs 
is reflective of a broader shift in sales strategy. The term key account management 
(KAM) derives from business-to-business marketing, whilst academics have 
attempted to pin down its precise definition for decades. Drawing upon previous efforts 
to define the term, informed by their own consultancy work within the pharmaceutical 
industry, Smith (2009) identified five ways in which KAM differs from traditional sales 
management. The first way in which KAM differs from traditional sales management 
is that ‘Key accounts create more than financial value’ (Smith 2009, p 90). This means 
that, in addition to financial value, KAMs are providing other ‘values’ in the form of 
relationships and possibly services. The other differences Smith identifies centre 
around the ‘value’ posed to both sides: ‘Key accounts are key to both partners’ (2009, 
p 90), ‘Key accounts have longevity’ (2009, p 91), ‘Key account managers facilitate 
rather than sell’ (2009, p 91), and ‘Key accounts have multiple relationships’ (2009, p 
91)’.  Smith’s article also points to five species of KAM and five lessons in applying 
KAM. Overall, Smith (2009) suggests that KAM is defined as a long-term, mutually 
beneficial relationship, one which goes beyond a financial transaction to deliver added 
value. A PSR who held the title of a key account manager echoed this sentiment of 
attempting to add value beyond the financial: 
When I started in the industry, it was much more of what we’d refer to 
now as a transactional sell. So, very traditional. I would go in, the 
healthcare professional would sit in front of me and I would go through 
this is the disease area, this is the patient, this is what the product does, 
this is what’s different about us. Very much one way, getting the 
message to the healthcare professional … Today, it’s much more kind 
of what we’d call a consultative approach. So, rather than going in with 
your agenda straight away with this is the disease area I want to talk 
about, trying to understand firstly from the customer that you’re in front 
of, what’s their agenda, what are they trying to achieve and what are 
they trying to work towards, and what’s important to them before you 
start talking about how you feel you could perhaps support and add 
value to what they’re trying to do. So, it’s a lot more integrative in some 
ways and it’s looking for opportunities to work in partnership or work 
together on a project, normally in an area where the company has 
obviously got products (Fieldwork Interview, PSR 7). 
The described changes to the role in the extract above are in keeping with Smith’s 
(2009) definition of KAM. However, as the informant alluded to, financial value is still 
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the ultimate aim. Relationship value and collaboration are window dressing for the 
overall financial agenda. 
 
7.3.3 PSR Attitudes 
Earlier, Ashforth’s (1999) work on how dirty workers develop a positive professional 
identity was used to account for changes in PSR job titles. Ashforth (1999) notes that 
workers in stigmatised professions often develop a strong, positive professional 
identity. Each PSR I spoke to was proud of the industry they worked in, and, contrary 
to research in other ‘clean’ industries, they were pleased with increased regulation. 
I think it’s really good, I think the industry should be regulated and 
should be really transparent about what they’re doing, and if they are 
providing education for healthcare professionals then it should be a 
proper medical speaker who comes in and presents his (sic) own 
opinion and his (sic) own views, rather than me stood up there talking 
about a company product, then everybody sits down and has a curry 
(Fieldwork Interview, PSR 8). 
Reputation was frequently cited as a key argument in support of regulation. 
Nobody would probably share anything like that (unethical) with me, 
because I’m a bit of a stickler. Mainly because it’s only by being like 
that that we are going to improve the industry’s reputation (Fieldwork 
Interview, PSR 1).  
So, now, even how regulated we are, I think it’s good that people see 
a difference and think “ah, actually this is completely different to how 
the industry used to be allowed to work.” I think it’s really good for the 
reputation of the industry (Fieldwork Interview, PSR 8). 
None of the PSRs I interviewed admitted to partaking in any behaviours forbidden by 
The Code. This, however, does not necessarily indicate that infractions never take 
place. Due to selection bias, it is wholly possible that only PSRs who felt they behaved 
in a manner in keeping with The Code would speak to me, or, alternatively, they may 
not have felt comfortable disclosing any such infractions. Having said this, informants 
did discuss rumours of infractions by others: 
I’ve heard stories, usually with other companies where you know 
someone, and some that made the headlines, some companies taking 
doctors to a blooming strip club or something like that, and, you know, 
I’ve heard those kinds of stories, you know, but other than that there 
might have been like the odd presentation that’s got used that’s not 
fully gone through (Fieldwork Interview, PSR 1) 
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Informants referred to their own behaviour as ethical, citing following rules such as 
The Code as a benchmark, e.g. ‘I’ve always been really ethical and followed any rules’ 
(PSR 1). Regulation was consistently pointed to as evidence of the industry’s new 
‘goodness.’  
 
7.3.4 Discussion: The verdict 
A long tradition of critical literature exists that presents PSRs as unethical 
manipulators, who use gifts and personality typing to covertly influence healthcare 
professionals into doing their bidding. Indeed, PSRs still engage in personality typing 
(although an informant assured that ‘it’s not in a manipulative way’…). However, in 
other areas which have been criticised, such as gift giving and provision of hospitality, 
the activities of PSRs have become much more regulated. A strategic shift towards 
patient-focused work and KAM emphasise a de-prioritisation in profit in favour of more 
noble goals. Changes in regulation and strategy point to an improvement in the ethical 
standards of the industry, however, as a trainer of PSRs explained, the underlying 
motivation remains unchanged: 
I’ve had it when a rep said to me “I'm trying to make a difference to 
people’s lives because I'm selling an antidepressant.” I said, well, hang 
on a minute you're working for a company that sells a product for 
shareholders and has to make a profit. Your product is the same as 
Kellogg’s selling cornflakes. It's just that you're bound by more 
regulation and have to do it in a slightly more ethical way. But it's still a 
product, and you still have shareholders, and you mustn’t forget that, 
you know’ (Fieldwork Interview, Pharmacist 8). 
 
As noted in the extract above, antidepressant manufacturers are accountable to their 
shareholders. They are guided by ‘the invisible hand’ to maximise profits, and changes 
in regulation and strategy both serve to support this underlying motive. The ABPI 
prioritise the reputation of the industry to the extent that discrediting the industry is a 
breach of The Code punishable by the PCMPA. Abraham (2008) refers to this 
regulatory phenomenon as ‘neo-liberal corporate bias’. Self-regulation by 
corporations, such as is the case in the pharmaceutical industry, leads to a self-serving 
regulatory structure which only enacts rules which benefit the industry. In the case of 
PSRs, they have been regulated away from the parodied image of them as 
manipulators precisely due to this criticism and the harm that it did to the industry’s 
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reputation. Recent years have signalled an increase in regulation pertaining to those 
activities where PSRs intersect with industry outsiders, such as healthcare 
professionals. However, activities which are unseen by outsiders remain unregulated, 
such as the use personality typing. Another example of this is the lack of regulation 
over targeting and bonuses. 
 
Targets 
Each informant spoke of targets they were given. Targets came in many forms, 
including the number of prescriptions, number of individual calls, number of healthcare 
professionals contacted, and number of formularies accessed. Targets changed 
depending on the job.  
As a hospital representative, I would have been targeted on things like 
how many formularies I could get the product on. That was kind of my 
aim (Fieldwork Interview, PSR 8) 
Informants reported that targets were generally achievable simply by ‘doing the job’ 
(PSR 1), and thus did not require them to be overly competitive or engage in unethical 
behaviour to achieve. The only informant across the interviews who reported 
questionable behaviour in relation to PSRs was a pharmacist, who said they were 
sometimes asked to make their orders for generic medications slightly earlier or later 
depending on the timeframe of the PSRs target. 
 
Additionally, PSRs who perform well may also receive awards at annual ceremonies, 
as well as prizes and bonuses. The only mention of targets in the 2016 ABPI pertains 
to how often a PSR can visit a healthcare professional: 
When briefing representatives, companies should distinguish clearly 
between expected call rates and expected contact rates. Contacts 
include those at group meetings, visits requested by doctors or other 
prescribers, visits in response to specific enquiries and visits to follow 
up adverse reaction reports. Targets must be realistic and not such that 
representatives breach the Code in order to meet them. (ABPI 2016:23) 
The rationale underlying this portion of The Code appears to be that, if PSRs were to 
call on individuals too often, then it could be inconvenient for a healthcare professional. 
The Code therefore states that, unless requested by the healthcare professional, 
individual calls to a healthcare professional should not exceed three annually. There 
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is no specified number around the maximum ‘contacts’ permitted. Indeed, the sales 
and formulary targets mentioned by informants do not appear in The Code. Moreover, 
The Code offers no guidance on the incentives to be offered to PSRs for attaining their 
targets. 
 
Incentives for individuals working in the financial services have been heavily 
scrutinised and regulated in response to the scandals surrounding the financial crisis. 
However, there has yet to be a similar level of public scrutiny over incentives for PSRs. 
Although job listings for PSR roles advertise bonuses, I have been unable to gather 
exact information about the size of bonuses that PSRs may expect. One hint in this 
direction comes from a complaint logged to the PCMPA about a healthcare 
professional who went on a Caribbean holiday awarded to her PSR husband. The 
husband was awarded the trip along with a ‘significantly increased cash incentive’ after 
exceeding a sales target for a drug used at his wife’s hospital. In this case, the PCMPA 
(2011) ruled that The Code had not been breached. 
 
Once again, this supports Abraham’s (2008) notion that pharmaceutical industry 
regulation is influenced by ‘neo-liberal corporate bias.’ There has yet to be a scandal 
over the use of incentives to motivate PSRs, and, consequently, there is no financial 
incentive for the industry to increase its regulation of targets or bonuses. The current 
regulation for bonuses is as follows: ‘15.7 Representatives must be paid a fixed basic 
salary and any addition proportional to sales of medicines must not constitute an 
undue proportion of their remuneration’ (ABPI 2016, p. 22). It is not specified what is 
meant by ‘undue proportion’. 
 
Bonuses in the financial services were deemed unethical in that they motivated 
employees to push products on customers for whom the product may not have been 
suitable.  In the pharmaceutical industry, the sales of a drug should be limited to the 
number of people who have the condition and could realistically benefit from using that 
drug. For antidepressants, sales should thus be limited to the population of people 
who have a condition that the drugs can treat. However, the socially constructed, 
elastic nature of diagnoses complicates this issue further. Whether bonuses have the 
potential to encourage PSRs to aggressively promote their product in such a way that 
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sales might exceed the population of patients who may benefit, is, ultimately, unclear 
due to the lack of transparency surrounding bonuses. 
 
7.4 Conclusion 
Because of increasingly stringent regulation on the behalf of the ABPI, PSRs no longer 
partake in the marketing activities which have been subject to ethical criticism. Gift-
giving in the form of pens, stationary and such like has been banned by the ABPI. 
Furthermore, the hospitality PSRs were previously able to offer healthcare 
professionals has significantly reduced in its luxuriousness.  
 
As with the changes observed in other chapters, improving the reputation of the 
pharmaceutical industry appears to be the principal motive driving these changes in 
operations. Pharmaceutical companies’ desire to distance themselves from the 
parodied image they acquired in the 1990s is evident in the job titles of salesforce 
employees. Hospital specialists, key account managers, amongst many others, stand-
in for the contemporary, penless versions of PSRs.  
 
The regulatory changes enacted by the ABPI have been welcomed and go some way 
to reducing the ability of PSRs to influence prescribers based on ‘reciprocity norms’ 
(Martin 2006). Furthermore, criticism of industry practices, and the work of 
investigative journalists in exposing these scandals, have thus made it profitable for 
the industry to adopt a more ethical marketing strategy. However, this success 
demonstrates that allowing the industry to self-regulate in this manner means that only 
observable, publicly criticised activities become regulated. This supports Abraham’s 
(2008) characterisation of pharmaceutical regulation as driven by ‘neo-liberal 
corporate bias’. That is to say, regulation is driven by the interests of the industry, 
rather than the public interest. The onus is thus placed on journalists and academics 
to examine industry practices and campaign for change when objectionable activities 
are uncovered. This reactive regulation can be slow, as demonstrated by the length of 
time it took for gift-giving to be banned by the ABPI. However, until pharmaceutical 
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8: The Healthcare Professionals 
8.1 Introduction 
In the UK, it is illegal to advertise prescription medications directly to the public. 
Therefore, pharmaceutical companies must target different points in the supply-chain 
to increase sales of their drug. Healthcare professionals are the primary target of 
antidepressant marketing messages due to the prescription-only status of the 
medications. Pharmaceutical companies also collaborate with charities to increase 
demand for their products by increasing awareness about the condition the product 
treats. This section looks at the targets of antidepressant marketing efforts. Firstly, this 
chapter examines the role of healthcare professionals and their complex relationship 
with companies. The following chapter focuses on disease awareness campaigns, 
arguing that, whilst these have been co-opted by companies to promote marketing 
messages, more recent campaigns have included less disease mongering. 
 
In addition to being the targets of the pharmaceutical industry, healthcare 
professionals are also its paid collaborators and advisors. However, this distinction is 
often a blurry one. Critics argue that any contact with the pharmaceutical industry has 
the potential to influence attitudes towards a specific drug and, ultimately, even in 
relation to prescribing. Therefore, even whilst working on behalf of the pharmaceutical 
industry, they may also be subject to marketing messages. Whilst this is a compelling 
argument that will be explored in this chapter, the phenomenon of healthcare 
professionals receiving funds from pharmaceutical companies will be discussed 
separately from the discussion of healthcare professionals as consumers of marketing 
materials. This separation is a practical one, which allows for a better exploration of 
the issue of healthcare professionals being paid by pharmaceutical companies, rather 
than acting as a statement on the nature of these interactions. 
 
This chapter investigates the ongoing and ever evolving relationship between 
healthcare professionals and Big Pharma antidepressant manufacturers, through 
focusing primarily on three kinds of healthcare professionals: GPs, Psychiatrists and 
Pharmacists. Firstly, the roles of healthcare professionals in the antidepressant 
supply-chain will be presented, with particular reference to both how this influences 
the extent to which they are targets of marketing messages and how they manage 
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this. Secondly, I focus on interviews with informants who have received thousands (in 
some instances hundreds of thousands) of pounds in exchange for consultancy work. 
I present their experiences and examine their motives in relation to existing literature 
on the ethics of pharmaceutical collaboration. I then explore the role played by 
antidepressant manufacturers in educating healthcare professionals, ultimately 
characterising this as a no-win situation. 
 
8.2 The Gatekeepers 
All antidepressants produced by the pharmaceutical industry are classified in the UK 
as prescription-only. Resultantly, the drugs can only be legally obtained under the 
authorisation of a sufficiently qualified medical professional and cannot be sold directly 
to patients. Therefore, as is the case with antibiotics and asthma inhalers, if you require 
a SSRI, you first need a prescription from a medical professional. This places 
healthcare professionals in an integral position in the antidepressant supply-chain. 
They are the gatekeepers of medical resources and therefore a valuable target 
audience for antidepressant marketing efforts. In this section, I focus on interviews 
with healthcare professionals most involved in gatekeeping: GPs, psychiatrists and 
pharmacists. 
 
In addition to acting as an intermediary between Big Pharma and patients on a case-
by-case basis every time they encounter a patient, healthcare professionals also act 
as gatekeepers on a more macro level. Very senior healthcare professionals work with 
NICE to decide whether a medication should be granted marketing authorisation, and 
in what circumstances it should be recommended. Furthermore, on a local level 
healthcare professionals are involved in deciding which medications should be 
included on the formulary (a list of drugs from which practitioners are advised to or 
allowed to prescribe). The term ‘postcode lottery’ is used to describe the different 
healthcare provisions available in different areas. The decision about whether to 
include a drug on the formulary is complex, and sometimes requires decision-makers 
to assess conflicting evidence over the safety, efficacy and cost-effectiveness of a 
medication, as well as patient accounts about the impact their condition has on their 
lives. Again, healthcare professionals act as the gatekeepers here. In the postcode 
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lottery they are Camelot, selecting the numbers which may (or may not) appear on 
your ticket.  
 
Healthcare professionals occupy a trifecta of gatekeeper roles: on a macro level via 
granting marketing authorisation; on a meso level via curating formularies; and on a 
micro level via writing prescriptions. For medications where there is a generic 
alternative, pharmacists occupy a forth gatekeeping role via deciding which brand of 
medication should be dispensed.  Before an antidepressant reaches a patient, it must 
overcome at least three hurdles guarded by healthcare professionals. Healthcare 
professionals are therefore at the centre of antidepressant manufacturers’ marketing 
strategies. However, in a post Bad Pharma (Goldacre 2012) society, the access 
companies have to gatekeepers is changing, which is the focus of this chapter. 
 
The following section explores healthcare professionals’ roles as decision-makers in 
the antidepressant supply-chain and their experiences as the targets of antidepressant 
marketing campaigns. The chapter demonstrates that healthcare professionals 
occupy diverse roles in their relationship with pharmaceutical companies, and 
presents findings for each of these professions in turn, before, finally, exploring how 
these findings relate to existing regulation. 
 
8.2.1 General Practitioners (GPs) 
As the first port of call for most individuals when accessing healthcare services, GPs 
are responsible for diagnosing the majority of cases of depression, and, hence, 
prescribe the most antidepressants. Every GP interviewed reported using the local 
formulary and NICE guidelines when deciding what antidepressant to prescribe, in 
addition to their personal experience.  
 
GPs reported less interaction with the pharmaceutical industry than psychiatrists. 
Although I interviewed fewer GPs than psychiatrists (5 GPs vs. 10 psychiatrists), this 
finding was supported by my interviews with pharmaceutical industry employees. 
I’ve not actually had any interaction with anyone (from the 
pharmaceutical industry) regarding depression. I think that’s probably 
more psychiatrists than GPs, trying to appeal to them (Fieldwork 
Interview, GP 2) 
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It’s been a long time since I’ve seen anyone or anyone’s even asked! 
(Fieldwork Interview, GP 1) 
One GP informant did report seeing a PSR. For this doctor, PSRs were 
their only source of information on new drugs.  
I see a drug rep, so I can practice my critical appraisal skills. They’ll all 
say they’re the best. They’ll say it’s not addictive but that’s just because 
there’s no data to say it’s not addictive, not because there’s evidence 
to show that it’s not addictive. They’ll show it has a favourable side-
effect profile, but that’s just because the patients haven’t mentioned 
side-effects (Fieldwork Interview, GP 3) 
Interestingly, although this GP had contact with key account managers about new 
treatments, they reported not prescribing any on patent antidepressants. In addition to 
being aware of new drug treatments, this GP was well-informed of non-drug 
treatments. This GP was also the only healthcare professional I spoke to who, without 
prompt, spoke about offering computerised CBT, which is a first-line option 
recommended by NICE. 
 
Overall, GPs described treating depression as relatively routine and formulaic. Each 
GP had preferences based on personal experience about which SSRI to prescribe 
first, but otherwise followed NICE guidelines in a similar way. If a patient had not 
responded by a third-line treatment, ordinarily involving another off-patent 
antidepressant with a different treatment mechanism, then the patient would be 
referred to a psychiatrist. This finding conflicts with larger sample surveys studying 
GPs adherence to NICE guidelines for the treatment of depression (Toner et al. 2010; 
Herzog et al. 2017). Such studies find that GPs do not always follow NICE guidelines, 
particularly in relation to changing the dosage of an antidepressant, or changing to a 
different antidepressant if the patient is not responding to treatment. In these studies, 
GPs report treating depression less rigorously than the recommendations by NICE. It 
is therefore possible that my sample is biased, due to the fact that only those GPs who 




Those individuals referred to psychiatrists tend to either have very severe depression, 
treatment resistant depression or other co-morbid (co-occurring) mental health 
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conditions. Psychiatrists have more freedom in prescribing newer antidepressants 
than GPs, due to the more specialist patients they see. Therefore, they represent a 
more lucrative target for pharmaceutical marketing. Indeed, one psychiatrist I 
interviewed turned up with a Lundbeck lanyard around their neck (Lundbeck are 
currently actively marketing the antidepressant, Brintellix). Of the healthcare 
professionals I interviewed, psychiatrists reported the most contact with PSRs. 
They sometimes call a secretary and book an appointment to come and 
see me or a colleague, and they’ll have 15-20 minutes and they’ll give 
us refreshments, tell us about new products (Fieldwork Interview, 
Psychiatrist 4). 
Although they received more attention from the industry and were more likely to agree 
to meet with PSRs, psychiatrists described being wary about the fact that the 
information they received was underpinned by marketing motives. 
I try to take what they say with a pinch of salt, although it’s interesting 
… it’s kind of marketing, you have to keep pretty sceptical about what’s 
being said and the motivations for promoting the medications 
(Fieldwork Interview, Psychiatrist 2) 
Although, overall, psychiatrists reported more contact with the pharmaceutical 
industry, my most critical informant was a psychiatrist who refused contact with the 
pharmaceutical industry: 
I like tried and tested and I like a good evidence-base … and I don’t 
mean, you know, look at this graph, that line goes up and that line goes 
down therefore this drug is brilliant, and the others are crap. I just don’t 
fall for that. I’m profoundly sceptical … I’ve read Ben Goldacre 
(Fieldwork Interview, Psychiatrist 3) 
Overall, psychiatrists reported finding PSRs useful for providing some information on 
new medications, although they were sceptical about the information they received. 
The one psychiatrist I spoke to who actively avoided contact with the pharmaceutical 




Prior to undertaking this research, I did not realise the vast scope of career options 
available to pharmacists beyond the local chemist. The tasks undertaken by the 
pharmacists I interviewed included ordering and dispensing medicines, engaging with 
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patients, changing medications, diagnosing, prescribing, advising doctors, 
researching prescribing patterns in marginalised communities, deciding what should 
be allowed on formularies, deciding what drugs should be approved, not to mention 
frequently making life-or-death decisions about what medicines the NHS should fund. 
Pharmacists proved to be particularly integral to the prescription of generic 
medications. 
 
In terms of contact with the pharmaceutical industry, the pharmacists interviewed did 
not report seeing PSRs often. Most PSRs work on newer drugs which are still on 
patent. Consequently, pharmacists do not have the option of switching to a generic 
medication and instead must dispense the branded version. The lack of input of non-
prescribing pharmacists in this process means they are not hugely desirable to PSRs 
working on branded drugs. 
 
The exceptions to this trend are more senior pharmacists who have additional 
decision-making roles, such as contributing to local formularies, NICE guidelines, and 
so on.  One pharmacist that I interviewed had previously been responsible for deciding 
what medicines should be provided for by their health board. New medicines are 
expensive and so it is often down to the health board, trust, or clinical commissioning 
group to decide whether to pay for a drug. We hear about this most often in media 
discussions about the ‘postcode lottery’. The pharmacist I spoke to had to consider 
the price of the drug, the burden of the disease, the efficacy of the drug, and the 
experiences of people with the condition to decide whether to fund the treatment. I 
asked whether they had contact with the pharmaceutical industry as part of this role: 
Yes, yes, I had representatives coming to see me. I thought about 
whether that was appropriate or ethical or not and I decided I would 
rather meet them to understand their marketing strategies, because I 
knew they had access to our prescribers in the community … some of 
my colleagues would not see industry representatives at all, because 
they felt that it was a conflict of interest and unethical, and I took a 
different view (Fieldwork Interview, Pharmacist 3).  
As aforementioned, one pharmacist I interviewed even reported being recruited to 
work for an antidepressant manufacturer whilst working as a pharmacist on a health 
board. Pharmacists are also often key decision-makers when it comes to generic 
medications. Pharmacists are incentivised to prescribe the cheapest possible generic 
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drug via a system which allows them to keep a portion of the money saved against the 
drugs budget. This incentive encourages pharmacists to ‘shop around’ to find the 
cheapest generic drug. However, there is also an incentive to keep to the same generic 
drug, even if a cheaper option is available. Although the active ingredient is the same 
in all generic versions of a medicine, the size, colour, and shape may differ. These 
changes can cause confusion in older patients or patients with learning disabilities, 
thus compromising patient safety. Moreover, changes in medication appearance can 
cause anxiety and produce a different placebo response to the medication. One 
community pharmacist noted that, if they were to frequently change generic providers, 
they may lose customers who could simply go to the pharmacist five minutes down 
the road to get the generic drug they had previously been getting.  
 
Due to the decision-making power community pharmacists have over generic 
prescriptions, PSRs from generic companies sometimes visit. 
They may well come once a month and, say, go through the order and 
say, ‘okay, what do you need this month, is there anything else I can 
give you?’ Sometimes it’s on spec, and they’ll just call in and say ‘I’ve 
got a good deal on this that or the other’ (Fieldwork Interview, 
Pharmacist 5).  
Generic PSRs operate differently from their counterparts working on branded 
medications. Generic sales representatives often sell all the drugs a company offers, 
rather than one or two as is the case with branded medicines. They also have far 
smaller budgets and tend to have more of a supplier relationship with community 
pharmacists, capitalising on existing demand and competing on price, rather than, say, 
trying to generate demand for a new compound as is done by PSRs with branded 
medicines. 
 
Overall, pharmacists form an integral and complex part of the antidepressant approval, 
research, marketing, prescription and dispensation process. Each of these roles leads 
to different interactions with the pharmaceutical industry. 
 
8.3 From Gatekeepers to Locksmiths 
In 2003, the British Medical Journal (BMJ) published an iconic illustration on its cover, 
depicting cartoon pigs drinking wine, eating expensive looking food, playing golf and 
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delivering presentations, all while lizards in suits greedily watch them – see Figure 5. 
The title read ‘Time to untangle doctors from drug companies’ (BMJ 2003). In addition 
to being the targets of the pharmaceutical industry’s covert marketing activities, 
healthcare professionals are also its paid collaborators and advisors. This distinction, 
however, is a blurry one. Critics argue that any contact with the pharmaceutical 
industry has the potential to influence attitudes towards a specific drug and, ultimately, 
in terms of prescribing (e.g. Wazana 2000). Therefore, even whilst working on behalf 
of the pharmaceutical industry, they may still be subject to marketing messages.  
 
Figure 5: BMJ (2003) 
 
 
On the 30th June 2016, the ABPI published a list on their website titled ‘Disclosure 
UK’. The list contains information on payments received by healthcare professionals 
from pharmaceutical companies. With 50,2083 entries on Disclosure UK amounting to 
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364 million pounds, the extent to which doctors have been ‘untangled’ from drug 
companies over the last fifteen years is open to debate.  
 
This section presents the findings of in-depth interviews with ten individuals on the 
Disclosure UK list. Of the healthcare professionals interviewed, six were psychiatrists, 
two pharmacists, one a neuroscientist and a healthcare economist. Disclosure UK has 
been analysed using quantitative methods by the BMJ. This analysis is crucial for 
providing a digestible snapshot of the contents of the database. However, this 
qualitative investigation represents the first attempt to go beyond these figures to 
understand the motives and experiences of healthcare professionals on the industry’s 
payroll.  
 
8.3.1 History: Drug-fuelled hedonism  
This section begins by presenting a historical account of healthcare professionals’ 
experiences collaborating with the industry prior to (and in some ways contributing to) 
the BMJs call to untangle. The discussion is then brought into the present with an in-
depth examination of the nature of this modern collaboration. Ultimately, this section 
presents the argument that, whilst doctors have yet to ‘untangle’ from Big Pharma, the 
way in which they interact with pharmaceutical companies has changed for the better 
due to increased transparency. 
 
The relationships between healthcare professionals and PSRs has received the 
Hollywood treatment, in films such as Side-Effects and Love and Other Drugs. These 
films present the pharmaceutical industry as sexy and manipulative, in addition to 
having undue influence over healthcare professionals. Non-fiction books and 
academic literature have supported this popular image of pharmaceutical companies 
using money and gifts to bribe healthcare professionals to do their bidding (e.g. 
Goldacre 2012; Healy 2006). 
 
Four of my healthcare professional informants had collaborated with antidepressant 
manufacturers during the late 1980s and 1990s, during the time in which many of the 
blockbuster drugs were launched. Each confirmed that the popular depiction of Big 
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Pharma companies as being lavish with their gift-giving and flying people to exotic 
destinations for meetings was true at this time. 
I think 20 years ago some of the things that the companies did in terms 
of entertainment and remuneration, etc., you know, they were clearly 
very questionable. And I think that some of the concerns that have been 
raised about uh, NHS clinicians and academics interacting with industry 
have been very well made, and I think tying up some of the regulations 
have massively improved things. I mean sometimes some of the 
entertainment when you went to an ad board was lavish in the extreme. 
And it was completely and utterly unnecessary (Fieldwork Interview, 
Psychiatrist 9).  
Informants spoke at length, often with fondness, about their lifestyles in the 1980s and 
1990s. Their accounts support the caricature depicted the cover of the May 2003 issue 
of the BMJ in uncanny detail. 
Go back 20 years and if you were at an important advisory board or an 
international board, I remember going to one at a beautiful island on 
the great barrier reef and we were flown to Melbourne and then flown 
on there, and we were staying in a hotel that was normally only 
populated by film stars. Uh, so, it was quite ... apart from doing the 
work, it was quite a nice lifestyle. People enjoyed doing it because the 
companies made a fuss of them and this was at a time when even the, 
sort of, all the meetings, the launch meetings with consultants and 
junior doctors and people could happen abroad and were in fairly lavish 
hotels (Fieldwork Interview, Psychiatrist 6). 
 
The conflicts of interest which arise when healthcare professionals receive funds from 
pharmaceutical companies have been extensively documented. Payments influence 
prescribing (Wazana 2000) and bias the results of research (Lexchin et al. 2003). As 
discussed in the previous chapter, gifts and hospitality can also trigger ‘reciprocity 
norms’ (Katz et al. 2010). Healthcare professionals can subconsciously feel obliged to 
behave in a way which favours those who have compensated them. Although 
healthcare professionals are aware of the potential for a conflict of interest, they do 
not believe that they themselves are biased (e.g. Rutledge et al. 2003). Again, 
corporations are legally-bound to prioritise generating a return on the investment of 
their shareholders. Indeed, if healthcare professionals were impervious to the 
influence of pharmaceutical companies, then prescription patterns would be similar for 
healthcare professionals who co-operate with the pharmaceutical industry and those 
who do not. Instead, researchers such as Muikers et al. (2005) show that ‘pharma 
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friendly’ (PSR 1) healthcare professionals have more expensive and less efficacious 
prescribing patterns than their more hostile counterparts. 
  
Each informant that was interviewed as part of this investigative social science 
approach, and who had worked during the blockbuster era, noted that, whilst 
companies had ‘spoiled’ them in the past with luxury and excess, this popular image 
of pharmaceutical industry interactions was now out-dated. Instead, they noted that 
regulation and reputation preserving sentiments had steered companies away from 
the grandeur of golf courses and five-star hotels towards more down-to-earth 
accommodation. 
Personally, I think it's gone slightly, maybe only slightly, but slightly too 
far in the opposite direction. There are times when companies are 
saying, “well, we can't put you up at that hotel, we've got to put you up 
at this one because we don't want to be seen to be overly influencing 
you”. And their sort of threshold is we won’t pay for you to go and stay 
in any hotel that would be better than one you would pay for yourself. 
Well there's plenty of hotels I've been put up by companies there's no 
way on earth I would have paid for that myself. I wouldn’t, you know, 
they were horrible hotels and I wouldn’t have gone there, but, you 
know, it's probably better to err on that side than on the side of being 
over lavish (Fieldwork Interview, Psychiatrist 9). 
All that's changed radically. Everything’s done on a shoestring and not 
just because they don't have as much money, but because of the 
pressure on drug costs and also just because it's not seen as good 
(Fieldwork Interview, Psychiatrist 6). 
The ABPI code of practice now condemns ‘excessive hospitality’, which they define as 
facilities that are so lavish that the meeting or conference becomes secondary (ABPI 
2016). This change coincides with the banning of small gift-giving. Both of these 
practices have been publicly, most notably in Goldacre’s (2012) Bad Pharma, criticised 
due to their propensity to bias healthcare professionals. 
 
This shift away from activities which have been publicly denounced as unethical is a 
conscious one. In the previous chapter, the pharmaceutical industry employees 
emphasised the importance of improving and preserving the reputation of the industry 
in the wake of scandals. However, scandals, such as the ‘Seroxat Scandal’ discussed 
in Chapter 5, have undoubtedly damaged the reputation and therefore the profitability 
of the industry. Resultantly, companies are improving their ethical standards to protect 
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and improve their reputations. However, profit is still the principal motivation of 
pharmaceutical companies, as I show below when exploring the role of pharma money 
in persuading professional gatekeepers to continue opening their doors to drug 
solutions. 
 
8.3.2 Pharma Money for Professional Judgement  
The previous section demonstrated that the way healthcare professionals are 
incentivised to, and compensated for, interacting with industry has changed. There 
has been increasing regulation of healthcare professional/industry relationships, 
however, as exemplified by Disclosure UK, pharmaceutical companies still pay 
hundreds of millions of pounds each year to healthcare professionals and the 
organisations they work for. This section examines the motivations and experiences 
of healthcare professionals who received money from an antidepressant manufacturer 
in 2015. The term ‘Dark Money’ has been used to describe the power and influence 
that money has in the realm of politics (Mayer 2016). Throughout this section, the term 
‘pharma money’ will be used, partly as shorthand for more cumbersome phrases, but 
also to emphasise the power and influence wielded by such money.  
 
The collaboration between healthcare professionals and pharmaceutical companies is 
a complex and contentious subject, due, in part, to the conflict of interest it gives rise 
to. We would expect healthcare professionals to behave in a manner which prioritises 
patient outcomes, but, conversely, pharmaceutical corporations are structured to 
prioritise profits, in a way that, according to Bakan (2012), renders them psychopathic. 
The two principal ways that healthcare professionals receive pharma money are via 
advisory boards and speaker meetings. Eight of my informants had been paid by 
pharmaceutical companies to partake in advisory boards. Since both advisory boards 
and speaker meetings are reserved for academic healthcare professionals at the 
forefront of their field, there is significant overlap between these two groups of 
collaborators. Everyone I spoke to who had taken part in advisory boards had also 
spoken at meetings paid for by pharma money. One younger psychiatrist had spoken 
at meetings, but not taken part in advisory boards. Healthcare professionals who 





Advisory boards (commonly referred to as ad boards) comprise panels of around eight 
academics/healthcare professionals who give their expert-opinion on various aspects 
of a drug’s development. These are healthcare professionals from a variety of 
disciplines who are well-respected within their field, and who have a good relationship 
with pharmaceutical companies. The decisions they advise on can include advice 
about what research methods to use in a clinical trial, how best to present trial data, 
and what marketing messages the company should focus on. They often take place 
at varying intervals over the course of several years, and the same healthcare 
professionals are usually present throughout the entire ad board process, albeit some 
may leave due to retirement or other work commitments.  
The company people sit in the background and take copious notes, and 
it’s run by a chairman who’s usually one of the academics who all of 
the others trust (Fieldwork Interview, Psychiatrist 6).  
Speaker meetings generally refer to occasions on which a healthcare professional is 
paid by a company to do a presentation. Often the presentation will include slides, 
which are thoroughly vetted by the pharmaceutical company to ensure that all claims 
are evidence-based, that are developed by either the pharmaceutical company or 
created by the speaker themselves. These speaker meetings are ordinarily described 
as educational and tend to focus on disease areas, rather than merely the specific 
company drug. At speaker meetings, healthcare professionals often present to other 
healthcare professionals. The issue of healthcare professionals thus being recipients 
of pharmaceutical industry funded education is explored in a later section. In this 
section, I present the findings of my investigation into the phenomenon of healthcare 
professionals collaborating with antidepressant manufacturers.  
 
The popular depiction of healthcare professionals’ motivations for interacting with the 
pharmaceutical industry is greed. This is exemplified by the use of chubby pigs to 
represent healthcare professionals in the iconic BMJ cover – see Figure 5. Many of 
the informants I spoke to were listed as receiving thousands (even tens of thousands) 
of pounds from pharmaceutical companies. I was therefore interested in the extent to 
which informants were motivated to collaborate with industry by the financial benefits. 
However, the accuracy of the figures listed in the database compared to the amount 
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of money that individuals ultimately received varied. Sometimes, money went to the 
organisation the individual worked for as opposed to directly to the individual, even 
though they were listed as the recipient, and despite the fact that universities and 
health boards can themselves be named on the database.  
You were able to find me through the disclosure of income. Now what 
that doesn’t do is, it doesn’t say where that money goes, it just assumes 
it’s going to me. 90, 95 per cent of the income I get through doing this 
sort of work goes into a university account. It does not come to me, 
personally. So, what it does is, it actually facilitates some of the 
research I do. It doesn’t personally benefit me in any way, in any 
pecuniary way (Fieldwork Interview, Psychiatrist 9).  
Furthermore, in answer to the question of what motivated their collaboration with 
industry, each informant that I had contacted via Disclosure UK claimed that the 
money was not a large factor in their decision-making. Each informant who regularly 
partook in such work was already well-paid from other work. Without prompting, two 
informants told me that they no longer needed to work for financial reasons and that 
they could afford to comfortably retire, but nevertheless chose to continue working.  
 
Contrary to the greedy pigs cartoon, then, which depcits healthcare professionals 
interacting with industry for financial gain, every informant highlighted that their main 
motivation for collaborating with industry was to gain knowledge. 
It’s basically learning. I mean, I don’t need to work, I’m past retirement 
age. I just enjoy it very much. Obviously, the money’s quite nice, but I 
don’t ask a huge fee, I just enjoy the work … It gave me a better 
understanding of clinical trials. It gave me a much better understanding 
of marketing. A better understanding of marketing material, how it can 
be sometimes less than obviously truthful, if you see what I mean. Um, 
how they use particular images to give particular impressions and how 
in the university it helped me teach really, because I was able to teach 
what I learned in terms of trying to engender a more collaborative 
attitude amongst other pharmacists, how to look at clinical trial material, 
and how to review papers to do critical appraisals (Fieldwork Interview, 
Pharmacist 7).  
The fact I’ve been able to get extra information because of going to that 
ad board just puts me further ahead of the curve. If I hadn’t gone to that 
ad board, I’d have still had to find all that information out and it would 
have taken much longer … one advantage of going to an ad board 
where you’ve got other KOLs is you can go, hold on, that doesn’t look 
right, and another KOL goes, no, it does, that’s absolutely fine … You 
can see if your view of the data is something that others would share 
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or whether you’ve completely misinterpreted the data. If you’re sitting 
in an office by yourself, you just had to entirely trust your own reading 
of the data (Fieldwork Interview, Psychiatrist 9). 
These healthcare professionals argue that they gain knowledge when attending 
multidisciplinary forums. Indeed, this argument is supported by the work of 
organisational researchers Randall and Munro (2006). They observed knowledge 
sharing when studying forums between groups of mental health professionals across 
different sectors.  Subsequent to emphasising how the opportunity to learn motivated 
them to partake in such work, each respondent mentioned how the information 
learned, particularly in ad boards, was shared amongst their institutions (Funding for 
educating healthcare professionals is waning in many areas as I discuss later in this 
chapter). A further motivation, closely linked to learning, is early access to data. 
It’s a way of knowing what’s coming before it arrives … I also like having 
access to all the data. I like the privilege of having access to the data 
that, for example, [COMPANY NAME] wouldn’t give NICE. I’ve seen all 
of that and it’s confidential, but it allows you to understand why claims 
are made (Fieldwork Interview, Psychiatrist 6).  
I get the best opportunity to see the full data set of a new medication 
… A lot of the data wouldn’t be (publicly) available, so I’m able to be at 
the forefront of my field (Fieldwork Interview, Psychiatrist 9).  
The availability of trial data is an ongoing hotly contested issue. Indeed, the Seroxat 
scandal was largely a result of hiding data which reflected negatively on the drug. The 
drug was therefore prescribed to adolescents as a safe medication, even though data 
suggested it caused suicidal behaviour. Critics of the industry, led by Ben Goldacre, 
are now campaigning for all trial data to be publicly released (AllTrials.net 2018). 
Whilst the AllTrials movement has made some headway, they have yet to reach their 
ultimate goal. Therefore, ad boards represent the only opportunity I have identified 
where healthcare professionals get to see the full data set for a new medication.  
 
The privilege of early access to data is likely to be personally rewarding, and, indeed, 
healthcare professionals may feel special or important by viewing such privileged 
information. However, there are noble benefits of accessing full datasets. One 
psychiatrist I interviewed specialised in very unwell patients with treatment resistant 
depression. These patients have tried multiple treatments without improvement, and 
so are likely to be the first patients to be prescribed new antidepressants. By viewing 
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the full dataset, my informant emphasised that they were able to be on the cutting 
edge of new treatments that could potentially help their most difficult to treat patients. 
Indeed, the idea that collaborating with the pharmaceutical industry could ultimately 
improve patient outcomes was a popular one in the interviews. As mentioned 
previously, some healthcare professionals felt that, by sharing the insider knowledge 
they gained from pharmaceutical companies with colleagues, they could improve the 
lives of more patients. Moreover, healthcare professionals acknowledged that it was 
only through working with the industry that they had any capacity to change it, and, in 
turn, improve it for patients: 
I feel very, very, strongly that it is important that there is constructive 
engagement with the pharmaceutical industry by clinical academics 
and leading clinicians. I think without that we have no possibility of 
being able to influence what industry does, and if we are not able to 
influence it in any shape or form that is to the detriment of our patients 
(Fieldwork Interview, Psychiatrist 9).  
It’s not work that I do because I have some messianic urge to work with 
drug companies. It’s worked that I do because it seems to me to be 
reasonable and ethical, and it seems to me that I may have an opinion 
that is useful in shaping what happens (Fieldwork Interview, 
Psychiatrist 8). 
Relationships were cited by all informants as an important factor in motivating their 
collaboration with antidepressant manufacturers. Healthcare professionals involved in 
collaborative activities such as ad boards were generally of high-status and well- 
established. Collaboration with industry thus provided valuable networking 
opportunities for my informants. 
I suppose there’s a networking component, it’s a way of meeting 
colleagues in a relatively relaxed setting … One element of what 
happens is the companies provide a forum in which academic 
colleagues meet and discuss and challenge each other (Fieldwork 
Interview, Psychiatrist 8). 
Furthermore, one healthcare professional spoke at length of the relationship they had 
with the pharmaceutical company. The nature of their experience working with a 
company dictated whether they would continue their collaborative relationship with the 
company. On the whole, the informants reported having positive relationships with 
companies during ad boards. They noted that usually companies seemed genuinely 
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interested in their perspective and expertise, and made changes to their marketing 
messages in response to their criticisms. 
They certainly do seem receptive to criticisms of claims that are 
unsound that shouldn’t be made (Fieldwork Interview, Psychiatrist 8).  
I’ve seen companies where they’ve attempted to put an unreasonably 
positive spin on their particular product, and then following feedback 
from uh, experts, they’ve gone “oh, right, well we shouldn’t really be 
saying that we can’t really justify that”, and their marketing message 
gets significantly toned down and more defensible on the basis of the 
evidence they hold (Fieldwork Interview, Psychiatrist 9). 
Yeah, generally, this sort of expertise is not held in house by any 
company, so when I have an opportunity to contribute it’s obviously 
scrutinised that I have to justify the position but, largely, the 
recommendations I made were adhered to (Fieldwork Interview, 
Psychologist 3).  
These accounts of positive experiences of ad boards demonstrate one way in which 
healthcare professionals can create value for pharmaceutical companies. As 
discussed throughout this thesis, in the wake of scandal the pharmaceutical industry, 
especially antidepressant manufacturers, have become increasingly risk-averse. 
Protecting and improving their reputation is paramount. Through consulting with very 
senior healthcare professionals, companies are able to prevent disseminating 
marketing messages which are not sufficiently evidence-based, which, in turn, protects 
them from scandal. Although informants noted that their recommendations were 
‘largely’ acted upon, they acknowledged that this was not the case in every ad board. 
I’ve been to advisory boards in the past where companies have clearly 
not wanted to hear what has been said at the advisory board and have 
got very upset when negative comments have been said. Then one 
really does wonder what the point of the advisory board was, and then 
one does start thinking are you just trying to market this drug to a bunch 
of KOLs and is it nothing other than marketing? I would have to say 
that’s the rarer, more unusual situation (Fieldwork Interview, 
Psychiatrist 9).  
As one can discern in the extract above, the informants noted that there were 
occasions in which they felt that, rather than providing a service to pharmaceutical 
companies, they were instead being used as a captive audience to advertise their new 
drug to. These overt instances were described as rare, but it is wholly possible that, in 
addition to wanting to gain expertise from KOLs, companies may use ad boards to 




Although healthcare professionals continue to receive pharma money, they do so for 
more complex reasons than those alluded to in existing literature. Rather than being 
motivated purely by financial greed, healthcare professionals report being incentivised 
by more intrinsic factors, such as their own curiosity and desire to help patients. 
Moreover, additional corroboration can be found in the shrinking budgets available to 
healthcare professionals for continuing professional development (Merrifield 2017). 
Having said this, this investigation into recent collaborations between industry and 
healthcare professionals suggests that the two have yet to ‘untangle’ in the manner 
proposed by the 2003 BMJ special issue. However, there may be some benefit for 
patients from this collaboration, as a pharmaceutical industry entirely independent of 
healthcare professionals would potentially lack specialist knowledge and expertise. 
 
Interview data from respondents who have received pharma money thus support the 
notion that companies have largely moved beyond the crude disease mongering 
practices of the 1990s and are increasingly focused on retaining and improving their 
reputations. Scandals are expensive (The Seroxat Scandal is partly responsible for 
the largest legal settlement in the industry’s history: $3 billion). Furthermore, 
investment in services which reduce the likelihood of scandal is fully in keeping with 
the profit motive. Although this scandal aversion is in many ways increasing the 
ethicality of industry collaboration with healthcare professionals, the marketing 
opportunities presented by a room full of influential healthcare professionals has not 
gone entirely unnoticed. Rather, industry marketing efforts are transitioning, from overt 
displays of hospitality and overblown claims, to more subtle methods such as 
continuing professional development. 
 
8.3.3 Pharma Money for continuing professional development. 
Healthcare professionals have historically (and still do in some cases) received funds 
from pharmaceutical companies to partake in educational activities, such as 
workshops, courses, and conferences. Pharmaceutical industry funded education has 
been characterised in academic literature as biased and untrustworthy (Takhar et al. 
2007; Donnell et al. 2009; Masood et al. 2012). Indeed, to warrant the funding of such 
education, it is expected that companies must receive some benefit. Hence, a conflict 
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of interest is clearly present when companies pay for the education of healthcare 
professionals. However, whether this conflict of interest produces a net negative effect 
is less clear. 
 
Once qualified, healthcare professionals are required to keep their knowledge up-to-
date by completing continuing professional development (CPD). However, funding, 
particularly for mental health pharmacists, is scarce. Therefore, the pharmaceutical 
industry often run training events, and sometimes even pay for conference attendance. 
I run training events in my trust for staff and these drug companies they 
provide speakers who are completely impartial, and they provide 
training on different aspects of care. So, I already have an 
acquaintance with them, so they do attend regularly and bring speakers 
because these are expensive to hire if you work in the NHS, as we get 
no funding for training at all. Zero. So, whatever you want to do you 
either ask for the good will of people to come for free, or if you want a 
speaker who is very well-known and very good in their field a lot of them 
charge a fee, so the drug reps will sponsor these speakers to come and 
speak and talk to us and do training (Fieldwork Interview, Pharmacist 
8).  
Here, healthcare professional informants outline a catch-22 situation, where they had 
to make a choice between receiving education funded by a biased source or receiving 
nothing. 
The majority, a lot of people in my workplace when they've attended 
(conferences) it's through this type of funding (pharma) that they've 
managed to go. Otherwise, nobody would go. Before, our trust used to 
have a training budget, but we've got nothing now, absolutely nothing. 
We're not allowed to do anything at all in my trust, it's not the same in 
every trust, but in my trust, pharmacy department, there's no funding 
for training … We don't have anything (Fieldwork Interview, Pharmacist 
8). 
Consequently, if healthcare professionals declined training from pharmaceutical 
funders or refused to attend conferences funded by them, then they run the risk of not 
keeping their knowledge up-to-date to the potential detriment of their patients. If 
healthcare professionals choose to attend such events they then risk receiving biased 
information, which could ultimately lead to over-medicalisation, pharmaceuticalisation, 




Healthcare professional informants on the receiving end of professional development 
education funded by pharmaceutical companies played down the risks associated with 
attending pharmaceutical industry funded training and were keen to emphasise the 
independence of speakers at these events. One pharmacist noted:  
They might bring a speaker to talk about medical legal issues with 
prescribing, so they'd bring a solicitor and their fees are extortionate 
and they'll come and talk about your stance as a prescriber. What you 
should do to protect yourself and make sure your record keeping or 
whatever. They come and provide that training, so it's good for peoples 
CPD as well. So, yeah. So, it completely varies, they're not there to 
promote their drugs because their own regulatory system is very, very 
strict, and they have to get lots of approvals and their slides, etc., are 
assessed to make sure nothing in there contravenes with the ABPI 
code, so they're not doing anything promotional when they come to 
train people (Fieldwork Interview, Pharmacist 8). 
This point was particularly made by individuals who were also involved with the 
organising of such events, as evidenced by one psychiatrist who was interviewed. 
They sometimes arrange free conferences, so they’ll do their own 
meetings and study days which will be free for us to attend and they’ll 
all be sponsored … they are educational days, but they will call 
independent speakers and it will be themed around whatever product 
they’ve got, so you’ll get information about what their new products are 
but it’s not directly. It’s not their representative talking about it all the 
time, independent speakers that’re normally called (Fieldwork 
Interview, Psychiatrist 4).  
Most of the healthcare professionals I interviewed who had delivered training funded 
by pharmaceutical companies supported this view and emphasised their own 
independence: 
I’ve certainly never felt pressured to say things I didn’t want to say, and, 
no, I can’t remember feeling particularly constrained or stopped from 
saying things that I wanted to say (Fieldwork Interview, Psychiatrist 8).  
However, some informants who had themselves presented at such events described 
a more conflictual state of affairs. As one psychiatrist observed: 
There were times in the past where I was asked to do things that I was 
very uncomfortable doing. Like, presenting a company’s set of data that 
was entirely created by them and over which I had very little editorial 
control, and I remember doing that and I didn’t realise … I mean it was 
a very low-key, local meeting and then I realised that’s what they were 
expecting, they were expecting me to actually act like a trade-rep and 
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I never did that again. I simply said I would not do that (Fieldwork 
Interview, Psychiatrist 5).  
Even those who were confident that their presentations were not unduly influenced by 
the funding pharmaceutical company, acknowledged that other healthcare 
professionals may be more malleable. All the informants who collaborated with the 
industry as speakers at these events were cognisant that their work was of value to 
the pharmaceutical companies, beyond being simply educational. 
I mean they call it non-promotional work, it can never be fully non-
promotional (Fieldwork Interview, Psychiatrist 9). 
  
The idea of educational presentations and events as being ‘non-promotional’ was also 
challenged by the following healthcare professional who likened their work to 
advertising. 
You would point out the advantages as well as the disadvantages of 
their product and compare their product to other products available. 
Just like TV advertising or TV programs. You know, there are other 
similar products available. You have to be fair. And to be credible, you 
see. To be credible, and to be a potential useful individual from the 
company’s point of view and to the audiences’ point of view, you have 
to be seen to be totally impartial as well as credible (Fieldwork 
Interview, Pharmacist 7). 
With the NHS under increasing strain, training budgets are being cut. Health Education 
England is the executive non-departmental public body responsible for the training 
and development of the NHS workforce. In their 2015-16 budget, they allocated £205 
million to ‘workforce development’, a fund predominantly used for CPD training. For 
2016-17, this figure was nearly halved to £104.3 million (Merrifield 2017). Many 
healthcare professionals are therefore left to choose between potentially biased 
education paid for by pharma money, no continuing medical education, or paying for 
their education out of their own pockets. Recipients of pharma-funded education 
characterise it as unbiased and evidence-based, perhaps to mitigate their own 
cognitive dissonance. However, those who deliver such educational programs present 
a more nuanced view that suggests that, whilst regulation is increasing, if such 





8.4 Over the Influence? 
In line with the trend in industry collaboration with charitable organisations, 
collaboration with healthcare professionals has undergone ethical improvements. 
Again, the desire to improve the reputation of the industry in the wake of scandals and 
criticism has played a key role. Informants noted that companies have become much 
more prudent and risk-averse in their dealings with healthcare professionals.  
I do think some of the activities in the past and some of the activities of 
my colleagues in the past was, um, unreasonable, potentially unethical, 
but I do believe we are in an era where that has changed substantially 
and I think that it is much harder, though not impossible, for people, 
companies and academics, clinicians like myself to behave in 
inappropriate ways. It’s much harder for that (Fieldwork Interview, 
Psychiatrist 8).  
My informants noted no breaches (or attempted breaches) of the ABPI code of 
practice. Rather, companies were anxious to meet and exceed regulatory 
requirements in this area. Furthermore, the informants noted that they had been 
encouraged by companies to disclose the information about their payments on 
Disclosure UK, with some companies even now refusing to work with individuals who 
are not willing to be transparent about their payments. 
 
It is important to note, however, that I was only able to interview industry collaborators 
who actively disclosed their payments on Disclosure UK. Therefore, it is possible that 
those who chose to have their information withheld from the list would not report the 
same dedication to transparency within the industry. The BMJs analysis of Disclosure 
UK found that 70 per cent of healthcare professionals chose to fully disclose their 
payments (BMJ 2016). Whilst this number may appear high, the 30 per cent of 
healthcare professionals who did not disclose received over half of the total value of 
payments. This means that the healthcare professionals who were paid the most were 
less likely to disclose. Consequently, further research needs to be done into these 
undisclosed interactions between healthcare professionals and antidepressant 
manufacturers. 
 
For each of the professional representatives that were interviewed, there were some 
who avoided contact with the pharmaceutical industry due to a perceived conflict of 
interest. PSR informants noted that this is an increasingly popular stance, especially 
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in light of the popularity of Goldacre’s (2012) ‘Bad Pharma’. However, when 
considering whether it is possible for healthcare professionals to completely shelter 
themselves from pharmaceutical industry messages, there are clear chinks in the 
armour. 
I tend to say I prescribe what I have to prescribe to each patient. 
However, at the end of the day, we shouldn’t forget that all of our 
recommendations which are based on NICE guidelines, which are 
based on RCTs, which are funded by pharma companies. So, 
regardless of whether or not you have attended a conference 
sponsored by a pharma company, or regardless of whether or not 
you’ve given a lecture which has been funded by a pharma company, 
to a large degree all of our recommendations in our practice are funded 
by pharma companies (Fieldwork Interview, Psychiatrist 7).  
Both GPs and psychiatrists reported using the Diagnostic and Statistical Manual 5 
(DSM-V) and the International Statistical Classification of Diseases and Related 
Health Problems 10 (ICD-10), with the DSM-V being the vastly more popular choice. 
The DSM-V, in particular, has been criticised for allowing pharmaceutical companies, 
and those with financial links to the companies, to sit in on decision-making panels 
and influence diagnostic criteria (Cosgrove and Krimsky 2012). More recently, 
pharmaceutical companies were blamed for the removal of a bereavement exception, 
which stated that if a grieving person was experiencing depressive symptoms that this 
was a normal human experience and did not require a medical diagnosis. The newest 
edition of the DSM, the DSM-V removes this caveat, meaning that grieving people 
now fulfil the criteria for depression, which some have argued is an example of over-
medicalisation or even pharmaceuticalisation (Abraham 2010; APA 2013). 
 
As discussed in Chapter 5, the very definition of depression, including its conception 
as an illness, has been influenced by the pharmaceutical industry. One psychiatrist I 
interviewed reflected in-depth on the nature of depression and how it is treated:  
There’s a perception that there is this disease, if you like, called 
depression. And these drugs are anti-it. And I think there’s a lack of 
education amongst prescribers. You know, it’s the complexity and 
subtlety of mood disorders. People just see depression and think “oh, 
I’ll give them an antidepressant and they’ll get better” without realising 
its substantially more complex than that (Fieldwork Interview, 
Psychiatrist 3).  
When I pressed the psychiatrist on where this view came from, they sighed and noted: 
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You know, I’m tempted to say from pharma, and I’m not sure it’s entirely 
that … we don’t really have a good understanding of the underlying 
epidemiology and what the hell is actually going on in somebody’s brain 
that makes them feel like that (Fieldwork Interview, Psychiatrist 3). 
In the absence of a clear understanding of depression, its causes and its mechanisms, 
pharmaceutical companies have pushed their own models. The chemical imbalance 
theory is a popular model still used by the pharmaceutical industry. It suggests that 
depression is due to an imbalance of chemicals in the brain, and idea which has gained 
traction to the point that it is referred to by popular ‘woke’ social media celebrities 
(Dunn and Raskin 2018). However, despite the simplicity and attractiveness of this 
model, there is no empirical evidence supporting it (Healy 2004). I interviewed both 
GPs and psychiatrists who referred to chemical imbalance in their discussion of 
depression and its treatments. 
With depression, there are three things we look into. Three aspects, we 
call it the biopsychosocial model. So, bio means medications, the 
chemical imbalance in your brain and how you can replace that with 
serotonin or another medication (Fieldwork Interview, Psychiatrist 4). 
I don't know how they [antidepressants] work. I say to patients they're 
like the oil in a car, they give your brain a richer mixture to run on, and 
help it get up and running again after it's stalled. And they say “yeah, 
yeah, that's fair enough”. It's an analogy I use and it bears some 
relationship to what we think is going on, but it's just a story that I give 
people that I like, and if it helps then good (Fieldwork Interview, 
Psychiatrist 3). 
 
GPs and psychiatrists also mentioned using questionnaires, such as the Patient 
Health Questionnaire 9 (PHQ-9), which they use to aid their diagnosis. Whilst 
questionnaires like these have been commonplace in practice for many years now, 
the PHQ-9 was, in fact, originally developed with funds from the antidepressant 
manufacturer, Pfizer (Kroenke et al. 2001). 
I grade the severity of their symptoms either with an official scale, such 
as the PHQ or the GAD score, and actually giving them a number… 
…you can tell patients, “well, when you first came in your score was 
17”, three months down the line they might not feel better but if you 
read them the score and they’ve got a score of 10, then you can tell 
them “actually, your score has gone down” (Fieldwork Interview, GP 5).  
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Healthcare professionals are increasingly finding themselves part of a system which 
frowns upon, or outright forbids, interacting with PSRs. Meanwhile, higher up the chain 
of command interaction with industry is encouraged: 
The government for some time now has been very much trying to 
encourage more and more work with industry. They see industry 
financially supporting the NHS as an important strand to try and shore 
up the creaking finances, and yet that is completely the opposite view 
of many of the people working within the NHS and involved in many of 
the services. Particularly, I think this is the case in mental health 
(Fieldwork Interview, Psychiatrist 9).  
Even if a healthcare professional chooses not to see a PSR or attend industry funded 
training events and conferences and has no physical interaction with the 
pharmaceutical industry whatsoever, it is impossible for their diagnostic and 
prescriptive decisions not to be affected by the pharmaceutical industry. 
With tight budget cuts across everything, unfortunately we have to rely 
on funds from pharma companies to carry on attending conferences 
and to do CPD, to keep training. So, I think it’s better to be aware of 
what’s going on, rather than living in an ideal world where you believe 
you are not being influenced by pharmaceutical companies at all, which 
is not true (Fieldwork Interview, Psychiatrist 7). 
Although there have been efforts to improve the ethics of healthcare professionals’ 
interactions with pharmaceutical companies, such changes are undermined by a lack 
of resources and inconsistent messaging. With training budgets being consistently cut, 
pharmaceutical industry funded education becomes an increasingly attractive option, 
and for some healthcare professionals, the only option. 
 
8.5 Conclusion 
There is a knowledge vacuum in the depression disease area. We do not know what 
causes it, or how it operates, and so the pharmaceutical industry steps in to provide 
definitions and potential disease mechanisms. As NHS training budgets are cut, a 
vacuum in the continuing medical education of healthcare professionals also opens 
up. Nature abhors a vacuum, and wherever one exists in the broad realm of mental 
healthcare, pharmaceutical companies will step in. Although they fill it in a way which 
is useful to some extent, they also serve companies quests for profit. The conflict of 
interest and subtle biases that result from pharmaceutical companies occupying these 
spaces are real and highly problematic. However, without a sufficiently funded mental 
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healthcare system with independent information and continuing medical education for 
healthcare professionals, industry provided substitutes are the best we have.  
 
Regulation has been successful in improving the ethical status of healthcare 
professional/industry collaborations, reducing the impact of the conflict of interest in 
some instances. Even informants who spoke frankly about being flown to exotic 
islands and who now lament being resigned to cheap hotels, acknowledge that such 
changes have been necessary for reducing the conflict of interest associated with 
interacting with pharmaceutical companies. However, the only way to completely 
eradicate the conflict of interest is to independently fund the education of healthcare 
professionals, the information resources they use, and the clinical trials which provide 
the evidence-base for drugs. This is an expensive ask and doing so would either 
potentially reduce the quality of expert-advice available to antidepressant 
manufacturers, or cause manufacturers to take their business to countries other than 





9. Raising Depression Awareness  
 
9.1 Introduction 
In the previous chapter, I considered the ways in which, via covert pharma money, 
pharmaceutical companies interact with (and market to) healthcare professionals. 
Moreover, the chapter examined the role of healthcare professionals in the 
antidepressant marketing process as gatekeepers to prescribing drugs and later as 
locksmiths. The gatekeeper status of healthcare professionals is further reinforced by 
the fact that advertising prescription drugs such as antidepressants to the public is 
illegal in the UK. Pharma money, here, operates to ensure that drugs continue to be 
used as cures for various disorders, including depression. However, pharma money is 
also used to influence the public or potential users – or, perhaps, that should be 
consumers - of antidepressants. It is here that awareness campaigns and charities are 
crucial. 
 
Although antidepressant manufacturers cannot promote their products directly to the 
end-user, they are able to promote the symptoms of depression via disease 
awareness campaigns. This chapter therefore focuses on big money from Big 
Pharma-funded depression awareness campaigns, examining the impact that such 
funding can have on a campaign. It appears that the rationale for these campaigns, 
and the pharma money behind them, is to convince the public that they are depressed, 
and, moreover, that they should not feel ashamed for being depressed. Further to this, 
I explore the potential motives behind what often appear to be charitable donations. 
 
In 2014, the ‘Ice Bucket Challenge’ went viral. Celebrities including Barak Obama, 
Charlie Sheen and Lady Gaga poured iced-water over their heads along with over 2 
million members of the public. The purpose of the challenge was to raise awareness 
for amyotrophic lateral sclerosis (ALS). Known as motor neurone disease in the UK, 
ALS is an incurable, progressive condition with an average life expectancy of 2-5 years 
after diagnosis. The challenge became one of the most recognisable disease 
awareness campaigns in history. In the case of the Ice Bucket Challenge, awareness 
was being raised to promote donations to ALS charities to help patients and, 




Disease awareness campaigns are diverse in terms of both their format and missions. 
They can be as pedestrian as the posters in GP waiting rooms that remind patients of 
the dangers of smoking-related illnesses. They might include coloured ribbons, 
YouTube videos encouraging viewers to get tested for gluten intolerance, or a leaflet 
on the correct way to self-examine for breast lumps. They can also include materials 
targeted at healthcare professionals, employers or politicians. What unites them is that 
they are media events which attempt to increase knowledge of a condition. 
 
For pharmaceutical companies, disease awareness campaigns present an expedient 
opportunity. Whilst it is illegal to advertise prescription medications to the public, it is 
entirely legal for companies to fund disease awareness activities. Researchers such 
as Lexchin et al. (2003) and Lundh et al. (2015) found that, when research is funded 
by a pharmaceutical company, the findings of that research are more likely to be 
favourable to the interests of that company. Moreover, Wazana (2000) found that 
healthcare professionals who receive gifts from, or attend events funded by 
pharmaceutical companies have more expensive prescribing patterns. The phrase 
‘there’s no such thing as a free lunch’ is often used in association with the 
pharmaceutical industry, and, indeed, many researchers agree that pharmaceutical 
funding is not without its strings. 
 
Over the course of Chapter 5, a pattern emerged. Throughout history, symptoms of 
low mood have been defined by those providing treatments. Following this narrative, 
in contemporary societies our understanding of depression is shaped and informed by 
private pharmaceutical corporations. We are sold the idea that depression is a 
chemical imbalance which requires a chemical solution. Disease awareness 
campaigns are integral to forming and changing public understanding of such 
conditions. Documents from pharmaceutical industry funded depression awareness 
campaigns thus have the potential to yield insights into how antidepressant 
manufacturers influence societal views on depression. 
 
Pharmaceutical companies have a vested interest in their drug being prescribed, in 
addition to the rates at which a condition is diagnosed. Therefore, if a campaign 
148 
 
receives money from a pharmaceutical company it could, albeit unintentionally, 
promote a specific treatment option to its members or the public. Furthermore, they 
may contribute to the over-diagnoses of conditions via overmedicalisation or 
pharmaceuticalisation. Disease mongering refers to how pharma-funded charities can 
contribute to the over-diagnosis of conditions by overemphasising the prevalence of a 
condition, as well as medicalising vague symptoms which even ‘normal’ healthy 
people may be able to relate to (Moynihan and Henry 2006). 
 
Since blockbuster SSRIs reached the UK market, depression awareness campaigns 
in the UK have consistently received funding from antidepressant manufacturers. This 
chapter explores each instance uncovered through the data collection process of 
pharmaceutical industry involvement in depression awareness campaigns. Beginning 
with the first UK depression awareness campaign, The Defeat Depression Campaign 
(DDC) in 1991 and concluding with The Work in Progress Campaign (WiPC) in 2016, 
this chapter examines how antidepressant manufacturers have used disease 
awareness campaigns as part of their wider marketing efforts. As identified in previous 
chapters, the context within which antidepressant manufacturers operate has changed 
vastly over the past quarter of a century. The impact such changes have had on the 
involvement of pharmaceutical companies in awareness campaigns is therefore 
discussed in detail.   
 
This chapter is organised into three sections which highlight changes in the 
motivations of antidepressant manufacturers, from disease mongering to political 
pandering. I draw upon Peter Conrad’s work on ‘the shifting engines of medicalization’ 
(2005) to argue that medicalisation continues to be driven to some extent by the profit 
motives of pharmaceutical companies. However, the way in which this ‘engine’ is 
expressed has changed. Ultimately, this chapter concludes that, whilst, historically, 
pharmaceutical companies have funded depression awareness campaigns to 
increase demand for their products, the motivations behind drug company investment 
in charities has changed in recent years. Rather than operating as a strategy to reach 
public audiences, antidepressant manufacturers now utilise these campaigns to 
satisfy the approval requirements of public and professional bodies, such as the British 
National Formulary (BNF) and NICE. Charities are imbued with multiple moralities, 
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which result in political and rhetorical power and engender trust (Loseke 1997) – a 
scarce resource for antidepressant manufacturers post Seroxat Scandal.  
 
9.2 Becoming Aware: The Defeat Depression Campaign  
A seminal moment in the understanding of depression and its pharmaceutical 
treatments in the UK was the DDC. Originally conceived of in September 1990 and 
running publicly from 1992 to 1996, the campaign was a collaboration between The 
RCPsych and The RCGP.  
 
The DDC was the first disease awareness campaign launched in the UK focusing 
solely on depression. Although it was the first depression awareness campaign in the 
UK, it was inspired by similar movements which had launched elsewhere, the earliest 
example of which was run on the Swedish Island of Gotland. Aimed at training GPs 
on depression treatment and diagnosis, the Gotland campaign was openly funded by 
Ciba-Geigy Pharmaceuticals (Rutz et al. 1989a; Rutz et al. 1989b). A study conducted 
throughout the Gotland campaign found that the campaign’s efforts to educate GPs 
on the diagnosis and treatment of depression resulted in increased competency 
amongst health professionals, which, in turn, translated into fewer psychiatric referrals 
and a lower suicide rate (Rutz et al. 1989a; Rutz et al. 1989b). The DDC was also 
influenced by the US campaign Depression Awareness Recognition and Treatment 
(D/ART), which was funded by American Prozac manufacturer, Eli Lilly. The DDC was 
also funded in part by Eli Lilly, although this was not always made apparent. Healy 
notes that one of the purposes of these campaigns was to ‘shame’ doctors into 
diagnosing depression by convincing them they were underdiagnosing the condition 
(Healy 2004, p. 10). 
 
The DDC had several aims which developed over the course of its conception. The 
original proposal for the campaign, submitted in 1990, outlined ‘a national campaign 
designed to assist general practitioners and other health care professionals in the 
recognition and treatment of depressive illness and to increase public awareness of 
the extent and treatability of depression’ (RCPsych 1990, p. 8). The proposal also 
explicitly stated throughout that it was concerned specifically with ‘Depression as a 
clinical illness’ (1990, p. 4). This distinction is an important one when considering the 
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campaign in relation to concepts like disease mongering and medicalisation, as it 
suggests that The RCPsych were not interested in increasing awareness about or 
treating a broader understanding of depression, which would include a degree of 
normal human experience. The proposal also made the argument that depression is 
underdiagnosed by GPs due to a lack of training, and a reluctance on the behalf of 
patients to discuss symptoms due to stigma (1990, p. 5-6). 
 
After the campaign concluded in 1996, several articles were published assessing the 
impact of the campaign (Donoghue et al. 1996; Orrell et al. 1996; Rix et al. 1999). 
Although prescribing both increased (Paykel 2001) and some argued improved 
(Donoghue et al. 1996) over the duration of the campaign, the campaign was less 
successful in its controversial aim to change the widespread public belief that 
antidepressants are not addictive (Paykel 2001). 
 
One major criticism of the campaign is that it was funded by the pharmaceutical 
industry. Funding is a key issue when discussing the motives of a disease awareness 
campaign, as pharmaceutical funding of disease awareness campaigns can result in 
disease mongering (Moynihan and Henry 2006). In 2004, The RCPsych admitted to 
receiving £129,530 from pharmaceutical companies, however this chapter makes the 
case that this disclosed figure could be lower than the actual amount received.  
 
Retrospectively, both Healy (Healy 2004) and (Moncrieff et al. 2005, p. 84) identify 
that the pharmaceutical industry played a role in the campaign, however neither 
reference how they came to know this information. Moncrieff et al. (2005) specify that 
the campaign received less than thirty per cent of its funds from the pharmaceutical 
industry, and whilst they do not provide the source of their information, it is likely they 
are referring to a figure noted in the minutes of a series of meetings on the influence 
of the pharmaceutical industry published by the House of Commons Health Committee 
(Committee 2004). In the minutes, Dr Kendall of The RCPsych claims that he believes 
that the DDC did not receive any funding from the pharmaceutical industry (Committee 
2004, p. 131). However, Kendall’s claim was queried and subsequently a copy of a 
letter from the RCPsych’s president was presented stating that ‘the campaign’s total 
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income amounted to £449,800, of which only £129,530, that is 28.8 percent, came 
from pharmaceutical companies’ (Committee 2004, p. 132). 
 
A useful tactic adopted by investigative journalists, and recommended by the ICIJ, is 
to unearth previously forgotten or unavailable public documents. This informed my 
own research methodology, as I used the document archives of The RCGP and The 
RCPsych. Here, I gathered archival documentary evidence to corroborate the claims 
of both Healy (2004) and Moncrieff et al. (2005) that the campaign was funded, in part, 
by the pharmaceutical industry. The documents suggested that the original concept 
for the campaign was conceived of by The RCPsych, whilst funding was sought 
afterwards directly from pharmaceutical companies. This is exemplified in the following 
extracts:1 
Funding will be primarily from pharmaceutical companies and will be 
channelled to The RCPsych who will take the lead with input from our 
RCGP representatives (Trent to Payne, 1992) 
The campaign itself is to be funded from a wide appeal directed mainly 
to the pharmaceutical industry and which will be endorsed by HRM the 
Prince of Wales as President of The RCPsych. According to Paul 
Freeling, funding has already been generously forthcoming but it is not 
clear how far these funds will go towards the depression campaign 
itself or towards the more general appeal which The RCPsych is also 
launching this year under the Presidency of HRH (Michaels to Long, 
1991) 
Perhaps most interestingly, in a letter to Long (1991) Butler notes that ‘the campaign 
activity seemed to be coming together quite well in preparation for the launch on 
Thursday 5th December. Funding of £175,000 has been obtained for the planned 
attitude survey from a drug company’. This figure of £175,000 is larger than the 
£129,530 figure cited by the president of The RCPsych as representing the total 
income from pharmaceutical companies for the campaign, whereas Butler’s letter 
suggests that this figure was donated by a single pharmaceutical company. Of course, 
these figures could differ for several reasons; perhaps the president’s figure does not 
include funds for preparatory activities which took place before the campaign. It is also 
possible that the funds Butler mentioned were later withdrawn; however, based on the 
                                            
1 Names have been changed for the purposes of anonymity. The original letters are available at The 
RCGP archive in London. Please contact me for extra information to locate these specific sources.  
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published results of the survey, it is clear that the survey was ultimately funded by a 
pharmaceutical company.  
 
Healy (2004) named Eli Lilly as the pharmaceutical company involved in the campaign, 
and multiple documents from the archives of both The RCGP and The RCPsych 
support this claim  (RCPsych 1992,1993a; Orrell et al. 1996). Eli Lilly were, and still 
are, the manufacturers of Prozac; therefore, it would have been realistically within Eli 
Lilly’s business interests to support a campaign which could lead to greater diagnosis 
and treatment of depression, thus growing the market for antidepressants. Although 
Eli Lilly were the company most directly linked to funding the campaign, they were not 
the only pharmaceutical company who contributed funds to the campaign. A fun run, 
organised as part of the campaign in 1995, aimed to raise funds and & awareness of 
depression, was backed by Seroxat manufacturer, Smith, Kline & Beecham (SKB). In 
correspondence to the Psychiatric Bulletin, Crown (1995) describes how the event 
‘had been well publicised and was generously sponsored by SKB’. Furthermore, an 
advert for the fun run appearing in the Psychiatric Bulletin acknowledged that the entry 
fee would be matched by SKB. In his correspondence, Crown (1995) noted that there 
were 250 runners, suggesting a donation from SKB of at least £750. 
 
As aforesaid, one of the principal aims of the campaign was to change the public 
perception that antidepressants were addictive. This aim was established after a public 
attitudes survey identified that the public held this belief, which they claimed to be 
false. The public attitudes survey was carried out by the market research company 
Market & Opinion Research International (MORI), hence why this survey is often 
referred to as the MORI survey (Vize and Priest 1993). Whilst the research paper 
publishing the results of the MORI survey described the paper as ‘Royal Colleges 
Commissioned’ but with no direct mention of funding (Vize and Priest 1993), an 
internal document obtained from the archive of The RCGP specifies that the survey 
was funded by £175,000 from a pharmaceutical company (Butler to Long, 1991). A 
second paper publishing the results noted that funding was provided by the ‘Defeat 
Depression Fund’ and states explicitly that there were no conflicts of interest to declare 
(Priest et al. 1996, p. 859). Although the objective of the research was ‘To investigate 
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the attitudes of the general public towards depression’, most of the ‘key messages’ 
highlighted related to antidepressants: 
  
- Before beginning its five year task, the campaign sought opinions 
from 2003 members of the public 
- Most of the sample (78%) thought that antidepressants were 
addictive, and only 16% thought that they should be given to 
depressed people 
- Most patients treated with antidepressants in primary care abandon 
taking them prematurely; fear of dependence is one likely 
explanation 
- Patients should be informed clearly when antidepressants are first 
prescribed that discontinuing treatment in due course will not be a 
problem (Priest et al. 1996, p. 858) 
 
To combat the alleged misconception identified in the MORI survey, many campaign 
materials, such as leaflets and media appearances, reassured GPs and the public that 
antidepressants are not addictive (RCPsych 1993b,1996; Tylee et al. 1996; Crow 
2017). However, this aspect of the campaign proved problematic. Sam Kent, a 
researcher unrelated to the campaign, wrote many letters to the Royal Colleges 
throughout the campaign. These letters were discovered at The RCGP archive. Kent 
specified that there are a number of different potential definitions of ‘addictive’, 
questioning the precise definition they were using, and asking exactly what evidence 
they had to come to this conclusion (e.g. Kent to Crow 1992a; 1992b; 1993). The 
following is an extract from one of Kent’s letters: 
The DDC used the media to publicise categorical assurance that anti-
depressive drug treatments were ‘not addictive’ and did not cause 
benzodiazepine-type rebound and withdrawal problems. I asked for the 
evidence on which the assurances were based (i.e. what scientific 
research has cleared all anti-depressive drug treatments of causing 
dependence, rebound and withdrawal problems?). This research 
evidence either (a) exists or (b) does not exist. If (a) applies, your 
assurances are valid: if (b) applies, they are not valid, and the most you 
are entitled to claim is that you do not know if the drugs cause 
dependence, rebound and withdrawal problems. We seem to be left 
with (b), as you have cited no scientific research that has cleared the 
drugs … Anyone with a knowledge of the history of medicine (which 
The RCGP has) knows that all psychoactive substances are likely to 
cause dependence: that doctors have successfully assured people 
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otherwise, and successfully been proved wrong, and large numbers of 
trusting patients have paid for their mistakes. These tragedies were 
easily avoidable. To avoid yet another repetition, one would expect The 
RCGP to tell the public: (i) these drugs are not tested for dependence 
before being given to the public, not systematically monitored for 
dependence afterwards, so we do not know to what extent they may 
cause dependence, and (ii) history (and what we know about the brain) 
suggests that they are almost certain to cause dependence to varying 
extents in some people (Kent to Crow 1992b). 
 
Kent wrote letters to individuals from both Royal colleges throughout the duration of 
the campaign demanding answers to these questions, however no answer was ever 
given. Upon receiving one of Kent’s letters, Crow, an individual involved in organising 
the campaign, forwarded it to a college in a memo saying simply: ‘Help!!!’. Although 
Kent raised valid concerns (which years later were proved correct), the campaign 
continued to promote the message that antidepressants were not addictive. It appears 
that the organisers of the campaign were conceptualising addiction as the presence 
of drug seeking behaviour, however it is likely the public understanding of addiction 
also included symptoms such as dependence and withdrawal 
 
The MORI survey that the depression awareness campaign drew upon was also 
subjected to methodological criticisms from medical anthropologists, Sushrut Jadhav 
and Roland Littlewood (1994). The pair argued that, through being over simplistic, the 
survey neglected to grasp the complexity of how illnesses are conceptualised. 
Furthermore, they stated that launching a ‘glossy educational campaign’ based on a 
‘restricted public opinion survey’ was ‘frankly disturbing’ (Jadhav and Littlewood 1994, 
p. 572). 
 
9.2.1 Campaign outcomes 
Although, as mentioned earlier, the reassurance that antidepressants are not addictive 
became a key message of the campaign, its impact was limited. Paykel (2001) notes 
that the prevalence of the belief that antidepressants are not addictive changed only 
slightly over the course of the campaign. Prior to the campaign, this belief was held by 
78 per cent of the population (Vize and Priest 1993, p. 574; Priest et al. 1996), it then 
stayed the same when measured in 1995, and dropped to 74 per cent in 1997 at the 
conclusion of the campaign (Paykel 2001).  
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Publicly held beliefs can be difficult to change, and why this widely-held belief did not 
change is almost impossible to decipher. It is possible that the disconnect between the 
public and professional definitions of addiction may have been partially responsible. 
As noted previously, addiction can be understood as a variety of conditions, including 
dependence, withdrawal, and rebound (Kent to Crow 1992a). However, it is clear from 
documentary sources that the Royal colleges conceptualised addiction only as drug 
seeking behaviour, as exemplified by Paykel’s reasoning that ‘there is no street market 
for antidepressants’ (Crow to Kent 1992a).   
 
The disparity between the common and technical understandings of addiction came 
to the public’s attention in 2002, when Panorama began airing a series of 
documentaries on GSKs SSRI, Seroxat (Jofre 2002,2003,2004,2007). In the first 
documentary, the audience was introduced to ‘Helen’, a 22-year-old woman who noted 
‘I've wanted to come off it for quite a few years now but when I stopped taking it, I was 
so ill that I had to start taking it again and doctors kept telling me that it was impossible 
to be addicted to them’ (Jofre 2002). It is therefore possible that, whilst campaign 
leaflets and media promoted the message that antidepressants are not addictive, 
some individuals taking antidepressants were experiencing symptoms they 
considered to be contrary to this message. 
 
Although the public perception that antidepressants were addictive changed little over 
the course of the campaign, prescriptions for all classes of antidepressants rose 
(Paykel 2001). The greatest increase in prescription was evident in the newer, SSRI 
category of drugs, which increased from half a million in 1991, to 5.4 million in 1996. 
However, older, cheaper TCA drugs remained the most popular kind of 
antidepressant, with 9.1 million prescriptions (Paykel 2001). Paykel (2001) notes that 
‘the Campaign was careful not to endorse any particular class of antidepressants’, a 
statement which was supported by earlier materials published by the campaign 
(Paykel and Priest 1992) but less evident in later campaign documents (Tylee et al. 
1996). Paykel posits that, although the increase in prescriptions cannot be entirely 




9.3 The Era of Added Benefits: Depression Alliance 
Whilst the DDC was the first depression awareness campaign in the UK, it was far 
from the last. From the late-1990s onwards, Depression Awareness Week was 
coordinated by the charity DA. The word charity often brings to mind words such as 
altruism and selflessness, and, indeed, the mission of charities is to improve the world 
in some way. However, it is often easy to forget that charities are organisations. They 
do not operate to generate a profit, but they still require money to come in to go about 
their charitable business. The government funds charities to some extent. Hence, even 
if you pretend to be in a rush when walking past a charity fundraiser on the high street, 
if you pay taxes you are already giving some money to charities. The rest of a charity’s 
funds ordinarily come in the form of donations. Some of these donations come from 
members of the public who may sponsor a friend in a fun run or drop 20p into a bucket 
in front of a supermarket, but some of these donations also come from private 
companies. With respect to depression charities, these donations sometimes come 
from pharmaceutical companies, which can lead to a conflict of interest. This is 
because charities may be (consciously or unconsciously) influenced by their funders 
and alter the messages of their campaigns, resulting in disease mongering or 
pharmaceuticalisation. 
 
Because of the potential conflict of interest which emerges when a mental health 
charity receives money from a company which profits from the treatment of a mental 
health condition, some charities refuse these donations. For example, the UK’s largest 
mental health charity Mind adopts a strong stance against the acceptance of funds 
from pharmaceutical companies or device companies due to this potential conflict of 
interest. On their website, they note that ‘Mind will not accept donations from or hold 
shares in companies manufacturing pharmaceuticals, lest this should compromise our 
position on the uses of medication’ (Mind 2017). However, this stance is not universal, 
and has especially not been the case throughout history. 
 
Throughout the 2000s, depression awareness activities have been most closely 
associated with the charity DA. Charities such as DA can be regarded as moral 
entrepreneurs to use Howard Becker’s (2008) term. Moral entrepreneurs seek to 
influence the adoption and maintenance of norms within a society or group. Labels are 
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integral to this process, and therefore campaigns which aim to label and identify 
conditions are perfect projects for moral entrepreneurs.   
 
In 2005, 2007, 2008, 2015 and 2016, DA received funds from antidepressant 
manufacturers in relation to their Depression Awareness Week activities. DA and its 
relationships with pharmaceutical companies will therefore be examined. Figure 6 
below presents a timeline of depression awareness campaigns’ antidepressant 
marketing authorisations. 
 





In her 1997 paper, Loseke examines the construction of the idea of charity throughout 
the 20th Century. Loseke (1997) found that charities are imbued with multiple 
moralities, such as the sacred morality of religion and the human morality of 
compassion. Loseke proceeds to argue that these multiple moralities give charities 
'political and rhetorical power’ (1997, p. 425). Whilst the incentives for using 
depression charities to disease monger have decreased in recent years, the political 
and rhetorical power of charities remains. By linking themselves to charities, 
pharmaceutical companies are thus able to bask in some of the glow of their perceived 
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moral goodness. Furthermore, as moral entrepreneurs, charities benefit by receiving 
funds to further their mission to alter societal norms. 
 
Prior to merging win Mind in August 2016, DA was the largest depression specific 
charity in the UK2. The website Seroxat Secrets (2005; 2008) points to two occasions 
where the charity accepted pharmaceutical funding for its annual depression 
awareness week. The accusations of this blog led me to file a FoIA request with the 
charities commission to obtain the company accounts, which confirmed that the charity 
was indeed a recipient of pharmaceutical funding. 
 
In 2004, DA admitted to receiving 80 per cent of their funds from pharmaceutical 
companies (Committee 2004, p. 146). Whilst they were receiving the majority of their 
funds from pharmaceutical companies, debates dominated the public sphere over 
whether antidepressants were addictive, and whether they were safe for children to 
use: The so-called Seroxat Scandal. Mind, a charity which refuses donations from 
pharmaceutical companies, spoke out about the scandal (Committee 2004). However, 
rather than criticising their funder GSK, DA turned their criticism towards Panorama 
(HCHC 2004, p. 147). 
 
Whilst bloggers have criticised DA’s extensive and ongoing relationship with the 
pharmaceutical industry (e.g. Fiddaman 2017; SeroxatSecrets 2017; Truthman30 
2017), it  has not yet been the subject of formal academic research. The remainder of 
this chapter is dedicated to presenting and analysing the information gathered on DAs 
collaborations with the pharma industry, which draws upon sources such as the 
charity’s accounts, leaflets, media coverage, and an interview with a DA board 
member. 
 
9.3.1 Early Period: 1999 
The investigative approach adopted for this research was particularly useful for 
uncovering and corroborating information from the past, when there was far less 
                                            
2 When writing the first draft of this chapter in 2017, I had a sentence here commenting on how a quick 
Google search of DA demonstrated their controversial nature. The first page of results included 
references to their ‘clumsy conflicts of interest’. However, this is no longer the case. In 2018, these 
results have been relegated to page 9… 
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transparency than there is today. The earliest instance of DAs collaboration with 
pharmaceutical companies that I was able to identify was in 1999. An interview with 
an informant from a medical PR company uncovered an instance where DA received 
funds from an unnamed pharmaceutical company. In 1999, DA was paid to issue a 
leaflet to its members highlighting the prevalence of sexual dysfunction as a side-effect 
of most antidepressants. The leaflet was commissioned by a pharmaceutical company 
who were promoting a new antidepressant which did not have sexual side-effects. The 
intention was that individuals would go to their doctors asking for an antidepressant 
which would not cause sexual side-effects. Although the PR informant did not disclose 
the name of the medication, based on my own investigation into what drugs were on 
patent at that time, the most likely candidate is, Mirtazapine, which does not have 
sexual side-effects, but does commonly cause increased appetite and weight-gain; 
hence, why is prescribed by vets as an appetite stimulant for cats and dogs. 
 
9.3.2 ‘Pulling Together’: 2005 
For Depression Awareness Week (Or National Depression Week as it was referred to 
at the time) in 2005, Eli Lilly and Boehringer Ingelheim collaborated with DA on a 
survey and subsequent report called ‘Pulling Together – Body & mind depression 
symptoms survey report’ (Depression Alliance 2005) – see Figure 7. The cover page 
highlights the statistic that ‘85% of patients believe that their quality of life would be 
improved if their aches and pains could be effectively managed’ (emphasis in the 
original document).  
 
Interestingly, the report comes three and a half months after the launch of a new 
antidepressant which claims to treat the aches and pains associated with depression 
(Lilly 2005). Duloxetine (brand name Cymbalta) was launched as the only 
antidepressant which also treats psychosomatic pain. The drug was discovered by Eli 
Lilly and then subsequently developed and marketed in collaboration with German 
pharmaceutical company, Boehringer Ingelheim, both of whom funded ‘Pulling 
Together’ via an ‘unrestricted educational grant’ (Depression Alliance 2005, p. 9). Prior 
to the launch of Duloxetine, the link between psychosomatic pain and depression was 
unclear and had not been explored in a great amount of detail (Korff and Simon 1996). 
‘Pulling Together’ notes that depressed people experience aches and pains at four 
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times the rate of people not diagnosed with depression (Depression Alliance 2005, p. 
5). However, it is important to note that the relationship between pain and depression 
is complicated by several factors. For example, people with chronic illnesses (of which 
a symptom may be pain) are more likely to experience depression (Korff and Simon 
1996). Therefore, statistics emphasising the increased rate of ‘aches and pains’ in 
people with depression compared to those without depression do not necessarily point 
to the pain being psychosomatic or caused by depression. 
 
The rest of the report presents the findings of two surveys conducted in November 
2004. The first of which comprised responses of 644 DA members who were contacted 
via the charity. The second was conducted by market research company, TNS 
Healthcare, who surveyed 205 general practitioners. The results of the first survey 
present a comparison of what symptoms are experienced by people with depression 
versus what they would talk to a doctor about. The largest disparity occurred in relation 
to the symptom of sexual dysfunction, which was experienced by 48 percent of the 
respondents but reported to doctors by only 14 percent of them. Irritability, lack of 
pleasure and anger were also poorly reported with only 50 percent or less of the 
respondents who experienced these symptoms discussing them with their doctors. 
However, the symptoms discussed in the most detail in the report are ‘general aches 
and pains’ which were experienced by 49 percent of respondents, 33 percent of whom 
discussed the symptom with their doctor.  
 
Throughout the report, aches and pains are privileged above other symptoms, 
regardless of what the survey data appears to show. This is most evident on page 6 
of the report which presents data from the GP survey – see Figure 7. The symptom 
reported to be least likely to be resolved by antidepressant treatment was fatigue, as 
reported by 62 percent of the respondents. However, attention is given instead to 





Figure 7: Pulling Together 
 
 
The privileging of aches and pains in Figure 7 in a way which corresponded to the 
interests of the report’s funders was noticed by the anonymous industry commentator 
and critic who writes the blog ‘Seroxat Secrets’ (2017). The author noted that the 
stated purpose of ‘Pulling Together’ (to show how people pull together to combat 
depression) was not evident at all in the report. The author was vocal about their 
criticisms of the campaign and continually reached out to the DA for comment and 




I apologise for not addressing your point about “Pulling Together” and 
have just spent time re-reading it (in fact, I’m not even sure if I was still 
with DA when it was published, but I may have been). I have also been 
reading your critique of it, which is conspiracy theory of the first water. 
I doubt I can convince you of this, but I can assure you that the research 
was undertaken for very different reasons than those you assume …   
a piece of research was planned, to try to underline that somatic 
symptoms are (or can be) very much a part of the illness. That was the 
strategy – it had nothing to do with Cymbalta. You can take my word 
for that or not – it is immaterial to me because, whether or not it satisfies 
your concerns, it is the truth. If you want to take it further, then take the 
matter up with the ABPI – and before you counter that the ABPI is an 
industry body, I would remind you that they have suspended, I believe, 
at least three of their Big Pharma members in the past year, for the sort 
of activity you imply (Seroxat Secrets 2007).  
The author of Seroxat Secrets noted that Thompson’s response still failed to explain 
how the report links to ‘Pulling Together’. Furthermore, my own analysis of the 
document suggests that, even if the initial strategy was ‘nothing to do with Cymbalta’, 
it is clear that ‘Pulling Together’ privileges information which supports the interests of 
its funders. This is most telling when a simple search function is executed on the 
document. The term ‘aches and pains’ appears twenty-two times in the eight-page 
document. Sexual dysfunction comparatively occurs seven times. The most common 
symptom of depression, low mood, occurs once. ‘Pulling Together’ can therefore be 
considered an example of pharmaceuticalisation, in that the boundaries of the 
diagnosis of depression are being expanded and blurred to suit the motives of the 
pharmaceutical industry. 
 
9.3.3 ‘Now We’re Talking!’: 2006/7 
In December 2006, in collaboration with mental health charity SANE and the 
pharmaceutical companies Eli Lilly and Boehringer Ingelheim, DA developed another 
campaign called: ‘Now We’re Talking!’. As with ‘Pulling Together’, ‘Now We’re Talking!’ 
consisted of a survey sent to DA members – see Figure 8. Moreover, the survey was 
posted on SANEs website. The final report presents recommendations for the 
diagnosis, informed treatment, and ongoing management of depression. The report 
also formed the basis of Depression Awareness Week, 2007. 
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Figure 8: Now We're Talking  
 
 
(Depression Alliance, 2007) 
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The symptoms of aches and pains are mentioned four times across the sixteen-page 
document, a huge reduction compared to the twenty two citations in the eight-pages 
of ‘Pulling Together’. Indeed, ‘Now We’re Talking!’ is altogether more nuanced in its 
reflection of the aims of its funders. More varied phrasing is used to emphasise that 
depression has many symptoms, including physical symptoms, which both healthcare 
providers and patients need to be educated about.  
 
9.3.4 ‘The Inside Story’: 2008 
In 2008, DA received funds from Servier, as well as the Medical PR company they 
hired, to release a report titled ‘The Inside Story’ (Depression Alliance 2008). Servier 
had released a new drug which operated in a different way to many existing drugs. 
Instead of working on neurotransmitters like serotonin, Servier’s drug, Valdoxan, was 
similar in structure to melatonin, the hormone associated with sleep. It is for this reason 
that the drug is characterised as a melanotonic antidepressant, and one of the main 
symptoms of depression that it treats is the regulation of sleep. Sleep disturbances 
have long been considered to be a symptom of depression, with patients either 
reporting being unable to sleep or unable to stop sleeping. The inclusion of sleep 
disturbance as a symptom in DA’s 2008 campaign is therefore not absurd. However, 
similarly to 2005, messages from the 2008 campaign appeared in national news 
media, including The Guardian, with no reference to Servier’s funding (Gaines 2008).  
 
The Guardian article and others appear to be based on a newswire press release that 
states that Servier’s funding was used to conduct a survey referred to in a report called 
‘The Inside Story’ (Press Association Mediapoint 2008). The first-half of the press 
release for the survey foregrounded the survey’s investigation into the experiences 
and opinions of workers with depression. However, the second-half of the press 
release focuses on sleep-related questions, noting that 83% of the 288 survey 
respondents felt their work was negatively affected by poor sleep, whilst 40% reported 
that they had lost their job because of poor sleep. 
 
Indeed, the only quote in the press release is from DA Chief Executive, Emer O’Neil, 
who notes: ‘Sleep disturbance can have a major impact in people with depression, 
and this data also highlights the importance of healthcare professionals and patients 
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working in partnership to manage their depression in a way that will not negatively 
impact on their sleep.' (Press Association Mediapoint 2008). 
 
O’Neil’s acknowledgement, here, that sleep is an important issue in depression is 
supported by numerous peer-reviewed studies (Tsuno et al. 2005). O’Neil’s second 
point appears to be the most telling with respect to the DAs funding. The most 
commonly used class of antidepressants, SSRIs, can have the side-effect of causing 
insomnia in some patients. O’Neil’s argument that depression should be managed in 
a such way that does not negatively affect sleep thus appears to be directed 
specifically at SSRIs. Both depression itself and SSRIs are associated with sleep 
disturbances, but yet the survey does not appear to differentiate between the two. It is 
therefore interesting that O’Neil’s conclusion is that depression should be managed in 
a way not to negatively affect sleep, rather than, say, in a way that improves sleep. 
One reason as to why she may use the double negative when focusing on sleep 
disturbance as a side-effect of other treatments, is that there are multiple treatments 
that do not cause sleep disturbance. Notably, sleep disturbance is not a side-effect of 
talking treatments. Servier’s drug, Agomelatine, is the only antidepressant that 
regulates sleep. Therefore, had O’Neil recommended that depression should be 
managed in such a way which improves sleep, then the press release would have 
been defined as ‘promotional’ by the ABPI, thus making Servier guilty of direct to 
consumer marketing.  
 
Although O’Neil’s statement avoids being promotional by the ABPIs standards, it is 
clear that her comments on how depression should be managed are influenced by 
DAs funders. The press release is therefore indicative of a conflict of interest, because, 
as a charity, DA are trusted and relied upon to give unbiased information on the 
management of depression. The ability to give clear unbiased information, in this case, 
is inhibited by the funding they received from Servier.  
 
The impact of the conflict of interest evident in ‘The Inside Story’ is unclear. As 
mentioned previously, sleep disturbance is a widely-documented symptom of 
depression. Moreover, there is evidence to suggest that SSRIs cause insomnia in 
some individuals (Dording et al. 2002). The problems Servier were attempting to solve 
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with Agomelatine were thus not fabricated to market the drug. However, what is 
evident is that DAs statements regarding the management of depression were 
influenced by the funding, and, as such, the impartiality of the charity was undermined. 
 
9.4 The Shifting Mediators of Medicalisation 
In 2005, Peter Conrad published an article titled ‘The Shifting Engines of 
Medicalization’. In the paper, he used case studies to examine the factors informing 
the expansion and contraction of medical diagnoses. Ultimately, he found that 
medicalisation had become increasingly driven by commercial and market factors, 
namely, pharmaceutical companies (Conrad 2005). In the past, medicalisation had 
been driven, in part, by healthcare professionals. However, Conrad found that, from 
the mid-1980s onwards, they had been relegated to a mediator role in the 
medicalisation process. Conrad’s findings are reflected in disease awareness 
campaigns such as ‘The Inside Story,’ which surveyed healthcare professionals, who, 
as discussed in the previous chapter, were the target of marketing campaigns. In this 
section, I suggest that, having already experienced a shift in the engines of 
medicalisation, we are now witnessing a further shift in the mediators of 
medicalisation. Campaigns such as the DDC focused on the public as meditators of 
medicalisation, The Inside Story focused on GPs, whilst the 2015 and 2016 campaign 
‘Work in Progress’ turned its attention to politicians. This shift correlates with a broader 
trend within the industry away from overt marketing towards a political agenda. As is 
discussed later in this chapter, disease mongering among the public is no longer 
profitable. Rather, the issue of whether a drug is approved, and whether it can be 
prescribed in a given geographical area, is an increasingly political one.  
 
9.4.1 ‘Work in Progress’: 2015/16 
In April 2015, as part of Depression Awareness Week, DA launched the ‘Work in 
Progress’ (WIP) campaign. As was the case with previous campaigns, the funder of 
WIP had a new antidepressant which had recently been released to market. The 
funder was Lundbeck, and the new antidepressant was a drug with the chemical 
name, vortioxetine, which was being marketed under the brand name, Brintellix. 
Similar to agomelatine and duloxetine, vortioxetine has a key feature which 
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differentiates it from its competitors – it claims to improve cognitive function and 
decision-making in depressed individuals. 
 
As with ‘Pulling Together’, ‘Now We’re Talking!’ and ‘The Inside Story’, WIP consisted 
mainly of a report based on a survey. Rather than being a survey of DA members or 
healthcare professionals as was the case with past campaigns, the survey conducted 
for WIP was with members of parliament. Furthermore, unlike previous surveys 
commissioned by DA, the full survey data is publicly accessible online – see Figure 9. 
This transparency enabled me to see the specific questions posed to respondents. In 
doing so, I identified two questions (Q9 and Q11) out of 21 which reference specific 
symptoms of depression, including cognitive symptoms such as trouble concentration 
and indecisiveness, which vortioxetine aims to treat.  
The other questions posted to the MPs mainly assessed respondents’ understanding 
of depression and perception of stigma. The transparency of the survey, and the 


























Figure 9: Work in Progress Survey 
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The 32 page WIP report draws upon a number of sources in addition to the MP survey 
data, with the proposed aim of ‘Improving employment outcomes for people with 
depression’ (Depression Alliance 2017, p. 0). The report contains three instances in 
which cognitive symptoms are discussed; the following excerpt from page nine, in 
Figure 10, includes two, whilst the other is on page 12. 
 




Cognitive dysfunction had long been understood as a symptom of depression prior to 
both WIP and Lundbeck’s development of vortioxetine (e.g. Vasic et al. 2008). This 
point was emphasised by a researcher I interviewed, who had been researching the 
link long before being approached by Lundbeck to assist with measuring cognition in 
clinical trials.  
There's a very rich literature on that (cognitive dysfunction in people 
with a diagnosis of depression) and I've contributed to that in the past 
… that's why I get hired by companies (Fieldwork Interview, 
Neuroscientist 1). 
 
The inclusion of cognitive symptoms of depression in the MP survey and the WIP 
report are therefore not necessarily indications of bias, albeit their inclusion is certainly 
in keeping with the interests of Lundbeck.  
 
Overall, then, WIP represents an ethical progression in the collaboration between DA 
and pharmaceutical companies. When compared with ‘Pulling Together’, there is a 
vast reduction in the instances of what could be interpreted as covert marketing 
messages. In the following section, I attempt to explain why. 
 
9.4.2 Same engine, different paintwork 
A clear change is evident when comparing earlier Depression Awareness Weeks and 
the DDC with the latest Depression Awareness Week. In earlier campaigns funded by 
pharmaceutical companies, we see echoes of marketing messages (Depression 
Alliance 2005,2008) and an over-emphasis on symptoms However, the Depression 
Awareness Weeks funded by Lundbeck do not over-emphasise the depressive 
symptoms that Lundbeck’s latest drug uniquely treats. This change begs the question: 
if companies are no longer funding disease awareness campaigns to subtly promote 
the features of their new drug, then why are they funding them? Conrad (2005) found 
that the pharmaceutical companies’ profit motive was a key engine of medicalisation, 
in that corporations are obliged to make money for their shareholders. This 
prioritisation of profit above all else is what leads Bakan (2012) to argue that 




The critical argument in extant literature is that Lundbeck would fund an awareness 
campaign to increase awareness of depression, because it makes more people think 
they have it, which, in turn, grows the pool of potential patients via disease mongering 
(Moynihan and Henry 2006). However, whilst this might have been a useful tactic in 
the 1990s, it is unlikely that disease mongering in 2016 would benefit Lundbeck in the 
same way. Firstly, awareness of depression is already high, and the recent campaigns 
funded by Lundbeck do not contain evidence of attempting to widen the definition of 
depression by focusing on lesser-known symptoms.  
 
Secondly, Lundbeck’s new drug is a second-line antidepressant, meaning it would only 
be used with those patients who have already tried at least two (cheaper) 
antidepressants without experiencing improvement. Therefore, if Lundbeck were 
attempting to widen the definition of depression to include ‘healthy’ individuals, then it 
is unlikely these new patients would progress straight to a second-line antidepressant. 
Furthermore, as emphasised by several pharmaceutical representatives, companies 
no longer want their new drugs prescribed in healthy populations as it erodes trust and 
provides healthcare professionals and patients with a bad experience, which, in turn, 
leaves the company vulnerable to scandal and harms their profitability. As one 
respondent observed: 
Obviously, every company is not a charity, every company has to 
generate profits to their shareholders, and, more importantly, have the 
funds to continue investment into research and development, bring the 
drugs to market, and that's a massive cost. So, absolutely, companies 
are driven by generating profit. But, because we are such a regulated 
industry, the main thing is that medicines are used in the right patients. 
So, a lot of the conversations over the years I've spent having are, 
whether it be policy makers, budget holders or clinicians, etc., are, you 
need to get this medication right in the right patients, because the last 
thing you want is it being used over here in the wrong group of patients. 
Particularly, say, in mental health, because the patient is going to have 
a bad experience, the clinician is going to have a bad experience, and 
then, potentially, everyone’s going to say “oh, that medicine doesn’t 
work”, but they're not going to know that it didn't work because it was 
used in the wrong patient (Fieldwork Interview, PSR). 
Whilst companies appear to have moved beyond actively promoting antidepressants  
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in healthy populations, antidepressant prescriptions continue to rise. This is possibly 
due to societal changes such as reduction of stigma, and the persistence of the 
chemical imbalance theory which will be discussed in more detail in chapter 11. 
 
Beyond the straightforward disease mongering of early campaigns, my interviews with 
pharmaceutical representatives, PR professionals and pharmacists uncovered wholly 
different reasons for industry investment in charitable organisations: to influence policy 
and regulators. 
  
In the UK, before new drugs are made available to the public they go through an 
approval process, during which the manufacturers must demonstrate that the drug is 
safe and effective. In addition to this, to make it on to formularies the drug must 
demonstrate good value for money. As discussed in the history section of this thesis, 
Malerba and Orsenigo (2015) argue that the pharmaceutical industry has now entered  
into the era of ‘the winter of discontent’. Today, drugs must compete against an ever-
growing selection of drugs. If the Olympics operated like the drug market, then every 
four years 100m sprinters would be racing against every other former Olympic 
champion who would not have aged a single day. In such a climate, winning becomes 
increasingly difficult. The pharmaceutical industry’s response to this scenario can be 
likened to increasing the number of medals and increasing the prize money to be 
shared amongst the winners. One way through which they do this is by emphasising 
the ‘disease burden’. 
 
Disease burden is defined as the impact of the condition, which is ordinarily 
understood in terms of mortality, financial cost and the propensity to disable (Lopez et 
al. 2006). Manufacturers use disease burden in applications for marketing approval, 
and in discussions with medicine management committees who decide what drugs 
are included on a formulary. If companies can demonstrate that the condition their 
drug treats has large costs, particularly financial costs which politicians are most 
sensitive to, then they are better able to make the case for their new drug which is 
likely more expensive than existing treatments. For this reason, in some marketing 
materials for, Brintellix, Lundbeck focus on the financial costs of cognitive dysfunction 
in depression, particularly how these symptoms impact upon the work performance of 
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depressed individuals. Presently, Brintellix is the only antidepressant which treats 
cognitive dysfunction. Hence, whilst the drug is more expensive than generic SSRIs 
and off-patent third-line treatments, Brintellix may work out cheaper for society overall 
due to the money saved in sick days, mistakes, poor decision-making and so on.  
 
Disease burden is not only an area in which the interests of pharmaceutical companies 
and charities align, but, rather, it is an area which also aligns with the interests of 
politicians. If DA were to say ‘Depression is a very mild condition which barely impacts 
the lives of people who have it’, then they would be undermining the premise for the 
very existence of their charity and the jobs of the people who work there. Charities 
thus have a vested interest in communicating about the impact a condition has on the 
lives of its sufferers. Furthermore, individuals who work for such charities often have 
personal experience of the condition and may even have experienced stigma due to 
a lack of societal understanding. Charities are advocates for conditions. It is for these 
reasons that charities organise disease awareness campaigns, whilst the overlap in 
interests between charities and companies make such campaigns ideal for 
collaboration and building relationships. Depression charities therefore have an 
interest in wanting depression to be taken seriously by politicians and regulators. 
 
In addition to using quantitative data to communicate the magnitude of a condition and 
its costs, qualitative data is also used to demonstrate disease burden. Patient 
narratives are rich sources of information about the day-to-day experiences of 
someone living with a condition. Charities such as DA have access to numerous 
patients willing to talk about their experiences. An informant who worked in the field of 
medical PR explained the importance of charities gaining access to patient case 
studies. 
Charities are very important in pharmaceutical communications. They 
allow the patients' voices to be heard illustrating the impact of the 
disease or condition, easing access to opinion leaders and patient case 
studies and in proving a credible and relevant third-party perspective 
on your story. Charities are also vital in calling for changes in policy and 
in supporting the case for access to medicines, whether that means 
drug approval or budget allocation (Fieldwork Interview, Medical PR 
Professional 5).  
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To be approved and make it onto formularies, manufacturers must make the case that 
their drug provides value for money. Charities therefore add legitimacy to the condition 
and its treatments and, as highlighted in the above extract, provide access to patient 
case studies that illustrate the impact of a disease on a personal level. PR informants 
noted that, rather than being used as distributors to promote marketing messages to 
potential patients, charities are now valued for their reputation. Charities are not 
benign entities, rather, as Loseke (1997) suggests, they have political and rhetorical 
power. In the wake of the Seroxat Scandal and others like it, pharmaceutical 
companies strive to retain and, where possible, improve their reputation. However, 
public trust has been depleted by these scandals. Due to their power and perceived 
moral virtue, charities are imbued with the very trust pharmaceutical companies lack. 
This, along with their overlapping interests in demonstrating disease burden, makes 
charities desirable partners for pharmaceutical companies. 
I think some patient groups really are patient groups and they start off 
with the best of intentions, and perhaps they get infiltrated or they 
change over time. And others are complete total examples of 
astroturfing. They're set up by the drug companies to create credibility, 
to commission the research by the same drug company that ties in with 
the marketing (Fieldwork Interview, Industry Commentator 1). 
Due to their personal and financial connections to charities, interests can overlap with 
the interests of pharmaceutical companies. It is in these instances that charities can 
use their political and rhetorical power (Loseke 1997) to influence decision-makers. 
WIP is an example of the political power of charities in action. The campaign stood out 
from its predecessors due to methodological differences in the survey which informed 
the campaign. Rather than polling patients or GPs, the survey focused on MP’s. The 
results of the survey highlighted gaps in the knowledge and understanding of MPs, 
along with emphasising how important MPs perceive mental healthcare to be. The 
survey demonstrates a change in focus from patients towards policy, a change which 
is in keeping with the profit motives of pharmaceutical companies. Therefore, these 
interactions are still motivated by profit. The ‘engine’, as Conrad (2005) puts it, is 
therefore unchanged. However, because of societal changes, partaking in overt 
disease mongering aimed at potential patients is simply no longer profitable. 
Consequently, there has been a shift in the targets of these campaigns from the public 
to politicians. This change of focus in industry-charity relations within the depression 
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sector from the public to regulators has yet to be explored in the literature, and, as 
such, offers a rich area for future enquiry. 
 
9.5 Conclusion 
Historically, pharmaceutical companies have used charities, particularly disease 
awareness campaigns, to fund a covert marketing message: that depression exists 
and that pills manufactured by Big Pharma corporations offer a cure. Such campaigns 
exemplify Conrad’s (2005) argument that pharmaceutical companies are the key driver 
of medicalisation. This was evident in the DDC where the potential to become 
dependent on antidepressants was downplayed (e.g. Priest et al. 1996), as well as in 
the 2005, 2007 and 2008 Depression Awareness Weeks. In each of these Depression 
Awareness weeks, a lesser-known symptom of depression was highlighted, which 
corresponded with the symptom that the funder's new drug uniquely treated. More 
recent collaborations between pharmaceutical companies and charities, however, 
show less evidence of this kind of subtle marketing. Most interestingly, the 2016 
Depression Awareness Week document, which was produced via a collaboration of 
mental health charities and funded by Lundbeck, did not over-emphasise the 
depressive symptom that their drug uniquely treats: cognitive dysfunction. 
 
This chapter has argued that, whilst there has been a positive move away from 
antidepressant manufacturers using charities to contribute to subtle disease 
mongering, pharmaceutical companies are incapable of behaving altruistically due to 
their commitments to shareholders (Bakan 2012). Interview data suggests that 
pharmaceutical companies are now using charities to improve their reputation and 
strengthen their applications to regulatory bodies. The 2016 Depression Awareness 
Week campaign WIP was reflective of this change in motive, whereby instead of 
aiming to influence the actions of patients or practitioners, the focus turned to policy. 
 
Leisinger has written extensively on pharmaceutical industry corporate social 
responsibility and reputation management (e.g. 2005,2009,2011). However, no 
research has yet been carried out on the data from charities funded by pharmaceutical 
companies that is used in applications to regulatory bodies, formularies and policy 
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makers. The consequences of this newer motivation for pharmaceutical collaboration 



































In the 1989 film Back to the Future II, Marty McFly and co. travel through time to 2015. 
The film depicts flying cars, hoverboards and pizza rehydraters. Whilst we have yet to 
master the art of pizza rehydration, technology has indeed developed significantly 
since the late 1980s, which also saw the launch of blockbuster antidepressants like 
Prozac and Seroxat. This thesis began by investigating the history of depression and 
its treatments, both to better understand current issues and to situate the empirical 
findings. A narrative emerged. The marketing of treatments consistently corresponds 
with the marketing of a diagnosis. Or, phrased otherwise, the dominant treatment of 
the era frames how symptoms of low mood are understood and categorised. Since the 
late 1980s, SSRIs have been the most popular treatment for depression, and their 
manufacturers – large pharmaceutical companies – have, in turn, influenced the 
diagnosis of depression. The success of SSRIs such as Prozac have contributed to 
the image of Big Pharma as omnipotent and immovable as the leaders in depression 
treatment. However, throughout history certain institutions and interest groups have 
enjoyed hegemony over the market for depression treatments, and one-by-one their 
hegemony, which also seemed invincible at the time, eventually diminished. The 
adoption of this historical approach has helped to demonstrate that the future of the 
industry is uncertain. Malerba and Orsenigo (2015) even go as far as to call the current 
era ‘the winter of discontent’ for Big Pharma, which may bring about their downfall. 
Antidepressants have been considered as an analogous case for the wider 
pharmaceutical industry. This section explores the future of the antidepressant market, 
and considers the stability of the pharmaceutical industry’s position as the 
manufacturer and distributor of the most popular treatment for depression. 
 
A SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis is commonly used 
by professionals in the world of marketing and strategy to critically examine the 
position of a product or organisation in the market. When looking towards the future, 
the two latter headings become the most important: opportunities and threats. This 
chapter and the one which follows it outlines the emergent issues coming out of my 
interviews and documentary investigation, presenting them in terms of opportunities 
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and threats to both the pharmaceutical market and the ability of Big Pharma to market 
antidepressants as the main treatment for depression. 
 
This chapter explores the threats facing the antidepressant market from two directions: 
internal and external. Internal threats constitute those factors which tend to push 
demand away from antidepressants, such as questions over the safety and efficacy of 
antidepressants. Conversely, external threats correspond to those factors which pull 
demand away from antidepressants towards non-pharmacological treatments. 
 
10.2 Internal Market Threats 
When SSRIs reached blockbuster status in the 1990s, they were deemed by some to 
be a miracle cure (Kramer 1994). Whilst the public had some reservations about using 
psychoactive drugs to treat mental illness, disease awareness campaigns were used 
to change perceptions and reassure the public about the safety of the medicines (See 
Chapter 9). However, throughout the SSRIs’ reign as blockbuster darlings, dissidence 
brewed beneath the surface. Investigative journalists and critical psychiatrists such as 
David Healy (2004) identified dangerous side-effects and anomalies in data previously 
reported. Together, they spearheaded efforts to increase public awareness of these 
potential dangers. 
 
Throughout the 2000s, Panorama released a series of documentaries looking at SSRI 
scandals, which possibly helped to create a moral-medical panic around 
antidepressants (Jofre 2002,2003,2004,2007). These documentaries were praised for 
initiating an investigation into the link between SSRIs and suicidality in young people. 
This link had been difficult to prove, as suicidality can also be a symptom of 
depression. However, over time some healthcare professionals noticed a pattern of 
some young people engaging in suicidal thoughts and actions after beginning using 
SSRIs or after having their dose increased. Ultimately, this Panorama investigation 
culminated in the reanalysis of clinical trial data which demonstrated that GSK actively 
ignored the suicidal side-effect and excluded it from research papers, all the while 
attempting to get NICE to recommend their drug for use in adolescents and young 
people. Panorama also drew attention to the withdrawal symptoms some individuals 
were experiencing upon ceasing SSRI treatment.  Withdrawal symptoms ranged from 
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gastrointestinal problems to emotional problems. An industry commentator I 
interviewed spoke of their personal experiences of trying to come off Seroxat 
(Paroxetine): 
I think I was on 30mg a day, yep, 30mg a day and then I thought, well, 
I'll reduce down to 20mg, that will be a start, because I kind of knew 
even then, I kind of knew or my wife knew that you really should just 
stop taking it the way some people try. So, I reduced to 20mg a day 
and I think it was within four days I was an absolute wreck. I couldn’t 
function, I was tearful, I was all over the place I was absolutely in 
pieces. And, kind of, we sort of put the two together. It's amazing how 
you don't actually put the two together very quickly. I went back up to 
30mg and within 24 hours I was absolutely fine. So, of course, that set 
me wondering. I then started to do a little bit of research on the internet. 
I had purposely avoided that in the past, because I kind of thought if I'm 
taking Seroxat maybe I want to carry on taking it. I swallowed the line 
that it's like a diabetic and insulin, you've gotta keep that level of 
serotonin up. You know, depression it's a medical condition really. 
Which is an absolute load of bollocks, complete load of tosh. 
The commentator went on to recount how they eventually came off the drug nearly 
two years later: 
It took me two years, nearly 22 months to come off Seroxat. Little by 
little, withdrawing no more than 10% of what I was taking and then 
stabilising for 2 weeks, 3 weeks, 4 weeks, however long it took, and 
then reducing another 10%. So, the reductions would consequently get 
less and less. You know, if I was taking 5mg and reducing by 0.5mg. 
The only way to do that is to use liquid Seroxat. It comes in a 
suspension and you use a syringe to measure it more accurately than 
cutting a tablet. You can’t cut a tablet when you get to those last 
milligrams (Fieldwork Interview, Commentator 1). 
Their experience was not unique. Seroxat has a shorter half-life than Prozac and other 
SSRIs. This means it breaks down faster in the body, which, in turn, makes any 
reduction in dosage more noticeable than in drugs with longer half-lives. Everyone 
metabolises compounds differently and so not everyone experienced withdrawal 
effects when coming off Seroxat, although many did. Panorama drew attention to 
these stories of withdrawal and side-effects.  
 
The second Panorama documentary in 2003 focused on the over 1,400 emails 
received after the first documentary aired, drawing further attention to the magnitude 
and prevalence of the problems people were experiencing whilst taking, and 
attempting to stop taking, Seroxat. The documentary foregrounded the voices of 
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people who felt their lives had been affected by Seroxat. One man described finding 
his teenage son after he had hung himself. A 14-year-old girl recounted engaging in 
suicidal behaviour and self-harm whilst on Seroxat, which she never did before or after 
taking the drug:  
Cutting myself until I bleed, slitting my throat, walking in front of a bus, 
all sorts of things going from one extreme to the other really.  Stealing 
a car and driving it off a cliff, jumping off a bridge, all sorts of things 
(Jofre 2003). 
 
Personal narratives such as these proved extremely powerful. Indeed, the 
documentaries went on to have a large social impact and have been partially credited 
with leading to the re-examination of Study 329 (Le Noury et al. 2015). As mentioned 
previously, Study 329 was a clinical trial conducted by SKB (now GSK) researching 
the efficacy and safety of paroxetine in adolescence. The published results concluded 
that paroexetine was ‘generally well tolerated and effective for major depression in 
adolescents’ (Keller et al. 2001). However, reanalysis of the study found that 
paroxetine was not significantly better than a placebo, whilst it also increased the rate 
of suicide amongst adolescence.  
 
Following on from the success of their prior SSRI documentaries, in July 2017 
Panorama released another documentary on SSRIs called ‘Prescription for Murder?’. 
This episode tracked the case of American mass murderer, James Holmes, who killed 
24 people in a movie theatre, and questioned whether SSRIs may have been linked 
to the crime. This possible scandal is not new. However, the Panorama episode 
helped the idea to take root in the public’s consciousness. Panorama producers, 
contrary to previous SSRI related episodes, chose to focus on one case as opposed 
to presenting multiple cases and demonstrating a pattern.  
 
The psychiatrist David Healy had been involved in the Holmes case and featured 
heavily in the documentary, arguing that had Holmes not taken sertraline he would not 
have committed the crime. Healy has been an expert-witness in a number of cases 
where antidepressants have been potentially associated with violent behaviour. 
Moreover, he has collected numerous case studies where an individual has taken an 
antidepressant in the past, had a bad reaction, and then after taking a higher dosage 
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of the drug again in the future gone on to commit a violent crime (Healy 2013). I have 
seen Healy present on this topic, and he predominantly draws on those cases in which 
the person had no prior history of violence and had already reported experiencing 
negative side-effects of a SSRI, before later going on to take the drug again and 
commit a violent act. Healy selects these examples specifically to isolate the effect of 
SSRIs. Holmes, however, was a much more complex case. Holmes had a history of 
violent thoughts and had stopped taking an antidepressant weeks before the crime 
took place. This does not mean that it is impossible that the drugs in some way 
contributed to the crime, but the strength of the overall argument is weakened by these 
complicating factors. Furthermore, the documentary lacked the powerful personal 
narratives of masses of people affected by antidepressant side-effects, which had 
proved so effective in past documentaries. Instead, it focused on joining the ‘dots’ up 
on one, complicated case: 
Our investigation of the timeline of events, joining the dots of what 
happened with his medication, suggests Sertraline may have played a 
part. We found no evidence Holmes planned to kill before the 
antidepressants, and plenty to show how afterwards his mental state 
went rapidly downhill. No one joined these dots up at his trial (Sommers 
2017). 
 
Resultantly, the episode has been met with considerable criticism. Media reviews 
referred to the program as ‘propaganda not journalism’ due to the magnitude of the 
claim and the relative paucity of evidence presented to support it.  
 
From the moment I heard about 'A Prescription for Murder', I felt the 
marketing and the details made available before airing alone was 
sensationalising the myth that mental health and violence are bound, 
when in reality all the data available shows the opposite. During the 
programme itself, I felt demonised. I feel sorry for anyone who sat 
through last night’s show who takes medication or has a family member 
who uses a SSRI drug, because it was an awful piece of documentary 
work which I have no doubt will create and inflame stigma around 
mental health and medication (Woods 2017). 
 
For antidepressant manufacturers, the critical reception of the documentary provided 
some much-needed relief. However, there was a concern shared by healthcare 
professionals that the programme may lead individuals to stop taking their 
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antidepressants. Whilst the program actively discouraged this action, this does remain 
a possibility. Furthermore, the sensationalist title and promotion of the programme 
could contribute to the stigma associated with taking psychiatric medications, even 
amongst individuals who did not watch the programme. The program has also been 
criticised for its irresponsibility in handling the issue of mental health and violence 
(Sommers 2017). A stereotype exists suggesting that people with mental illnesses are 
violent, when research suggests that they are far more likely to be the victims of crime 
than the perpetrators. Mental health campaign ‘Time to Change’ released a statement 
following the airing of the documentary: 
Media portrayals of mental health problems are very powerful in 
shaping attitudes and informing people. This is why it's so important to 
get it right by ensuring the coverage is balanced and provides context. 
People with a mental illness are more likely to be a victim of violence 
than a perpetrator, so we are concerned that the Panorama broadcast 
about medication causing homicidal behaviour feeds into outdated, 
negative stereotypes and fuels stigma (Baker 2017). 
 
‘Time to Change’ is run by ReThink Mental Health, who receive less than 1% of their 
funds from pharmaceutical companies, and Mind, who, as said previously, receive no 
funds from pharmaceutical companies. Mind had been supportive of Panorama’s 
previous investigations, however, ‘Prescription for Murder’ failed to garner their 
support.  
 
I have been unable to find a single positive review of the episode. With the exception 
of Healy, the medical profession responded negatively to the content of the 
documentary. Healy (2017) suggests that this may be due to the formation of the 
Science Media Centre (SMC) organisation, which was set up in 2011 to do the 
following: 
 
To provide, for the benefit of the public and policymakers, accurate and 
evidence-based information about science and engineering through 
the media, particularly on controversial and headline news stories when 




SMC does not allow corporate donors to make donations which exceed 5 percent of 
their total donations. However, it does receive large donations of up to £30,000 from 
multiple pharmaceutical companies. I have not found evidence to suggest that the 
SMC influenced media coverage of the Panorama episode, and there are multiple 
differences between the newest documentary and previous Panorama episodes on 
SSRIs, which, in part, explain the difference in reception. However, investigating the 
role of the SMC in detail is beyond the scope of this project, although it could be an 
interesting area for future enquiry.  
 
Thus far, the most recent Panorama investigation of antidepressants has not had the 
impact of previous episodes. The key thesis of the program was less convincing than 
that of previous episodes. However, there are other, less high-profile and more 
straightforward cases which provide more compelling evidence of the possibility that 
SSRIs can lead to violence in an extremely small number of individuals who take the 
drug.  David Healy leads the push for further investigation into this issue in  academic 
publications (e.g. Healy et al. 2006), in courtrooms as an expert-witness, and in public 
forums. Healy draws upon a variety of cases to support this argument, such as this 
example taken from his blog: 
David Hawkins was a 74-year-old man with a 20-year history of minor 
episodes of nervousness, no violence. In one of these he was treated 
with Zoloft and had a bad response to it. His doctor recorded “Do not 
give this man SSRIs” … A number of years later feeling unwell he was 
seen by a locum doctor who didn’t know the history and didn’t read the 
notes and put him on Zoloft. He didn’t know that he was being put back 
on a pill that he had reacted poorly to before. He felt worse after one 
pill and thinking that more would help took four and the next morning 
strangled his wife to death. The judge and prosecution agreed with 
Tania Evers for the defence that, but for the drug, it was unlikely this 
would have happened (Healy 2013). 
 
Healy typically presents examples where the individual has taken antidepressants 
before, had a bad reaction, then upon being prescribed SSRIs again later in life, 
usually at a higher dosage, committed a violent crime. Whilst the sensationalist case 
presented in Panorama left the audience largely unconvinced, it is possible that 
Healy’s collection of more straightforward case studies could be more convincing. It is 
185 
 
therefore likely that the debate surrounding the link between SSRIs and violence will 
persist over the coming years, posing a continuing risk for SSRI manufacturers. 
 
10.3 External Market Threats 
The pharmaceutical industry has dominated the market for depression treatments 
since the launch of SSRIs in the late 1980s. Since, the industry has become known 
as Big Pharma, a seemingly omnipotent entity. At various points across history, the 
status-quo in the treatment of low mood appeared unlikely to be challenged. However, 
as discussed in earlier chapters, the condition has been treated under the domain of 
four humours practitioners, the church, and psychoanalysts at different points in time. 
hence, it is entirely possible that in the coming decades the treatment of depression 
will be dominated by different industries. This section examines the external market 
threat posed by newer industries entering the market, most notably the medical device 
and tech industries. The commercialisation of mindfulness and its impact on the 
market will also be explored. This section thus looks at alternative treatments to 
antidepressants for depression. 
 
10.3.1 The Alternative Market 
Although depression is largely a medicalised condition, it also has non-medical 
treatments. Some of these treatments are used instead of medical treatments, whilst 
some are used in addition to medical treatments. This section explores commercial 
treatments for depression which currently fall outside medically prescribed treatments. 
Whilst these are not necessarily new entrants to the depression treatment market, 
their popularity has increased in recent years due to cultural shifts.  
 
St John’s wort 
The herb, hypericum perfortatum, commonly known as St John’s wort, is a popular 
traditional herbal medicine (THM) available over the counter at pharmacies and health 
food shops. St John’s wort is available on prescription in many European countries, 
however this is not the case in the UK. St John’s wort is a THM and, as such, is not 
subject to the same rigorous testing as standard antidepressants. However, a 
systematic review did find the medicine to be superior to a placebo and as effective 
as standard antidepressants in the treatment of mild to moderate depression (Linde et 
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al. 1996). Although St John’s wort is deemed to have a favourable side-effect profile 
when compared to standard antidepressants, the medicine does interact with many 
other drugs. Amongst other things, St John’s wort can decrease the effectiveness of 
the oral contraceptive pill and increase the longevity of general anaesthetics. In terms 
of the market for antidepressants, then, the interactive nature of St John’s wort means 
that it cannot be taken with any standard antidepressants, which, in turn, makes it a 
potential substitute and competitor in the antidepressant market.  
 
5-Hydroxytryptophan (5-HTP) 
5-HTP is a supplement available from high-street retailers such as Boots and Holland 
and Barret. It is a precursor to serotonin, and once broken down is believed to increase 
serotonin levels in the brain. UK Google searches for 5-HTP have doubled since 2014 
(Google Trends 2018a). In their review of the evidence of 5-HTPs efficacy, Hinz et al. 
(2012) describe it as seductive. There is an intuitive appeal to taking a ‘natural’ 
compound to increase serotonin levels, which has contributed to a dedicated cult- 
following (including Jim Carey) proporting ‘exaggerated and inaccurate claims.’ 
However, there is insufficient evidence to suggest that it is an effective treatment for 
depression when taken alone (Hinz et al. 2012). The appeal of 5-HTP is thus 
ideological, rather than scientific. Furthermore, 5-HTP is cheaply available online with 
hundreds of listings on Amazon. Therefore, 5-HTP has the potential to capture would-
be patients who, after searching online, would rather buy a ‘natural’ serotonin booster 
on Amazon than visit their GP to be prescribed an SSRI. 
 
Mindfulness and bibliotherapy 
As aforementioned, mindfulness is now being used in combination with CBT as a 
talking treatment. With its roots in neuroscience, mindfulness is gaining traction within 
the medical community. However, due to its overlap with concepts from Buddhism and 
pop-spirituality, mindfulness has also become popular amongst the public. Most 
recently, this can be seen in the trend of adult colouring books. Mindfulness has been 
commercialised predominantly by publishers. The evidence-base for self-help books 
is mixed (Redding et al. 2008). Redding and their co-authors found that, whilst some 
books were written by authors with medical qualifications whose advice was supported 
by strong evidence, others lacked any evidence-base at all. One book which draws 
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upon evidence and has had its efficacy verified in subsequent research, is Burns’ 
(1981) ‘Feeling Good: The New Mood Therapy.’ Such books have traditionally been 
thought of as complementary products to antidepressants, rather than substitutions. It 
has yet to be seen whether this form of mindfulness will buck this trend and become 
a serious competitor to antidepressants in the treatment of depression, however its 
popularity is soaring, with Google searches for mindfulness quadrupling since 2011 
(Google Trends 2018b). 
 
Formerly Illegal Drugs 
Many large pharmaceutical companies have withdrawn from the therapeutic area of 
depression due to issues covered throughout this thesis: patent expiration, lack of 
profitability, scandal, and so on. Although many drug manufacturers have withdrawn 
from the therapeutic area of depression, research is still being conducted into possible 
helpful compounds. Many of these are not newly discovered compounds, but, rather, 
drugs which have previously been used recreationally or to treat other conditions. This 
section focuses on these compounds and the manifold opportunities they present 
 
There are numerous examples of the media promoting sensationalist stories about the 
use of illegal narcotics to treat depression. Recent headlines include ‘“Party Drug” 
ketamine really does lift spirits’ (Borkhataria 2017) and ‘Magic mushrooms “reboot” 
brain in depressed people’ (Siddique 2017). Headlines such as these capitalise on the 
shock-value of taking these mind-altering substances. However, as frequently noted 
by Moncrieff, all drugs prescribed to treat mental illnesses are psychoactive drugs, in 
that they are all mind-altering substances. When this fact is considered, it is far less 
shocking that drugs such as ketamine and magic mushrooms could have therapeutic 
effects for some individuals. Referring back to Moncrieff’s conceptual framework about 
drug-based versus a disease-based view of substances, all psychoactive drugs have 
effects on the brain. Technically speaking, there is no such thing as a side-effect. 
Simply put, some effects are desired, and some are not. Moncrieff (2008) argues that 
the main difference between recreational drugs and other drugs prescribed to treat 




Ketamine is known by many to be a horse tranquiliser, as well as often being used by 
anaesthetists. Early trials have shown that ketamine also had an antidepressant effect 
in individuals with treatment resistant depression, specifically in reducing suicidality 
(Price et al. 2009; Murrough et al. 2013). The problem for antidepressant 
manufacturers is that ketamine is an old compound, and thus cannot be patented and 
is not profitable. The profit potential for ketamine lies in its mechanism of delivery. 
There are active and pending patents covering the use of a nasal spray to administer 
ketamine to treat depression (Charney et al. 2017). It is the owners of these patents 
who would ultimately benefit from ketamine succeeding as a depression treatment. 
 
Another illegal narcotic currently being researched as a potential treatment for 
depression is magic mushrooms, more specifically, the active chemical, psilocybin. 
Two patents for the drug were originally held by UK pharmaceutical company, Sandoz 
Ltd. (Heim et al. 1965; Hofmann et al. 1965). These patents covered the extraction of 
psilocybin from the raw material. However, these were both filed over 20 years ago 
and have since expired.  
 
Probiotics 
The vagus nerve, although usually a pair of nerves, is typically referred to singularly 
within scientific literature (e.g. Borovikova et al. 2000).The vagus nerve links the brain, 
the heart and the gut. The nerve is one of the largest in the body and is responsible 
for a vast multitude of bodily functions.  Most of the functions of the nerve can be 
described as ‘parasympathetic’, meaning that the nerve stimulates unconscious 
activities linked to the digestive system and sexual function. However, the vagus nerve 
also causes us to cough if inadvertently prodded with a cotton bud.  
 
Due to the sheer size of the nerve, and its presence in and around many vital organs 
(vagus literally means ‘wandering’ in Latin), the nerve can be stimulated a number of 
ways. In terms of the medical device market, small, hand-held devices have been 
developed which can be applied externally to the side of the neck. There is also 
evidence to suggest that the nerve can be stimulated via the digestive tract.  In an 
experiment involving mice, researchers found that the vagus nerve could be stimulated 
via the ingestion of probiotics, and that mice on the probiotics exhibited less 
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‘behavioural despair’ then their control group counterparts (Dinan and Cryan 2013). 
These findings are very preliminary; however, they do present a possible opportunity 
in the market for drug manufacturers and ‘alternative medicine.’  
 
10.3.2 The Device Market 
The device industry is not an entirely new entrant within the market for depression 
treatments. Anyone who has seen the cult classic ‘One Flew Over the Cuckoo’s Nest’ 
will remember scenes of patients in pain struggling with the side-effects of 
electroconvulsive therapy (ECT). ECT is still medically considered as an effective 
treatment for some individuals with depression, however publicly ECT is often 
perceived as dangerous. A study by Lauber et al. (2005) found that 57% of 
respondents considered ECT to be harmful, whilst only 1.2% considered it a treatment. 
In addition to being inhibited by its public image, ECT fails to prevent future episodes 
of depression, and, indeed, follow-up treatment with antidepressants is advised. It is 
for these reasons that ECT has not been a major competitor to the prescription of 
antidepressants. However, in recent years the device industry has taken a renewed 
interest in the treatment of depression, and, indeed, companies have been successful 
in releasing new products to the market. 
 
Vagus nerve stimulation  
Medical devices function by stimulating the vagus nerve electronically. This is usually 
done via a minimally invasive operation, whereby a device is inserted under the skin 
in the chest under local anaesthetic. The device is activated a few weeks after the 
surgery, and then, similarly to a pacemaker, the device electronically stimulates the 
vagus nerve. Although the operation is described as minimally invasive, it is still a 
relatively serious intervention in terms of depression treatments. Furthermore, the 
device and its implantation are expensive. Because of these factors, vagus never 
stimulation (VNS) has thus far only been used in a limited number of patients with 
treatment resistant depression. This is reflected in the 2009 NICE guidelines on VNS, 
which only discusses the use of VNS in patients with treatment resistant depression. 
Therefore, currently VNS is not considered to be a serious competitor to drug 




A counter culture of brain hacking has emerged in recent years (Koch 2010). Brain 
hacking refers to the use of drugs or, more commonly, electricity to activate and 
deactivate certain areas of the brain. It is used for relaxation, increased focus and 
concentration, rapid learning, in addition to recreational purposes. Devices can also 
be used externally on the vagus nerve; indeed, a US start-up has already developed 
a hand-held vagus nerve stimulator that they hope will eventually become the first-line 
of treatment for depression. Therefore, although VNS and repetitive transcranial 
magnetic stimulation (rTMS) is currently only used in cases of severe treatment 
resistant depression, it is possible that it could pose more of a threat to the drug market 
in future years. 
 
Transcranial Magnetic Stimulation  
Similar to VNS, transcranial magnetic stimulation (TMS) operates by administering 
electricity. However, instead of being directed at a pair of nerves, with TMS electricity 
is administered to areas of the brain via external magnetic stimulation. Thus far, TMS 
has most notably been used to study the brain by stimulating and suppressing certain 
areas and monitoring the results. In addition to being a useful research tool, TMS also 
has therapeutic uses. For example, TMS has been explored as a possible treatment 
for depression since the 1990’s (George et al. 2000). Studies investigating the use of 
TMS to treat depression initially stimulated the vertex with mixed results. Researchers 
have also been investigating the possible benefits of stimulating the left prefrontal 
cortex. In December 2015, NICE released new guidelines advocating the use of 
repetitive transcranial magnetic stimulation (rTMS) as a treatment option for patients 
with depression. The guidance notes that one of the advantages of rTMS for patients 
is that some patients may be able to stop using oral antidepressants.  Furthermore, it 
is important to note that, unlike VNS, the guidelines for rTMS are not limited to cases 
of treatment resistant depression. Therefore, rTMS appears to be a more serious 
competitor to antidepressant drug treatment than VNS. Having said this, rTMS is still 
a new and novel treatment. The interviewed psychiatrists expressed hesitation 
towards using device treatments for depression, choosing instead to opt for familiar 
drug treatments and talking treatments. As with VNS, brain hackers are building their 
own machines for TMS and rTMS at home, however there is hitherto no commercial 




Transcranial Direct Current Stimulation  
Another treatment utilising electrical currents is transcranial direct current stimulation 
(tDCS). As with TMS, electrical stimulation of the brain takes place externally, and thus 
tDCS is less invasive than traditional VNS. One benefit that tDCS has over other 
electrical device treatments, is that it can be done at home. However, research into 
the efficacy of this treatment is limited; consequently, NICE guidelines request that 
clinicians inform patients of the uncertain efficacy of the treatment, as well as informing 
the clinical governance leads of their NHS trust before administering the treatment. 
Therefore, although tDCS shows promise, once again, it is not presently a competitor 
to traditional antidepressant treatments. 
 
Previously, the only medical devices that were used to treat depression were the ones 
used to administer ECT. In recent years, however, the number of new devices being 
developed and entering the market is far greater than the number of new 
antidepressants. Although many consider the new developments in medical devices 
to be promising, in practice the use of these newer interventions is rare. 
 
10.3.3 Apps and technology 
As suggested by the name, computerised cognitive behavioural therapy (CCBT) refers 
to the administration of CBT via a computer program and, in some cases, a telephone. 
Although they are only now taking off, the idea of using computers to administer 
therapy is not a new one. In the 1960s, individuals corresponded with a chatterbot 
named ELIZA (Weizenbaum 1966). A chatterbot is a program which attempts to 
emulate human conversation. An individual would be able to type to ELIZA and she 
would respond basically in keeping with a style of psychotherapy known as Rogerian 
Psychotherapy. ELIZA would function by encouraging the user to vent about their 
feelings with responses such as ‘Can you elaborate on that?’ and ‘What makes you 
say that?’ Even individuals who knew ELIZA was just a computer program found 
themselves talking to her for hours about their feelings.  
 
In 2013, NICE updated their guidelines on the use of CCBT. The three programs 
specified by the guidelines are: Beating the Blues (BtB), COPE and Overcoming 
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Depression. BtB is specified as an option for individuals with mild or moderate 
depression, whist COPE and Overcoming Depression are only recommended to be 
offered as part of a clinical trial. As BtB is the only CCBT program available to patients 
outside of clinical trial, BtB will be the specific focus of the discussion on CCBT 
programs. Although BtB was included in the NICE guidelines as a first-line treatment 
option for depression, none of the healthcare professionals interviewed mentioned 
considering prescribing CCBT for a patient. In theory, CCBT has an advantage over 
traditional CBT, in that it is cheaper and does not require the presence and time of a 
qualified- professional to be administered. However, the NICE guidelines do suggest 
that sessions are to be completed within a GP surgery, which could go some way to 
explaining the lack of adoption by GPs. Whilst one of the perceived benefits of CCBT 
is that sessions can take place at any time of day or night without an appointment, 
restricting usage to GP surgeries could aid in allowing individuals to remember to do 
the sessions and motivate them to complete homework, although this practice could 
also act as a deterrent for some individuals. In addition to being available via the NHS, 
BtB can be purchased and downloaded from the company website for a discounted 
price of £49.99 including tax. The legal availability of the program off-prescription could 
make the treatment favourable to those individuals who do not wish to visit their GP. 
Those wishing to take antidepressants without visiting a health professional are thus 
forced to partake in the risky business of buying drugs online. Although there are some 
advantages to CCBT, the lack of adoption means that treatments such as BtB pose 
no real threat to antidepressants’ market share. 
 
The smartphone has revolutionised many aspects of human life, and when it comes 
to depression, as the famous Apple tagline goes: ‘there’s an app for that’, or, to be 
more precise, apps. Another famous tech industry adage is ‘move fast and break 
things.’ Resultantly, cyberspace is less regulated than the offline world, which presents 
numerous opportunities for companies across various fields. Shen et al. (2015) 
codified the different kinds of depression apps available in the marketplace. Their 
study found that the apps could be split into: those which provided therapeutic 
treatment or psychoeducation; those which provided medical assessment; those 
which provided symptom management; and those which served as a supportive 
resource. The study only considered apps which specifically mentioned depression, 
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however it is worth noting that other apps which do not directly mention depression 
are also being used by individuals to aid in the treatment of their symptoms. For 
example, the app ‘Headspace’, which provides guided meditations, and similar apps 
are routinely cited by individuals on depression discussion boards as being helpful.  
 
Traditional therapies and antidepressants are both finite treatments, in that once a 
tablet has been taken, that same tablet cannot be taken by anyone else. If someone 
receives an hour of one-to-one therapy, that hour cannot then be used by someone 
else. In theory, an app can be used by multiple people at the same time without being 
‘used up’. Although the fixed costs associated with developing a high-quality app can 
be high, the variable costs which typically arrive with increased users are low.  
 
Apps also have the potential to monitor one’s mood and provide real-time interventions 
in a way that traditional treatments are unable to. For a large portion of society, our 
phones are with us almost 24 hours a day. As a result, your phone knows things you 
may never tell a therapist. It knows how long you spent stalking your ex-partner on 
Facebook, your recent Google searches for symptoms which are probably nothing, 
but still concern you, as well as the last time you left the house. Moreover, your phone 
can compare these things with your past behaviour, as it knows whether you are taking 
longer to respond to texts than you normally do, or whether you are spending more 
time than normal watching cat videos on YouTube. Whilst the sheer magnitude of data 
held about each of us on our phones and laptops can be alarming, especially 
considering how much of this will likely end up in the hands of advertisers hoping to 
make us offers we literally cannot refuse, it does also have the potential to be helpful.  
 
Currently, no apps for depression have been developed that draw upon this data in 
any meaningful way. However, such technology has been used to some extent in apps 
aiming to aid the treatment of addiction. For example, A-CHESS, developed by the 
University of Wisconsin-Madison, uses GPS to find out when a user is in a high-risk 
area, such as if an alcoholic is near a store they have habitually used to buy alcohol 
in the past. The app then alerts the user, encouraging them to stop and think about 
what they want to be doing. In this instance, the app functions similarly to CBT by 
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disrupting the user’s typical behavioural patterns and making them more cognisant of 
their behaviours. 
 
The American app, TalkSpace, is the closest to traditional talking treatments. Users of 
the app have access to a therapist who they can message and talk to 24 hours a day. 
Although the app is based in the US, the 24-hour nature of the service means that it 
can also be accessed by residents of the UK. Other apps which are associated with 
the treatment of depression include apps which remind individuals to take medication, 
meditation and mindfulness apps, and feelings journals. There are currently dozens of 
depression apps available on Google play store, however the quality and efficacy of 
these is unclear. 
 
10.4 Conclusion 
Over the past two decades, the market for antidepressants has become increasingly 
crowded. New developments in terms of drug treatments have been rare and failed to 
recreate the success of blockbuster drugs such as Prozac. As the blockbuster drugs 
of the 1990’s went off-patent, a competitive generics market has arisen causing the 
cost of SSRI’s to fall further. The low cost of existing antidepressants means that 
expensive newer drugs must outperform old drugs greatly to warrant prescription. 
Resultantly, the largest pharmaceutical companies have retreated from the 
antidepressant market place. Current research into the pharmaceutical treatment of 
depression is turning to existing compounds, such as probiotics, and narcotics like 
ketamine. 
 
The device industry has produced some more promising innovations in recent years, 
such as VNS and TMS. Device treatments are currently aimed at more severe, 
treatment resistant cases of depression, and, as such, do not appear to be a 
competitor to standard antidepressants. However, with the development of portable 
devices and an increased move towards ‘brain hacking’ in certain realms of counter 
culture, it is possible that such devices could become more commonplace in the 




Recently, the practice of mindfulness has increased in popularity in the UK. From the 
use of adult colouring books, meditation, and even apps, mindfulness is being touted 
as a form of prevention and potential cure for milder forms of depression (Morgan 
2003). Whilst this sentiment is not entirely shared by the healthcare professionals 
interviewed, there remains some possibility that mindfulness practices could mitigate 
specific facets of modern life which may be contributing to depression, as emphasised 
by a GP informant: 
I think modern life is probably quite conducive to being anxious or being 
depressed just because the world is so fast-paced. And I suppose 
younger people nowadays with the pressures of sort of modern life, 
technology and things like social media where they always have to be 
there in the moment, and you're sort of documenting every aspect of 
their lives, that puts a lot of pressure on them (Fieldwork Interview, GP 
1). 
Previous chapters have outlined the various paradigm shifts in the treatment of 
depression, from the church, to psychoanalysis, to the pharmaceutical industry. In 
each instance, it appeared like the prevailing approach was too big to be overtaken. 
From scoping out the current market context for depression treatments, it is possible 
that we are on the brink of another paradigm shift, whereby the device industry 
potentially takes over the treatment of certain kinds of depression. Whether this will 
happen or not is unclear. However, what is known is that the market for depression 
treatments is vastly different from the blockbuster heyday of the late 20th century. So, 
what does this new horizon mean for the marketing of antidepressants? Are we 
witnessing what Malerba and Orsenigo (2015) referred to as the ‘Winter of Discontent’ 
and the fall of Big Pharma? The next chapter explores the other side of the coin, that 
is, the opportunities which hint at a more hopeful future (for antidepressant 










11: Opportunities  
 
11.1 Introduction 
The previous chapter highlighted several threats to the future of antidepressant 
manufacturers based on data gathered throughout the research process. However, 
the future of the industry is not entirely bleak. Technological advancements, policy 
developments and societal changes are all creating new opportunities for Big Pharma 
companies. This chapter outlines these opportunities. Rather than serving as a how-
to guide for industry practitioners, this chapter aims to unearth and present the 
opportunities already identified by a secretive industry by using interview data, industry 
reports and other documents. This chapter is organised into three sections. Firstly, 
opportunities from developments within the field of antidepressants will be examined. 
Secondly, technological advancements in other fields will be presented, and, finally, 
sociological factors with the potential to favourably impact upon the antidepressant 
market, specifically in terms of facilitating covert marketing practices, will be 
presented.  
 
11.2 Response to Previously Identified Threats  
The previous chapter highlighted the challenges facing Big Pharma in the treatment 
market for depression. Threats broadly fell into two categories: questions about the 
safety and efficacy of antidepressants, and competition from other treatment options. 
This section considers developments which may reduce the impacts of such threats. 
Firstly, I discuss the factors which could increase the safety and efficacy of 
antidepressants or, at the very least, increase the public perception of safety and 
efficacy. Secondly, I examine the pharmaceutical industry’s investment in possible 
new pharmaceutical treatment options.  
 
11.2.1 Safety and efficacy of antidepressants 
“The drugs do work!” exclaimed the Telegraph earlier this year with a headline so 
creative that it was also used by nearly every other newspaper in circulation (Donnelly 
2018). The journalists were referring to a metanalysis conducted by Oxford University 
researchers which found that, over an eight-week period, antidepressants perform 
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better than placebos (Cipriani et al. 2018). One of the paper’s authors, Professor John 
Geddes, has since been hitting the media circuit arguing that these findings 
demonstrate that a million more people in the UK should be taking antidepressants, 
even though the academic article itself makes no such recommendation. Furthermore, 
the media coverage of the research was also incorrect in its reporting that 
pharmaceutical industry funding has no impact on trial outcomes. The researchers 
found very few non-pharma funded trials, and an increase in reported efficacy for trials 
which took place whilst the drug was new and novel (Cipriani et al. 2018).  
 
The hyperbolic media coverage led to criticism from prominent figures in the field such 
as Moncrieff (2018). Moncrieff criticised the methods of the systematic review as it 
only looked at studies over an 8-week period, whereas in practice people take the 
drugs for longer. Furthermore, the studies included depression rating scales which 
inflate changes, such as the Hamilton Depression Rating Scale. Moreover, Moncrieff 
(2018) questions the usefulness of placebo-controlled trials in psychoactive drugs, 
because individuals can often tell if they are on the active drug as they may experience 
side-effects. Moncrieff raises a number of valid criticisms, which are particularly 
pertinent given the media hype surrounding the research. However, the research is 
useful insofar as it contributes to a broader evidence-base assessing the efficacy of 
antidepressants. The research does not tell us categorically that antidepressants work, 
but the paper does demonstrate that over the course of eight weeks some 
antidepressants have been found to improve people’s depression scores. As Becker 
(2007) notes, everything tells us something. Furthermore, whether warranted or not, 
the media coverage may go some way to improve the reputation of antidepressants. 
 
The efficacy of antidepressants could also be improved by individualising medicine. 
Earlier chapters highlighted how the corporatisation of depression treatments 
coincided with the homogenisation of treatments. This contrasts quite dramatically with 
the treatment of depression (or melancholia) in the pre-pharmaceutical/medical era of 
the late twentieth century. Pre-medicalised melancholia was characterised by Burton 
(1857) as so diverse that in some cases it could be caused, and in other cases be 
cured, by more sex. Reading and writing alone could cause melancholia in some 
scholars, yet Burton used the writing and editing of ‘On Melancholia’ to alleviate his 
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own symptoms. Throughout the two millennia history of melancholia, its treatment was 
very much dependent on the circumstance and disposition of the individual 
experiencing it. However, in the UK today an individual diagnosed with depression will 
almost certainly be offered an SSRI antidepressant.  The treatment of depression has 
thus become homogenised. In England last year, over 64.7 million antidepressant 
prescriptions were written, compared with under 9 million contraceptive prescriptions 
and under 14.5 million non-steroidal anti-inflammatory drugs (NSAIDs) such as 
ibuprofen (NHS Digital 2017).  Although, as aforesaid, SSRIs especially are often 
turned to as the first port of call in the treatment of depression, their efficacy is still 
questioned. Most studies conclude that the drugs, on the whole, are little better than 
placebos (e.g. Moncrieff and Kirsch 2015). The lack of efficacy of antidepressants has 
negatively impacted on the reputation of the whole drug class. In recent years, 
however, highly publicised-developments in drug tests and DNA testing present an 
opportunity to increase the efficacy of antidepressant prescriptions, by moving towards 
more individualised medicine. Jha et al. (2017) found that SSRI response can be 
predicted by using a blood test which measured inflammation in the brain. Whilst those 
with higher inflammation did not respond to SSRIs alone, they did respond better to 
the SSRI when it was used in combination with the anti-inflammatory drug, bupropion.  
 
Currently, only around half of patients will respond to the first antidepressant they are 
prescribed. If they do not respond to an antidepressant, they will then be prescribed a 
different type of antidepressant. If the second antidepressant is also ineffective, then 
a patient is considered to have ‘treatment resistant depression’ (Al-Harbi 2012), and 
will often be prescribed a third or fourth antidepressant or combination of 
antidepressants in the hope that this will lead to improvement. This can be a long 
process for some patients, because it takes weeks for antidepressants to take effect. 
Cattaneo et al. (2016) conducted research into the blood-brain barrier, which 
subsequently found that participants’ responses to specific antidepressants could be 
predicted by a blood DNA test. In the US, the company, Genomind, have already 





If the use of DNA tests to inform prescribing antidepressants becomes commonplace, 
it would undoubtedly have some impact on the market for treatments. It is possible 
that antidepressant prescriptions would increase, as patients will find that the drug 
they have been prescribed will be more effective, and, as such, they may be more 
likely to stay on the drug. However, there is also a possibility that this could have a 
negative impact on the market for antidepressants. Current research does not explore 
if, when a patient is prescribed a drug which will definitely have an effect, they are also 
more likely to experience the less desirable side-effects of the drugs. 
 
11.3 Social, Political, Cultural and Demographic Opportunities for Maintaining 
and Expanding Pharma Market 
Thus far in this chapter, the opportunities presented by developments in research and 
technology have been presented. The culturally iconic status of Prozac exemplifies 
the interconnectedness of the antidepressant market and wider society. This section 
examines how sociological changes may impact upon the market for antidepressants.  
11.3.1 The evolving diagnosis of depression 
Depression has been subject to multiple evolving definitions since the late 19th century 
(Lawlor 2012). Lawlor (2012) notes that a new, biomedical understanding of 
depression began to emerge in the 1980s, with researchers believing that depression 
may be caused by a chemical imbalance in the brain, a model which Lawlor suggests 
was influenced by the discovery of SSRIs. Similar to how Freud argued melancholia 
was caused by repressed thoughts, coincidentally the same thing his therapy sought 
to uncover, the pharmaceutical industry created and promoted a causation of 
depression which mirrored the treatment they were selling. The idea that depression 
is caused by a chemical imbalance in the brain is compelling, and entirely within the 
realm of possibility. However, it has never been proven. Furthermore, the correct 
‘balance’ of chemicals in the brain has never been established either, in part, due to 
the impossibility of measuring the chemicals in a living person’s brain. Therefore, 
healthcare professionals looking to diagnose this so-called chemical imbalance would 
have to rely on other methods. 
 
Diagnosing depression is complex, and healthcare professional informants reported 
relying on intuition and personal experience, in addition to the two, more formal 
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diagnostic criteria for depression: The Diagnostic and Statistical Manual of Mental 
Disorders (DSM) and the International Classification of Diseases (ICD). The DSM is a 
US publication from the American Psychiatric Association (APA). The ICD is published 
by the WHO. Each provides criteria on the diagnosis of depression and is updated 
every few years to reflect changes. 
 
Changes in diagnosis are common. The mission of the DSM has been to “expand the 
scientific basis for psychiatric diagnosis and classification” (Kupfer and Regier 2008). 
However, as succinctly argued by Esposito and Perez (2014), ‘the classification of 
mental disorders is a process that, far from purely scientific, is shaped by political 
and/or profit-driven objectives associated with the increased corporatization of 
medicine, including the mental health field.’ The inclusion of homosexuality as a 
mental illness in early editions of the DSM and its subsequent removal in the third 
edition, is the most commonly cited evidence that mental health diagnoses do not exist 
in a sterile petri dish. Rather, they are shaped and influenced, as I explore in this 
chapter, by social, political and economic factors. 
 
In the second edition of the DSM, which was released in 1968, there are four 
conditions listed in which fragments of what we now call depression can be found: 
‘Involutional Melancholia’; ‘Depressive Neurosis’; ‘Manic-depressive illness depressed 
type’; and ‘Psychotic Depressive Reaction’ (APA 1968). Each of these diagnoses 
refers to depression as a symptom but does not make any attempt to define the term. 
The DSM-II thus exemplifies a transition period, located after the introduction of 
depression but before the abandonment of melancholia. 
 
The formal diagnosis of depression in the 1990s was published in a revised third 
edition of the DSM (DSM-III-R) in 1987 (APA 1987).  In the DSM-III-R, as with the 
original third edition DSM-III, depressive disorders were collapsed into one category 
titled major depressive disorder (APA 1987; Healy 2004, p. 8). DSM-III-R listed several 
possible symptoms for depression, including depressed mood, fatigue, feelings of 
worthlessness and recurrent thoughts of death, which could be used as an aid to 




The most recent version of the DSM is the DSM-V. In the DSM-V, depressive disorders 
get their own chapter, having previously shared a chapter with bipolar and related 
disorders. The chapter describes multiple depressive disorders, but notes: 
The common feature of all of these disorders is the presence of sad, 
empty, or irritable mood, accompanied by somatic and cognitive 
changes that significantly affect the individual’s capacity to function. 
What differs among them are issues of duration, timing, or presumed 
etiology (APA 2013, p. 155).  
The DSM-V criteria for major depressive disorder is unchanged from DSM-IV. 
However, there is one major amendment in the notes beneath the criteria. Earlier 
versions included a caveat which specified that the criteria were not applicable to 
someone experiencing the early stages of grief, for whom depressive symptoms may 
be a normal part of the grieving process. The omission of this caveat was controversial. 
Critics argued that it was an example of ‘over-medicalisation’ and a result of the APA 
being too cosy with pharmaceutical companies (Cosgrove and Krimsky 2012). In the 
text, the authors directly refer to antidepressant treatment: 
Bereavement may induce great suffering, but it does not typically 
induce an episode of major depressive disorder. When they do occur 
together, the depressive symptoms and functional impairment tend to 
be more severe and the prognosis is worse compared with 
bereavement that is not accompanied by major depressive disorder. 
Bereavement-related depression tends to occur in persons with other 
vulnerabilities to depressive disorders, and recovery may be facilitated 
by antidepressant treatment. (APA 2013, p. 155) 
 
To aid medical professionals in differentiating grief from depression, the DSM-V 
contains the following footnote: 
In distinguishing grief from a major depressive episode (MDE), it is 
useful to consider that in grief the predominant affect is feelings of 
emptiness and loss, while in MDE it is persistent depressed mood and 
the inability to anticipate happiness or pleasure. The dysphoria in grief 
is likely to decrease in intensity over days to weeks and occurs in 
waves, the so-called pangs of grief. These waves tend to be associated 
with thoughts or reminders of the deceased. The depressed mood of 
MDE is more persistent and not tied to specific thoughts or 
preoccupations. The pain of grief may be accompanied by positive 
emotions and humor that are uncharacteristic of the pervasive 
unhappiness and misery characteristic of MDE. The thought content 
associated with grief generally features a preoccupation with thoughts 
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and memories of the deceased, rather than the self-critical or 
pessimistic ruminations seen in MDE. In grief, self-esteem is generally 
preserved, whereas in MDE feelings of worthlessness and self-loathing 
are common. If selfderogatory (sic) ideation is present in grief, it 
typically involves perceived failings vis-à-vis the deceased (e.g., not 
visiting frequently enough, not telling the deceased how much he or 
she was loved). If a bereaved individual thinks about death and dying, 
such thoughts are generally focused on the deceased and possibly 
about “joining” the deceased, whereas in MDE such thoughts are 
focused on ending one’s own life because of feeling worthless, 
undeserving of life, or unable to cope with the pain of depression. (APA 
2013, p. 161) 
 
The idea that grief is experienced differently by different people is well-established. 
Following on from this, the concept that a small number of people experiencing grief 
may be affected in such a way that they meet the criteria for a major depressive 
episode is not absurd. However, whether such individuals require a diagnosis of 
depression remains questionable. 
 
During the development of the DSM-V, articles were published advocating for the 
inclusion of a diagnosis for Prolonged Grief Disorder (PGD) (Prigerson et al. 2009) 
and Complicated Grief (CG) (Lichtenthal et al. 2004). Part of Lichtenthal et al.’s (2004) 
argument for the inclusion of CG is that healthcare professionals are diagnosing 
grieving people with depressive disorders and post-traumatic stress disorder (PTSD), 
although, as the authors explain, literature on grieving characterises it as different to 
both these. Lichtenthal et al. (2004) argue that CG can lead to poor health outcomes 
and suicide in some people, which warrants further research. They argue that to 
conduct research into this area, formal diagnostic criteria must first be established. I 
was unable to find pharmaceutical industry connections for any of these authors, and 
they do seem to advocate for further research into talking treatments for CG, rather 
than purely pharmacological ones. 
 
Prigerson et al.’s (2009) paper on PGD paints a similar picture. PGD should be 
differentiated from other conditions and have its symptoms specified. Furthermore, the 
authors use empirical evidence to demonstrate early predictors of PGD, suggesting 
the use of psychotherapy soon after death to aid in a normal grieving process. Of the 
paper’s nineteen authors, only the eighteenth author listed, Michael B. First has 
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pharmaceutical industry ties. In the five years prior to the publication of the paper, First 
had done paid consultancy work for eight pharmaceutical companies.  
 
These papers are indicative of a push to separate abnormal responses to grief from 
existing diagnoses. They also abstain from advocating the pharmacological treatment 
of grief, instead suggesting prevention and treatment may be aided by talking 
treatments. These papers are the most cited, most engaged with papers on the DSM-
V and grief. The APA prides itself on using empirical evidence to support its DSM 
editorial decisions, which begs the question: why did the APA respond by providing 
guidance on how to diagnose depression in grieving people, and why does the DSM 
explicitly refer to antidepressant treatments in these cases? 
 
When a new version of the DSM is being created, a panel is formed by the APA to 
assess the evidence and decide what changes, if any, should be made to diagnoses. 
Of the panel formed to assess the Mood Disorders chapter, 67% had ties to 
pharmaceutical companies who manufacture treatments for mood disorders or 
companies that service the pharmaceutical industry (Cosgrove and Krimsky 2012). 
Cosgrove and Krimsky (2012) obtained information on the interests of panel members 
via the APA’s disclosure policy. However, the policy does not require panel members 
to disclose ‘unrestricted research grants,’ meaning that the actual percentage of panel 
members with industry ties could be even higher. Furthermore, there is no evidence 
that a large, unrestricted research budget from a pharmaceutical company protects 
individuals from bias. Conversely, research published on the outcomes of such 
research suggests that it makes authors more likely to publish positive results (Lundh 
et al. 2015). 
 
It is therefore entirely possible that the exclusion of a grief caveat in the DSM-V, rather 
than constituting a separate diagnosis or an abstention from wholly medicalising grief, 
is a result of a biased panel. That is to say, the decision reflected the interests of the 
pharmaceutical industry, particularly in its specific reference to antidepressant 
treatments. This discussion about the contemporary diagnosis of depression serves 
to reinforce Esposito and Perez’s (2014) point that the classification of mental 
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disorders is shaped by political and/or profit-driven objectives associated with the 
increased corporatisation of medicine, including the mental health field. 
 
11.3.2 Privatisation and neoliberalism 
Although it is often considered the ‘jewel in the crown’ of the UK, the future of the NHS 
is by no means certain. Previous chapters have highlighted a pattern of covert 
privatisation. NHS budget cuts create space for pharmaceutical industry involvement 
in areas such as disease awareness and continuing medical education. There are 
however, also indicators that privatisation is occurring via overt, formal pathways. This 
section firstly presents the evidence that points to increased privatisation in the UK, 
before proceeding to explain why a private healthcare system represents opportunities 
for antidepressant manufacturers. 
 
Pollock and Roderick (2015) point to the Health and Social Care Act (HSCA) 2012 as 
marking the end of the NHS in England. For decades, Pollock has published papers 
exploring the rationale for policies which invite privatisation, such as the Private 
Finance Initiative (PFI) in 1992. The PFI allowed old outdated hospital buildings to be 
refurbished with private investment, however it has since resulted in increased NHS 
spending. The HSCA 2012 was a controversial government act established on 1st 
April 2013, with the intention of reforming the NHS. The HSCA introduced new powers 
with the express intent of facilitating the introduction of future policies geared towards 
‘Making the NHS more efficient and less bureaucratic’ (Department of Health 2013b) 
and ‘Helping people make informed choices about health and social care’ (Department 
of Health 2013a). This focus on efficiency and choice contributed to the perception 
that the act was a veiled attempt to begin privatising the NHS. Prior to its enactment, 
the HSCA was criticised heavily by academics who drew upon empirical evidence to 
argue that the act should be dismissed (e.g. Greener and Mannion 2006). However, 
the evidence presented was ignored, resulting in claims that the act was, in fact, a 
vehicle through which to covertly move Britain towards a neoliberal political model 
(Pownall 2013). The impact of growing neoliberalism will be discussed further later in 




One of the principal points of contention with the HSCA was the reintroduction of 
general practitioner fundholding. General practitioner fundholding refers to the 
phenomenon whereby ‘general practitioners are given budgets from which they 
purchase services for patients’ (Petchey 1995, p. 1139). Popularised in the early 
1990s, the primary aim of GP fundholding is to increase the efficiency of care by 
making GP’s accountable for how funds are spent. However, the Cochrane 
Collaboration’s systematic review of the effects of general practitioner fundholding in 
the UK found no evidence to suggest that there was a significant relationship between 
fundholding and reduced drug spending (Sturm et al. 2007). Rather, as Pollock (2015) 
notes, the act has resulted in a fragmented, inefficient system, with an increasing 
dependence on private funds.  
 
In addition to explicit policies which have contributed to the increased privatisation of 
the NHS, previous chapters have outlined how privatisation can occur via other 
means. Most notably, cuts to training budgets create space for pharmaceutical 
companies to move in. While politicians are drawn to issues that curry favour with 
voters, such as waiting lists, training budgets are being cut which leaves space for 
pharma-funded education: 
If you work in the NHS, we get no funding for training at all. Zero … so, 
the drug reps will sponsor these speakers to come and speak and talk 
to us and do training, so I know some drug reps through that anyway 
and I know that some of them have a stand at the conference as well, 
so they're quite happy to support people to attend the conference, to 
support training and development of staff … It's about training and if I 
wasn’t to receive this support from the pharmaceutical industry then I 
would struggle with a lot of my own CPD, and it's not just about the 
training, it's about peer-support, about learning good practice from 
other people. There's so much more you can get from getting to these 
meetings, so if it wasn’t for the pharma industry I probably wouldn’t 
have attended the majority of them. So, you know it's thanks to them 
that I have. And I don't think that by attending I have been persuaded 
to use their drugs more than others or anything (Fieldwork Interview, 
Pharmacist 8). 
Through cutting training budgets, some healthcare professionals feel forced to obtain 
their education from private sources, mainly pharmaceutical companies. In a similar 
way, we see creeping privatisation across various areas of the NHS. The HSCA of 
2012 opened the doors for increased privatisation via policies such as GP fundholding 
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(Pownall 2013). Although the increasing privatisation of the NHS has been met with 
widespread criticism, a private healthcare system in the UK could be beneficial for 
antidepressant manufacturers. In the UK, one of the closest analogies we have for a 
private healthcare system is car mechanics. This is a private industry characterised by 
information asymmetry. The term information asymmetry is used by economists to 
describe a market where there is a large gap in knowledge and expertise between the 
customer and the seller. Taking your car to the garage can be a stressful experience, 
partly because a power imbalance exists in the form of information asymmetry 
between myself and the mechanic. The mechanic has expertise; however, they also 
have a financial interest in selling more products. As a white woman, the privilege I 
experience when going through airport security is turned on its head at the garage. I 
was recently quoted £300 for a repair which would require ordering parts in one colour 
and painting them white. When my father took the same car to a garage he was 
charged £80 and the parts could be ordered in white. The information imbalance 
between myself and the mechanic was perceived to be large, thus creating an 
opportunity for the mechanic to try to sell me services I did not need.  
 
Information asymmetry favours sellers, as it allows them to overcharge and sell 
redundant products and services (Vining and Weimer 1988). As Vining and Weimer 
(1988) note, this reduces economic efficiency, which is why it is considered one of the 
four traditional forms of market failure. Market failures are usually pointed to as areas 
which warrant public interventions; for example, the ‘invisible hand,’ if left to its own 
devices, would never build a lighthouse. The market failure generated by information 
asymmetry is evident in the US healthcare system, which is the most expensive in the 
world and yet yields the poorest outcomes of any high-income country (Schneider and 
Squires 2017). 
 
Consequently, more medicine does not always mean better outcomes; sometimes it 
means poorer outcomes (Glasziou et al. 2013). However, a private healthcare system 
driven by the profit motive always errs on the side of more medicine. This is evident in 
the US healthcare system. Expensive tests will be ordered ‘just in case’, benign lumps 
will be removed without question, and medicines are prescribed far more freely than 
in nationalised systems. The ‘too much medicine’ problem is epitomised by a 
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retrospective analysis conducted by Jena et al. (2015), who found that mortality rates 
improved among patients hospitalised with heart conditions during national cardiology 
meetings, because heart surgeons were out of town that weekend and unable to 
perform emergency operations. Rather than take place on Monday when the surgeon 
returned, it was found that these operations did not actually need to take place, which 
led to improved health outcomes. 
 
Antidepressants are already prescribed in the UK at a high-rate, however the price 
sensitivity of the NHS means that almost all of these prescriptions are for cheap 
generic drugs. However, private healthcare system features, such as information 
asymmetry and ‘more medicine’, create an opportunity for sales of branded, more 
expensive drugs. This idea is supported by a psychiatrist informant, who noted that 
agomelatine, whilst unsuccessful at reaching NHS patients, is very popular amongst 
UK private practitioners: 
It’s the favourite antidepressant in all of private practice … Almost every 
local primary care organisation, the CCGs, they have not approved it 
for GP use … So, it's just never happened but where people are paying 
for it themselves, and it costs just under 30 pounds a month and the 
25mg dose people are prepared to pay for it. The little bit of private 
work I do, it's the favourite drug and it's, you know, going through the 
pros and cons of all the medication it's the one that most patients would 
choose because of the side-effect profile, and it's more powerful than 
the standard SSRIs … in the private sector its very popular (Fieldwork 
Interview, Psychiatrist 6). 
 
Privatisation has the potential to increase access to patented antidepressants, 
therefore providing an opportunity for antidepressant manufacturers. Further to this, 
privatisation is a neoliberal tool, in the sense that it is both indicative of, and contributes 
to, what McGregor (2001) refers to as a neoliberal mindset. Such a mindset favours 
individualism and competition, which, in turn, creates further potential opportunities for 
the antidepressant market.  
 
Esposito and Perez (2014) also discuss the sociological implications of neoliberalism 
and their impact on mental health. In a neoliberal society, happiness is associated with 
success and prestige. A neoliberal society therefore problematises depression and, 
due to the individualism that characterises such societies, locates problems within the 
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individual. Depressed people are thus pathologised as ‘self-contained agents’ 
(Esposito and Perez 2014). The impact from social problems which the market fails to 
address, such as loneliness in the elderly, the isolation of disabled people, and the 
stress associated with job intensification, are ignored. The UK is already a capitalist 
society, and, as such, these aforesaid issues are already familiar. However, as a 
neoliberal tool, the privatisation of healthcare has the potential to intensify the 
‘obsession with medicalization’ (Esposito and Perez 2014:414).  A GP informant 
described an increasing trend for individuals wanting to be medicalised: 
I think there is a shift, in I think people do tend to be more wanting to 
explain behaviour through medicalisation. I think there seems to be this 
consumerist approach to healthcare where any sort of emotional 
instability, not always sort of, I think sometimes when you say this it 
sounds unfair, but I think people interpret melancholy or just being 
slightly sad, which, you know all humans have fluctuations in mood, but 
people often medicalise that and explain it as depression which is, 
obviously, is a diagnosis and perhaps when they sort of enter the sick 
role and they have some validation for that symptom. When, in fact, 
actually it’s probably low-grade sort of, you know, fluctuations in mood. 
So, I think lots of factors are cultural and societal (Fieldwork Interview, 
GP 1). 
 
11.3.3 Social Media and the Digital Pharmaceuticalisation of Depression 
One of the core arguments of this thesis, is that whist concepts such as medicalisation, 
pharmaceuticalisation and disease mongering prove incredibly useful when analysing 
the marketing of antidepressants before the mid-2000s, more recent behaviour is 
better understood as covert privatisation. Covert privatisation explains why 
pharmaceutical companies continue to fund disease awareness campaigns and 
continuing medical education. This privatisation allows pharmaceutical companies to 
promote their products without engaging in overt, unethical techniques such as flying 
doctors to Australian islands. However, disease mongering has not been eradicated 
completely. Rather, as with many socially undesirable activities, it has moved online.  
 
In the UK, it is illegal to advertise prescription medications directly to the public. 
However, the global nature of the internet is blurring these boundaries. Via the internet, 
UK patients have access to information from other countries, including foreign adverts 
for medications. Furthermore, companies have social media accounts where they 
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frequently post information about the disease areas they work in. For example, as 
Lundbeck are the only company currently actively marketing an antidepressant, they 
have several YouTube videos on depression. Earlier this year for World Health day, 
they posted a video titled ‘What is depression?’ The video comprised senior Lundbeck 
employee, Thomas Brevig, explaining what depression is (H. Lundbeck 2017). He 
notes that depression is very common, affecting around 350 million people globally. 
Brevig proceeds to say ‘It’s a brain disorder, so there’s chemical imbalance in certain 
areas, certain systems in the brain, and they can express themselves in different ways. 
So, there’s emotional, cognitive, and physical symptoms.’ As he says this speech, 
bubbles pop-up next to him saying ‘cognitive symptoms, emotional symptoms and 
physical symptoms’. The unique feature of Lundbeck’s newest drug is that it aims to 
treat symptoms of cognitive dysfunction in depression. Most interestingly, however, is 
the video’s framing of depression as a chemical imbalance, as the chemical imbalance 
theory of depression still has yet to be supported by evidence. Lundbeck’s video 
demonstrates that companies can use their social media presences for disease 
awareness activities and to prioritise information which is favourable to their marketing 
objectives. At no point in these videos does the company promote their medications; 
however, they do emphasise the cognitive dysfunction symptom and the disease 
burden of depression. 
 
Moreover, patients are increasingly using forums and social media to discuss their 
medications. With all psychoactive medications, there is a longstanding issue of 
adherence. Patients may experience side-effects and stop taking their medication, or 
simply not feel that the medication is making a difference. In terms of traditional 
marketing theory, this could be conceptualised as cognitive dissonance. As well as 
promoting the initial purchase and use of a product, marketing and advertising can be 
used to reduce cognitive dissonance. This is most common in the new car market, 
where adverts serve more to settle the worries of people who have already made the 
substantial purchase of the car, rather than speaking to individuals looking to buy a 
car. Similarly, the internet provides an opportunity for companies to spread positive 
information about their product globally. Individuals experiencing side-effects may 
search on Google for information on their drug. Patients may then be reassured that 
the side-effect may not last, or that the drug will become more efficacious over time 
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and thus choose to continue taking the drug, whereas in the past the cognitive 
dissonance could have caused the patient to cease treatment. 
 
Social media is also reducing the stigma associated with mental illnesses. Tumblr is a 
microblogging platform where users share media such as videos, blog entries and 
pictures to their followers. Perhaps most famously, Tumblr was responsible for 
#TheDress, a viral post which asked users whether a dress was blue and black or 
white and gold. The post ultimately brought attention to the scientific theory of colour 
constancy, where the brain takes cues from the surrounding context of an object to 
decide its colour. However, above all, it demonstrated the power of Tumblr, and how 
posts on the site can spill over onto more popular social media sites.  
 
There is a large community of mental health advocates on Tumblr, many of whom 
have mental illnesses themselves. The community is so prominent, and so active in 
its work, that Tumblr has been accused of glamorising mental illness (Bond 2012). 
Some users list their diagnoses (sometimes self-diagnoses) on their page, an activity 
perceived by some as stigma reducing, whilst others see it as romanticising mental 
illness. 
 
At the most extreme end of the spectrum, the site has been used by individuals to 
explicitly promote mental illnesses, most notoriously, tags which provide advice and 
motivation to encourage individuals with eating disorders to be as unwell as possible. 
Such pro-eating disorder content has been accessible on the internet since the 1990s. 
However, as Tumblr caters towards subcultures which are easily accessible via tags, 
the platform has become a key host of such content. Whilst Tumblr has tried to censor 
such content, the platform has still been used to share images of self-injury (Lewis and 
Seko 2016). 
 
Mental illness and identity have been discussed and explored by sociologists for 
decades, particularly in relation to stigma (Goffman 2009). However, mental health 
diagnoses can also be a profound source of comfort and pride for some individuals 
(Yanos et al. 2010). This has been identified in academic literature, however it is 
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Don't tell me "No, sis- 
Ter, you don't fit in." 
Doc, prescribe me my tribe, give me my throng 
Tell me that this whole time I've belonged 
With those other people who share my diagnosis… 
...I'm aware mental illness is stigmatised 
But the stigma is worth it if I've realised 
Who I'm meant to be, armed with my diagnosis (Bloom 2017). 
 
As Tumblr users list their diagnoses on their profile and tag their posts with condition 
names, such as #depression, they are easily identifiable to anyone who wants to 
search based on that criteria. For this reason, trade blog pharmaexec.com noted that 
‘What you will find when you take a closer look at Tumblr is a lot of potential patients’ 
(2013). 
 
In 2013, the pharmaceutical company, Janssen Therapeutics, created the Tumblr 
page ‘Positively Together’ to engage with the Tumblr community living with HIV. The 
page invited users to upload stories of their experiences with HIV, ticking a box to 
confirm whether they were over 18 and lived in the US. Although contributions were 
only invited from US adults, due to the global nature of Tumblr the page was visible to 
users across the world. In short, the increasing propensity of people to use Tumblr to 




The ‘fall of Big Pharma’ (Malerba and Orsenigo 2015) is not inevitable. Although 
changes in the market have increased competition for antidepressant manufacturers, 
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and reduced the profitability of the treatment area, there remains considerable 
opportunities for the future. Medical and technological developments, allied with 
societal changes, means that the antidepressant market may morph and grow in the 
future. Whilst these opportunities are indicative of factors which could improve the 
profitability of antidepressant manufacturers, they do not necessarily translate as 
opportunities for broader society. Privatisation is the principal example of a process 
which provides exciting opportunity for companies, whilst the evidence-base suggests 

























12.1 Introduction and Synopsis of Thesis 
Through exploring existing literature on antidepressant marketing, I identified that new 
research was necessary. There was a paucity of input from business management, 
despite the field being defined by large organisations. Once I made the decision to 
dedicate my thesis to addressing this need, numerous decisions about the 
methodological approach had to be undertaken. The methods chapter documents this 
decision-making process, and the choices that were ultimately made. Examination of 
methodological literature led me to decide upon a novel, investigative approach that 
draws on the work of investigative journalist, Mark Lee Hunter (2011), in addition to 
traditional academic scholars such as Derek Layder (1993), Michael Billig (2013) and 
Howard Becker (2007). 
 
The structure of the findings chapters have been heavily inspired by Derek Layder’s 
(1993) approach to structuration. He argues that history is a method in its own right, 
and, as such, that history and context should permeate every aspect of the research 
process. In the spirit of investigative social science, the structure has also been 
influenced by investigative journalism, particularly the narrative focus of Story-Based 
Inquiry (Hunter 2011). Drawing on each of these approaches, the first two findings 
chapters focused on the intertwining historical narratives of depression and its 
treatments. Analysing these highlighted a pattern that depression has been 
consistently defined by those with proposed treatments. The conclusion of this section 
took us up to the point where depression was being predominantly defined by 
pharmaceutical companies. The next section picked up and ran with this narrative, in 
a historically sensitive Layder-esque fashion, by examining the industry which 
manufactures pharmacological treatments for depression. Once the history of the 
industry had been established, Chapter 7 honed in on the front-line of pharma 
marketing efforts: PSRs. The concept of ‘Dirty Work’ was used to understand the 
omission of ‘pharmaceutical’ and ‘sales’ from PSRs’ job titles. Later in the chapter, I 
examined the extent to which PSRs manipulate prescribers to increase antidepressant 
sales. Ultimately, I concluded that, whilst reps are no-longer allowed to use gifts and 
excessive hospitality to influence healthcare professionals, they continue to engage in 
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personality typing to ‘better communicate’ with healthcare professionals. Techniques 
which have been publicly criticised have thus changed and improved with increased 
regulation, however, as explained by Abraham’s (2008) ‘neo-liberal corporate bias’, 
regulation is predominantly self-serving and reactive. Consequently, activities invisible 
to the public, such as personality typing, targets and bonuses, remain unregulated. 
 
The following section looked outside of the industry, to its customers and collaborators. 
Chapter 8 focused on healthcare professionals. Healthcare professionals occupy 
multiple rolls in the antidepressant supply-chain. They are the gatekeepers, standing 
with prescription pads between antidepressant manufacturers and patients, and, on a 
larger level, writing formularies and prescribing guidelines. In their role as 
gatekeepers, they are also the lucrative targets of antidepressant marketing. However, 
they also interact with the industry as collaborators, advisers and students. Through 
drawing upon interviews with 28 healthcare professionals, the chapter explored the 
complex and changing relationship between healthcare professionals and the 
pharmaceutical industry. I looked back at the iconic BMJ cover which depicted 
healthcare professionals as greedy pigs eating at the Big Pharma trough and 
questioned to what extent this is still the case. Informants recounted being flown to 
exotic islands by companies during Prozac’s blockbuster heyday, whereas more 
recent interactions were less lavish. Rather than being motivated by greed, the main 
driver of interaction with pharmaceutical companies was knowledge. In the same way 
that healthcare professionals are gatekeepers of prescriptions, through NHS budget 
cuts pharmaceutical companies have become the gatekeepers of knowledge. Some 
informants described how they felt stuck in a catch-22 situation, in which they must 
choose between receiving biased information or no information at all.  
 
As was found in the previous chapter, regulation has improved the ethical status of 
interactions between healthcare professionals and the pharmaceutical industry. 
However, regulation has failed to ‘untangle’ this relationship in the exact way called 
for in the BMJ special issue, as fully untangling would require removing the conflict of 
interest posed by industry-funded information. Instead, healthcare professionals’ 
continuing medical education, information resources, and clinical trials would all need 




Chapter 9 looked at the oft-overlooked organisations who work to increase awareness 
of depression. The first depression awareness campaign in the UK was the DDC 
launched in 1992. The campaign is often referred to in critical literature as a turning 
point for depression and its treatment (Healy 2004; Moncrieff et al. 2005). Funded by 
the manufacturers of Prozac and Seroxat, the campaign was criticised for being 
biased. Most notably, Eli Lilly funded a survey which found that 74 percent of the 
population believed antidepressants were addictive. The assertion that 
antidepressants were not addictive then subsequently became a key message of the 
campaign. Examination of archival material found that the organisers of the campaign 
were routinely questioned about the basis for this core message and asked for 
evidence and clarification. However, the message remained unchanged, and years 
later it became clear that antidepressants, particularly Seroxat, could cause 
dependence in some people.  
 
Later campaigns were dominated by the charity DA, who ran depression awareness 
week. When depression awareness week occurred around the time of a new 
antidepressant looking to gain marketing approval, the week would centre around a 
report. In 2005, the report emphasised the role of aches and pains in depression. It 
was funded by Eli Lilly, the manufacturers of Cymbalta, an antidepressant which was 
recently approved to treat neuropathic pain. Similarly, the reports used in 2006 and 
2007 depression awareness weeks were funded by Lilly and emphasised pain. In 
2008, a report called ‘The Inside Story’ was released by DA and funded by Servier. 
Servier manufacture the antidepressant, Valdoxan, which is similar in structure to 
melatonin and regulates sleep. The report that year, and the media coverage 
surrounding it, emphasised the role of sleep in depression. Campaigns up to this point 
thus reinforced the narrative identified earlier in the thesis, that depression is defined 
by those who are promoting a treatment. More specifically, however, these campaigns 
can be characterised as pharmaceuticalisation and disease mongering, as they 
promoted and broadened the symptoms of depression, influenced by pharmaceutical 
funding.  
The most recent depression awareness weeks in 2015 and 2016 were also funded by 
pharmaceutical companies. These centered on a report funded by Lundbeck called 
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WIP. Lundbeck’s newest antidepressant is called Brintellex, and its key point of 
differentiation from other antidepressants is that it also treats cognitive dysfunction. 
Again, as with previous chapters, we see an improvement in the ethical status of 
industry activities, as The WIP report does not over-emphasise the symptom which 
Brintellex uniquely treats. Disease mongering has been criticised in pharma-funded 
disease awareness campaigns (Seroxat Secrets 2005; Moynihan and Henry 2006; 
Seroxat Secrets 2008), which is harmful to the reputation of pharmaceutical 
companies as it makes them less profitable.  
 
Pharmaceutical companies are private entities which are required to make a profit. 
The chapter concluded by utilising Loseke’s (1997) idea of political and rhetorical 
power to demonstrate that, particularly in the wake of scandals, pharmaceutical 
companies seek to improve their reputation through associating themselves with 
charities. Furthermore, the political power of charities has the potential to positively 
influence decision-making at an altogether higher level than disease mongering 
campaigns – the realm of politics. 
 
The final section acts as a bookend to the first. This thesis began by looking towards 
the past, and ended with examining contemporary issues in the antidepressant 
market. This thesis has demonstrated that, whilst depression has historically been 
framed by those offering a treatment, throughout history the era defining treatment 
eventually subsides and is replaced. It is therefore entirely possible that 
antidepressants will be replaced as the treatment du jour. Chapter 10 highlighted the 
threats to antidepressants dominant position within the depression market. The two 
major points that emerged centred on the fact that, firstly, the safety and efficacy of 
antidepressants is constantly under question, and, secondly, that other treatment 
options are being developed and increasing in popularity. Chapter 11 examined 
contrary evidence, such as newer studies that suggest that antidepressants are 
effective and the possibility that efficacy will increase as medicine becomes more 
individualised. Finally, the sociological landscape and the ways in which it could 
benefit antidepressant manufacturers were discussed. Ultimately, the conclusion is 




12.2 Evaluating the Contributions of this research 
This thesis offers a range of unique contributions to extant literature. Firstly, this study 
represents the first research into antidepressant marketing from within a school of 
management.  The literature review demonstrated the need for business researchers 
to engage with this topic, and this thesis goes some way to addressing this gap. This 
research has also demonstrated the applicability of investigative social science for 
business research. The business world is dominated by large powerful organisations 
who are either likely to deny access or use their power to place stipulations when 
access is allowed. Therefore, when applied to business and management research, 
an investigative social science approach allows for the investigation of topics and 
issues which might otherwise have been avoided due to access issues. Dunne et al. 
(2008) found that business management consistently failed to engage with important 
sociological issues. Utilising an investigative methodology allows researchers to better 
engage with issues of social significance and serve the community as public 
intellectuals (Marinetto 2015). Adding investigative social science to the menu of 
methodological options available to business management researchers, thus allows 
scholars within the field to better address social problems. This research has 
demonstrated that combining aspects of traditional social science and investigative 
journalism can be successful in examining issues of broad social significance, such as 
corruption and mental health. The richness of data which was obtained via semi-
structured interviews – the bread and butter of many qualitative researchers - was 
complimented by an ‘open source strategy’ (Hunter 2011, p. 31) lifted from 
investigative journalism. 
 
In addition to its methodological contribution, this thesis also contributes to the 
empirical landscape of the field. It is the first qualitative investigation into the 
Disclosure UK database and the first academic investigation into DA. Resultantly, this 
research has produced findings which are novel to the field of pharmaceutical industry 
study. I have been able to demonstrate that the ethical status of antidepressant 
marketing has improved in several areas, including depression awareness campaigns, 
hospitality and gift giving. However, I have also drawn upon Abraham’s (2009) notion 
of neo-liberal corporate bias to explain how, whilst activities have improved, such 
improvement is distorted by the requirement to make a profit. Furthermore, through 
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engaging with history in a meaningful way, this research has identified a trend of 
depression being consistently framed by those who are promoting a treatment. This 
narrative has been reinforced by data gathered throughout this investigation, and, as 
such, provides a framework through which to explore future innovations in this 
treatment area. Furthermore, this research has contributed to Conrad’s (2005) 
argument that medicalisation is driven by pharmaceutical companies, through its 
examination of the business practices contributing to the medicalisation of depression. 
 
12.3 Limitations and Recommendations for Further research 
The release of the 2015 Disclosure UK database was a key turning point in this 
research. It enabled me to contact several healthcare professional informants who 
were in direct contact with antidepressant manufacturers. Since finished data 
collection, and began writing up this thesis, the data for 2016 and 2017 have been 
released. The BMJ have done an excellent job of analysing the data quantitatively in 
each instance, however this research has demonstrated that a deeper qualitative 
investigation that goes beyond the figures can be useful. In-depth interviews with 
informants from the database uncovered alternative motivations for collaboration with 
pharmaceutical companies that went beyond the infamous ‘greedy pig’ image. More 
qualitative studies into the Disclosure UK database would thus allow for further 
exploration of the motives and experiences of healthcare professionals who chose to 
engage with industry. Further research into this phenomenon could influence policy 
guidelines impacting upon such relationships, in addition to helping policy makers to 
address the negative factors pushing collaboration, such as the reduction of training 
budgets in recent years. 
  
12.4  Concluding thoughts 
This thesis represents the first research into antidepressant marketing from a business 
management perspective. Incorporating business knowledge and ideas with socio-
medical phenomena, such as pharmaceuticalisation and medicalisation, has allowed 
this thesis to contribute to two distinct bodies of literature: business management and 
socio-medical. Conrad (2005) noted that medicalisation is now driven predominantly 
by pharmaceutical companies. Abraham (2010) coined the term pharmaceuticalisation 
to describe medicalisation driven by pharmaceutical companies. This thesis has 
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contributed to these ideas by exploring the business management activities through 
which companies drive medicalisation/pharmaceuticalisation. Overall, the research 
has found that, although regulation has improved, and less overtly unethical marketing 
practices are now used to promote antidepressants, pharmaceutical companies are 
still able to covertly influence the diagnosis and treatment of depression. For example, 
companies can still fund continuing medical education, industry employees still 
determine diagnostic criteria and fund disease awareness. It is tempting to place the 
blame for pharmaceuticalisation entirely at the feet of the pharmaceutical companies 
themselves. However, as demonstrated throughout this thesis, these activities are 
consistently enabled by government. An underfunded NHS creates a vacuum which 
will be filled by those who profit from doing so: pharmaceutical companies.  
 
Pharmaceutical companies are companies. We want them to behave morally because 
they have our lives in their hands. Perhaps we should see them in the same way that 
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Appendix A: Table of Informants 
Name Notes 
Charity Worker 1 Surprisingly, I found workers for charity organisations 
most difficult to arrange interviews with. After some 
failed attempts to contact this informant via charity 
email addresses and phone numbers, I was able to 
contact them through a company I discovered they 
owned on Companies House. It was a medical PR 
company servicing the pharmaceutical industry. This 
was the last interview conducted for the thesis. 
Industry Commentator 1 All three industry commentators were contacted via 
their blogs and social media presences. 
Commentator 1 was difficult to contact as they work 
hard to keep their identity anonymous, however I was 
ultimately able to get contact information for them via 
commentator 2. 
Industry Commentator 2 
Industry Commentator 3 
Medical PR Professional 1  
Medical PR Professional 2  
Medical PR Professional 3  
Medical PR Professional 4  
Medical PR Professional 5  
PSR 1 Expecting them to be the most difficult to contact, I 
began contacting PSRs first. However, as they 
manage their own schedules they were the easiest 
group to arrange interviews with. PSRs 1 – 4 all 




PSR 5 Both this PSR and PSR 7 began their careers in 
nursing. Their path to becoming PSRs involved a 
hybrid role. As nurses, they applied for ‘nurse 
advisor’ positions which were sponsored by 
pharmaceutical companies. Progression in these 
roles led towards more typical PSR positions, but 
both reported retaining their passion for patient care 
from their nursing backgrounds. 
PSR 6 This PSR began their career as a pharmacist and 
was recruited by a pharmaceutical company whilst 
working as a pharmacist in a hospital.  
PSR 7 See PSR 5. 
PSR 8 This PSR entered the pharmaceutical industry after 
a short career in another industry. 
Healthcare Economist 1 This informant is a researcher that I found via 
Disclosure UK. They have consulted for 
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pharmaceutical companies and conducted pharma- 
funded research on the disease burden of 
depression. 
Neuroscientist 1 This informant is also a researcher I found via 
Disclosure UK. 
Pharmacist 1 Pharmacists were the most diverse group of 
informants I spoke to. Pharmacist 1 is one of the 
most senior pharmacists in the country and is 
involved in making very high-level decisions relating 
to the use of medicines by the NHS. 
Pharmacist 2  
Pharmacist 3  
Pharmacist 4  
Pharmacist 5  
Pharmacist 6  
Pharmacist 7  
Pharmacist 8  
Psychiatrist 1  
Psychiatrist 2  
Psychiatrist 3  
Psychiatrist 4  
Psychiatrist 5  
Psychiatrist 6  
Psychiatrist 7  
Psychiatrist 8  
Psychiatrist 9  
Psychiatrist 10  
Psychologist 1  
Psychologist 2  
Psychologist 3  
GP 1  
GP 2  
GP 3  
GP 4  




Appendix B: Consent form 
 






An Investigation into the Marketing of Antidepressants 
 
 
I understand that my participation in this project will involve taking part in a 60 minute 
interview on the marketing of antidepressants and the wider context of depression and its 
treatment. 
 
I understand that the interview will be recorded and transcribed at a later date. 
 
I understand that participation in this study is entirely voluntary and that I can withdraw from 
the study at any time without giving a reason. 
  
I understand that I am free to ask any questions at any time. If for any reason I have second 
thoughts about my participation in this project, I am free to withdraw or discuss my concerns 
with Dr Michael Marinetto (marinettom@cardiff.ac.uk). 
 
I understand that the information provided by me will be held confidentially and securely, 
such that only the researcher can trace this information back to me individually. The 
information will be retained for up to a year after the project’s completion and will then be 
anonymised, deleted or destroyed. I understand that if I withdraw my consent I can ask for 
the information I have provided to be anonymised/deleted/destroyed in accordance with the 
Data Protection Act 1998.   
  
 
I, __________________________________(NAME) consent to participate in the study 
conducted by Rachel Williams (williamsrd3@cardiff.ac.uk) PhD Student of Cardiff Business 
School, Cardiff University, under the supervision of Dr Michael Marinetto. 












Appendix C: Participant Information Sheet 
 




Participant Information Sheet 
 
An Investigation into the Marketing of Antidepressants 
 
 
What is the purpose of this study? 
This research aims to investigate how antidepressants are marketed and have 
been marketed over time. Furthermore, this study will explore the issues 
pertaining to the marketing of antidepressants. Part of this research will 
involve interviewing people from patient charities about their experiences and 
opinions of antidepressant marketing, in addition to the wider context of 
depression and its treatment 
 
What does participation involve? 
Participation in this research will involve at least one interview lasting either 
approximately 60-90 minutes if face-to-face, or 30-45 minutes over the 
telephone. The interview will be semi-structured, with the topics and questions 
depending on the role of the person being interviewed. Over the course of the 
interview, participants are not required to answer all questions, and can stop 
the interview at any time. 
The interview will be recorded using a voice recorder and transcribed at a later 
date. All data will automatically be anonymised, however, if preferred, 
respondents can opt to be identified in any published works.  
Participants will also be given the option of consenting to be contacted again 
after the initial interview should further questions arise during the research 
process. Consent for all aspects of this research can be withdrawn at any time. 
What will happen to the findings? 
The research findings will be published in a doctoral dissertation, and 
potentially academic articles. It is likely the findings will also inform further 















Dr Michael Marinetto 
Email: MarinettoM@Cardiff.ac.uk 
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